var title_f35_38_36448="Calf raise PI";
var content_f35_38_36448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calf raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand behind a chair, holding onto the chair. Slowly rise up and stand on the balls of the feet and toes. Hold for 5 seconds then slowly roll down onto the entire foot. Rest as needed. Repeat 10 to 15 times (one set). Increase the difficulty of this exercise by rising higher, holding longer, or moving up and down more quickly. Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36448=[""].join("\n");
var outline_f35_38_36448=null;
var title_f35_38_36449="Necrotic hepatic met melanoma";
var content_f35_38_36449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Necrotic metastases from melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large hepatic metastasis with central necrosis in a patient with metastatic melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Donohoe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36449=[""].join("\n");
var outline_f35_38_36449=null;
var title_f35_38_36450="Patient information: Whooping cough (The Basics)";
var content_f35_38_36450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/28/24002\">",
"         Patient information: Acute bronchitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/7/13427\">",
"         Patient information: Cough in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/61/33746\">",
"         Patient information: Tdap vaccine (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/7/18547\">",
"         Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/18/37156\">",
"         Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Whooping cough (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/whooping-cough-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27018422\">",
"      <span class=\"h1\">",
"       What is whooping cough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Whooping cough is an infection that causes a severe cough. It can spread easily from person to person. The term doctors use for whooping cough is &ldquo;pertussis.&rdquo;",
"     </p>",
"     <p>",
"      Most people get vaccines in childhood to prevent whooping cough. (Vaccines are treatments that can prevent certain serious or deadly infections.) Doctors recommend that babies and young children get 5 doses of the vaccine. They also recommend that children ages 11 to 12 and adults get 1 dose of the vaccine. It&rsquo;s especially important that adults who are around newborn babies get the vaccine.",
"     </p>",
"     <p>",
"      But children and adults can still get whooping cough. Babies can get the infection before they get all of their vaccine doses. Teens and adults can get it if they don&rsquo;t get their vaccines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018437\">",
"      <span class=\"h1\">",
"       What are the symptoms of whooping cough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, whooping cough usually causes sneezing, runny nose, stuffy nose, and other cold symptoms. It also causes a mild cough.",
"     </p>",
"     <p>",
"      After 1 to 2 weeks, the cold symptoms get better, but the cough gets worse. People have severe coughing attacks. During these attacks, children can gag, choke, or have trouble breathing. People can also vomit from coughing so hard.",
"     </p>",
"     <p>",
"      After 2 to 6 weeks, the cough starts to get better. But it can take weeks to months for the cough to go away completely.",
"     </p>",
"     <p>",
"      Whooping cough gets its name because many people make a &ldquo;whoop&rdquo; sound when they breathe in after a coughing attack. But not everyone with whooping cough makes this noise.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018452\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor should be able to tell if you have whooping cough by talking with you, hearing your cough, and doing an exam.",
"     </p>",
"     <p>",
"      He or she might also do tests that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Testing a sample of mucus from the back of your nose or throat",
"       </li>",
"       <li>",
"        A chest x-ray",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018467\">",
"      <span class=\"h1\">",
"       How is whooping cough treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors usually treat whooping cough with antibiotic medicines. The medicines can help the infection get better faster and keep it from spreading to others. Doctors can use different antibiotics to treat whooping cough, depending on the person&rsquo;s age.",
"     </p>",
"     <p>",
"      People living with the infected person might also need to take antibiotics, even if they aren&rsquo;t sick. This can help keep them from getting the infection.",
"     </p>",
"     <p>",
"      Most babies need to be treated in the hospital. That&rsquo;s because the infection is very serious and can be deadly in babies. In the hospital, doctors can watch a baby closely and give him or her oxygen, fluids, and nutrition (if necessary).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018482\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To feel better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get plenty of rest",
"       </li>",
"       <li>",
"        Drink plenty of fluids",
"       </li>",
"       <li>",
"        Eat small meals to avoid vomiting after coughing",
"       </li>",
"       <li>",
"        Avoid being around people who are smoking",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018496\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has whooping cough, call 9-1-1 for an ambulance if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stops breathing or has a hard time breathing",
"       </li>",
"       <li>",
"        Has a seizure",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Let the emergency workers know that your child has whooping cough so they can avoid getting or spreading the infection.",
"     </p>",
"     <p>",
"      Call the doctor or nurse if you or your child has whooping cough and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Gets a high fever",
"       </li>",
"       <li>",
"        Vomits over and over again",
"       </li>",
"       <li>",
"        Gets dehydrated &ndash; Dehydration is when the body loses too much water. It can make people feel thirsty, tired, dizzy, or confused, and have dark yellow urine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also call the doctor or nurse if you think you or your child has whooping cough. That way, you can get treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018511\">",
"      <span class=\"h1\">",
"       How can I prevent spreading whooping cough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cover your mouth when you cough, or wear a mask.",
"       </li>",
"       <li>",
"        Wash your hands often.",
"       </li>",
"       <li>",
"        Avoid being near babies and young children until you have been on antibiotics for 5 days. If you work with young children or babies, do not return to work until you have been on antibiotics for 5 days.",
"       </li>",
"       <li>",
"        Make sure the other people in your home get the pertussis vaccine if they haven&rsquo;t had it. If your child has whooping cough, make sure the people who live with and take care of him or her get the pertussis vaccine if they haven&rsquo;t had it.",
"       </li>",
"       <li>",
"        Not let your child return to school or day care until the doctor or nurse says it&rsquo;s OK.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27018526\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/28/24002?source=see_link\">",
"       Patient information: Acute bronchitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13427?source=see_link\">",
"       Patient information: Cough in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=see_link\">",
"       Patient information: Tdap vaccine (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/38/36450?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16553 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36450=[""].join("\n");
var outline_f35_38_36450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018422\">",
"      What is whooping cough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018437\">",
"      What are the symptoms of whooping cough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018452\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018467\">",
"      How is whooping cough treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018482\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018496\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018511\">",
"      How can I prevent spreading whooping cough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27018526\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/28/24002?source=related_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=related_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36451="Lumbar epidural nerve block";
var content_f35_38_36451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Approaches for lumbar epidural glucocorticoid injections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36451=[""].join("\n");
var outline_f35_38_36451=null;
var title_f35_38_36452="St Johns wort";
var content_f35_38_36452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    St. John's wort",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 487px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHnAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDf1+JZbOaJwNjLjNcHHBbwxlGI2LwT611vjS9a2sXCd+K8nnvpjKVRiwNfAZHCbou21zfNbSml1OukfTbm2aB1ym3C+1cDqWlrDI4jBbniuy8NQRybWnw7HjHpWpr8dpblE8hQ7jggV61HF/V6ns97nn8kuXn6I8lNlcySiOONmfGcAVVmaSBzHKpV16g17TpWn2ttafbQgMrccivOvGWmyNeyXKR8Mc8CvToY5Vavs7aAmuVNnOJqDjAPStWImRATxWZBEGIBHNbHCIo6V6OxExjx5FRvGqp8/SrYIxWbrsyxWLnODinYmF27DfMgiBaMgGnpdsVLKciuCa4lIwZGx9a3PDV0WZoZDn0zRytG8qdlc3EuDMWzwRUMsLvgE8VLImM7eDUKvIGwTxU2EnZ3RdhjVEHNXIYDjOKzo1aT7rHitVbny4QMfNik7jSVrtlCZirkEYOaljkV0xmqdyXaQvS2xAb5jzVJdxOF1dFTWYlZPnHy1gvKsUgMXQV1l5Gs8RUHmsKLSZDcAEblz0oNaUklqbehK8kIdu/OK2VIjUlutVrbZZW2XwMCqJ1NJpCM8ZqNxOTk7wJbmcyP8p6Vc08DAJ5Jqp5kA5yM1YglXqlWtB86WhsFFKdOahjjKvntTbaeQ9sirhBIyau5cZKQ8wiRDj0rDuLUJcb8dK2jOYVHp3rJmlae6JP3ewqJPQyrVOVWIyPmXHXNS6lcPBAAhwxp8MWZkBqvrToJVQ8msdJSSOem1OSTOavEmkcs5Le9VHYx5xniujwmM8Gs3UI42BwuDWx6CMy3vC0oAHNbFvHLPwOlZ9hYF3DAYAPWuktwsCYHFVYGx9pAIUGetOuZsAheTVC81EL8sZ59ao/bCOc5zQwRdDEtg1OiKeTWX9p5pwuvQ1IzbEalarTERnpkVBFegDDHilml3g7TkU7BcnjuFC84orO2Oec/rRSsFz1Tx/4kguHa0tSGGfmYVxNs4ViUB9810HiPwvcJf+bZRs6OeV/u1jS2k9lcIsiEHNfP5dTw1PDqFGV7/eTi4VZ1G5o6Pwqy7mZQc5wBXZyaWLvy5bwYC/dFVPBmiNBCby6UYflRXSzKZcgdBXy2YYr/AGh+zfzPSwmF/d++jOnsl+zbUGFHQCuQ8TPCLeRJABjivQbZDkow4rkvEGnWym7aRAwYHk1eW4506nLN3Msdg4zSlFWseRSywm8Cw9M1ZuRlce1UUgVNRYL0DHFaMwzX6Fe6R4stGkZEs9xCrbPm9KxNRe6uR+9+76CukljIGQcVTkaNiQwFXc3grao4uVCrkEYrS0JCLjeD0rUuNPguOVIBqGys2t59oOc1bd0WmmbsgzGCOtMjiMp9BUiIwUF6VJdp2gVFzmfkWI1WFcLUU7sOakVwcetSCMMwB6UWJRXmV/sjSY6DNZEdyZGruprSNrEhcciuQg0wxzPv4G7ihM60lBajoQzLuGa1rbaI9xHNZtxdR2yhFxmmNqIERVR82KLXMZ03LYqeJ7/anlqcZ7VjabcHfgniquqGZrlnlzjtVVHKMCDVqOhvBKCsdS7ErlasWN3g/McCqNjMs0AOfrVG+ka3nBU/KalFtXO9tb6NUBBFWorwSvnPFcVYXTThVU1vWZ2EDtTuJI07+cpGSOtULCfzpMNwwpb8loiw6Cq+lbJJA4+hqZaowxMdLm/bp+/LnpjisfULWY3rMec9K1b1xEihWyPaqctyShkfoBxWMNHdHJRbi7o5+9doW2AneaktbSSbDS9KcIzNcNLIOp4FXHuEt4/mwPaulHop9x4VIE7ACqdxciQEIRiqV9etL0OF9Kxlu3SbZnqeKL3HYu3oI5U4NQWayOxL8elWiDKo3A1JAu057Uh3HPD+7yOtZ7OyyYyDWq0mUIxiqIiVpQWpWC5PBGzKDU24xdc1NAUCYHao7nnmmALdLjmiqTDnrRSA+q7yzX5ZVIwa5+50eHUbrZKBlTurpZGFvG0LHch6E1hNdiK5l2HLYwDX5Nhp1I6wep9NOKmuVo09OINmIF42Nt5p7MjzNEhYMK546g0Z27iDnNasN9HYxm7vGATGQaJ0ZJ36sTtFGtMUtbZnmYcDk15P4v1seXc+Ux2nNT+MvF8t3GPs4Mds5wGz1rg7qY3yNGTnNfQZPlE01VrHkY3FR+GJlabM810zMDya2JTgZxUdparb4BxmpbkHYcV9qmeHKSlIzriYONqnmq32dm5NPFjPI+VGPrWrBAIox5hy1VexbfJszIj01mO7O0VcjgigGR8zVPdSMw2x8D1qjFHIjkMcg96NQUm1qyeNt74NMuITuBXinrEwYMoNWwAyZbimtiXpqjNiMiyAMKvjNUNR1G3txgMNwrOh10OSDxSVyuRvU7S0kZocEk9hiua8QXUlrchFztatfw1cpcBlJwaq+L7PeqPGPu96EtTaELq7OdkBnOcHdU1jA8SkzHcadajYORzTb27WGPI+8eMVRqhb+COWLoDmuZubdoXIxx61sRTuzZblT2qSSBZwSOc1SdhMytMlaOTb/Ca1Lu0M6iqEts1sSR0ra0eVbkqvcdamXcd7INHsnto2aQcnp9KvecRIqrz61sm0EkR28GoIbVYI23Abj1NJSuY/WIdB7gPb49RWJYO9rfOP4G7VtQZdMCs94QL0D1NHQ1mk1qX3Lsy9WBq4bJpYfnH4elXLe3QRIzCm32oxW8RUEA1MNVcxpUlZSMh0WAkAZYVgapLuY5PPpWtaym7nkdeVHes3TNKlu9XmabPkq3fvVOVty5VIxvfoZwgnMe/Y2z1xUthZLNOueSOa7u5W1jtDEqjAHWua02Ii8kZR8meKIy5iKNb2t3Ymls/LiJx2rJkbyxjIzXS3n+oI9a528tiQTVG9io1wDgE4NSqR9aoGPa/Oau2/y7cnPtQDJkD5yOlMlkwCCa0othXiq1xa+YDt4PrS3EmV4oyyA4zRWjbQbIgD1oosQ5s9rXW5pLYNPGwB6EdKzvtwDuxb5q3dS8q108oygLjgYriJLC7nk8y3Ushr88oxpVbyiuVHuqU6atJ3ZsW90ZrjKAswrM8QaxcxxeVdQOsYPBI4NaOk4tJfKnASR+hJ61syWzXEeyeJZYvcZq+eFGonKN0NylUjaLPIb3bcSqRKzqf4egFPhjSMfKPxr0O+8IW1wpMA8pz6dK5XUfDGpWO5hEZYx/EnNfTYLMcNV91Ss+zPGxWHqpbaGJc7uCD0qa3dXT5uTTJInXhwVPoRVfmNuK9fRrQ85w0sXJpCFwgxVbLfxdaejl1zVm7s3jgiuEPmW8nAkAxhu6n0NLmUbJ9SYplJVyeaR+GxipOgzjj1qaS32af9qkDKrHEfy8OAcMc+3H505TirXe5pGMnsQeZgcCgyK6lTTEdWQkVWO9cvtJXOM4p6DUbla60SO5cvnmsy40NoeUGcVtLflO1aWlTLdzqGT5cE9Pam5KKua+/EzvBUD/b3hZSCUJX6jmu4utBuL21MaRtJOyjZGvXJ9am8PaTFa6dLqc6jzto8lTxgev1NdH9vmj02CaOHETNkSe/TH5V4eJzJqo1Rezt8ypTlFq+zPN9d8FapomnLe3ixCIttZVfJT0z/APWrjb+Fe9enfEW4nm09ZLmRY/m2rHnLMf8A61eV38p2nmvQwFWrWpc1Xe5rzRb90YiBRxU1u/lyAdQaowykrg1ZtX2t83Wu0djUltBKm3A+ajTbE2DAYyWOc0/TJfPlKZztreMJVASKGRLYWCUiQA0t4cb/AKVXDASjPBq1MvmHjuKyvZ2POaSkiLSxlcHrTntwb5cDkdaktIjECant+Z3b0FVN6HozkvZtosTvsh2r1xXJ3lhLO8ryOcfwit6O5EkjqT0NQXDh3IAohorGdSfs4RSK+i2xhtMN1NaaKsMTPkLn9aaGSNFXIziqGrSOISwPy+lQ05M4tas/UoalqQViueCcVd0cq8e4dDXL3CmdvUmun0eAxWiD2rZKx6VOCirIk1R9oAFZplU5Dd61JQJJ9p7VUu7DcjFOGpsuxh3cShiU79qjjYZwe1LMkqTCNwRU/kbUJIqRMSMvnIPFaltkoN4wazbI/PtfseK202lRQnYwlU5SLeE4opzj5qKdxcyPQtU1xtQkWGP7gNdIkQttMRYuGI61xdpa7b6NF7vXpX2UGJUPOBX5zjHCkoxhsfQ0rzbbOI8T2jjT1ujIVkQ5BrY8Ca4l5biCfmZODnvU/jOzx4fn2jOBmvIrLUbnT7tLi3fY616mDwqzLBSh9pPQ5atV0K6fRn0ctvDIuQBUctpGFOMAe9YngvxRHqdkkgQZHDnAOG966wXdvMdksseXGAjqAD9K+c+pTpz5Kjs10OqWLTV4o5LUdAstRDCSFGYd1GCK8l8TacmnanLbxklB0z2r3rVdKeeIvbMFkA4B6j6GvGfG9hcQ3puZt53Ha4bqp/wr6fI6ko1eVzduzPIxs1JK8de5kWcFpNZCNGkXUC/G8gRlcdB7/WtLQsW3nQXjfJIwWS0kQ/vF/vA9iD0NYdwJHePylLExg4Uc8cf0rrPDF7HqlrbR3axTTWu4bXTJCnv7j1r1cfUlTpOW6e/df8D8ujMsJBVZq+j/ADK/9kyW9z9kId9PmcShXXHTIyx9uhx1qzrGjpcpbQ2zYUMLaNGPygOCAc+m7HXmt23QxQKk0okGCE+Y7oR0FPjjh+yvGxSWNm3iLYcoeoy2eeR26V4UsfUc1Jvb8el/Wx7EMJFQ5e/9W9DjPDngq+u5Z/tg8iCGQxE9TIwOCF9enWvR7bwLpTW9sklvvSI52ljhj7+tdB4ct0lhjmdPljyAEBwP881uDyBGsiuCjY2475rx8xz3E1qloysl2NqWBp01a12cGvw60TMx+xg+bjGSTtGc8elYfjfRdI0OOz+xQxQXZYoVjzyu0nJr1S6E8g2wKRzwc/z/AMK5HxzapZ6TI0+xppAQCevv+FRgMzxE68VUm3fpcnFUKcaUtEjhUkaeGJHkCoTuIJ7elWdZ1WJbf7LC3yFQCOtcpPcy7VMxaMbSFx/OoYbuQuEWLex/iJxivpo4Fu0ux8+6l7skv9PuNbZxH51zMgIjUH7v1rB1zwdqVnp7XM8L7V+9hDx9TXofh2JbA/aWLGbGdoFS+JvEksli8AwPMBXaO/1rop4+tGqqVNXRUI8sbtnh9rakyhDWhPYOCCo5qz5QivumOa2UToxGa+iFOry2KWjWf2ZACPm6k+9b0IZ4wGrP3gk4GGrUsgTGoNRKRzYipezizLvYT5uVOCKaZJF2ird5zOVqvPtyBnFNrqQpc1kywjuq855q1HiOzmkHXFR2TLLHskIx2Na62cIs9juAh6mspzVrDlUajynF6Y00l2wCthjWzNAY/vDBq01zaWgK2gUt/eNUfOFzJ88m4+1Wm3qVPmrNWRA5OcisfU7lpN0Knjua1tUDLF+64Fc2quZTuPXvVo6KVHl1kLboVwG9etdfYri2X6Vz0cW4qMd66KIbIQPQVSOixQuWKzkqeRT4rxGyG4YVVkctMze9U71CMupxQ2CJr3bPICoGaeIiqbXGaq6U2WKyH5vetd2R0x3qWG5iyx+XJkCrduzHg1I8YJwRmpViCU0Y1I9SNxzRTyvoaKVmZXR3El/FZzwTnG0MGyD2r1S0liuraGeEgrIgavnG5nM0ix7yQvHWvTvh14iUQw6bcEl1OEPqPSvjM3yeUaCrQ1cd/Q9jCYxSnyvS53PiC2FzotygHVDXgU9nM4fbGXUEg7Rkj6ivo27iMlo6RSpGzDgsuR+VecWHhCT+0rhrqCE7TnIlODn0Ax+tZcO42NCnUU+5GZtqUWkYHgO2lt2lmtZtkwIOAfvL3BHrXW3PiCKYvY6jFk8ZZf0PrTdV0UWkLy2zWsU+OFRyGPtk9a4G8unubkOXKyR/KW6n6GvUcIYyq6mx5cas43TOxW91KxmzZagzQk5QF849iDVHX9cGqRhL4IjjhnC9R7isOO5vCpQxCRSOCOf1p9npT3eWnuEgUdAfmJP+FX9WUWp1N11W/wCBndPSL0Zm6lEtqkEsUpaMH5JBweuR9D1/KtfS0ubqWO9MaxXC4PnHASUf7QzzWtb6Tp5hNvfPHLEx5RHxnHcHsaRvDXhxZlMV5dqn9wurY9s4rWriFOHK0797X07Wuv8AI3oSjF7/AI2NqFkdSCyA9wpBxU0a+Wh/uDp33E9aZDDYpBtSURRqMKBkn6k1Hazhoyu4MB3r5irSlHdNeqPoaWJhO1mn6HS+Hbkg7fNMaN3Pb/PNdLZSwxzFchj0z1NefR3SR7Y0DO2c7V5NXf8AhIre3icfYNTjlA4xBkMfqDXnVsI6rdkayqxjLVnZ+IPENpolg9xKQzD7qZ+8fSvH9V8Sz65PN50m1s5UHsPQCqetarq91qsd3c6dKYE+aKGZTs+pHesK7+0xXAv5whNwS+U4AOeRivoMqyinQjzOzk/P8Dw8fiZVXyrY0NYaGx0q4RlU3zKrJKRu3Bj2z0xXIabdS29xiVmdT1zziup13FzHbPKwCbAxbufbFcxqD5ASBdkYOT6sfevp8LSj7O1t9zhhO/us6M6jKlsxi3RnHfkN+Paubt72S9uXMx+ZT0BrUicy2Sj2rn7H9zqsqNxurelhoU22kaShaJeuUM0yySElumavIAEAqBx81NV2R+T8tbbHNJ80bErDDZFXrObaR6VmvdRk4HWpLeQh9rcA9KmUboylFtalq6wbhm7VnXLLhiTV+6UqmfWqLW7SofSiL0NKKvsR6RIWkI3EjNXfEt5LDaKkbEetU9DhK3JUjoeas6zAJ3x1FJq8jokr1EuxkWG6dckn8a0bdPJfNSWtskCbcc09P3jcdO9U9DeFSMk7dCWbEkePzrKltdr5xwa1UIyVAJokiyuDihO41UjJblO1hyy59a3vIAhz7Vl2w2SgNWhcXSxxEE8Yo1NFYyZoQrNWdfMqqRnmp57suTiqpjMpwwp7LUTd3oVI3G7eAcircF0ScHrThbbRwM1Tli8uUelDdxbGxb/McNViVD5eKrWmDGCOtWS5bANNI53WV7FZcgc0VbWHI5opXKUUYNo/nzMAPxroNHvZNNvYZ4vvIc/WsnTbZkj3EdavHCqSTSlBTi4y2ZgptPQ9MvPFdrqFsl1a6ktpcqoEltL0bHcHsa53/hL5DfmaKRH42spfBPvXn12wZz3FV7fbG+4Rbmz1J4/KvKpZPQpJqOx1Vpyqe89z0a71qOYtKzBSRzvasOC8aUyyfKqAZBI5arngyzgvrh47kKXYblDfxeorv5fCGlfYZbpVYlF3FfcdqxlUpYWp7OUWzm9ldOSMfwhLBLYTfbNOivUbk5PzKOnA/WjU7O102BrvT0DxMpY28jE7ceh64qnYXa2JljijIilbaXU/dz6+lV/EjyRo2ZNyFOMDkdjk1goOVa3RslTWiRn3Oui4iK21tHbyf3hhv0IrJlnvmORKpx6KBUYiIbIrovCGhnXNZitnYpCBvlYddo9PftXqzo4fCU5VGrJa9zVSnVko73Oj+HGkzXFs2pXxD4YrGvOBjqSK1fE2mLBbi6ViN8gVmHYGu0NpBZ2aW1nGsUKDaqr2FUr22WeyeFxlSOR/nvXwVTMnWxHtX8N9vI96OEUKXLHf9SjouipbMJNpz79a3mtQwBU8YqHw9Jm0WOYsZYxsct19s/hzWgSqyFR0JrzMRUm6judMIqysY16I4zmZGYAcdxXL6lpVvqMOHhLsG3qqELk+9dpfxB1PHWsrygvG3BHQ+tdWGxMqdpQdmjOpSU01I8b8TrPBrEsE8TQqp+RT0I9RWLdRnyywr0n4l2avYQXTo4mjbYGAyuD2PpXnkg3RYzX6LlmKWJw8alrdz52vR9hU5UP0mbfEVbqKpalbkXqSoOc4OKfany5OKvNhuTya9C4pVUlYhwSAe9Iy56in85oEuGC45NFu5gouT0I1ijXnbzVnYrAEdasGJRGM4z3rJa+Vbpo1OQDigcqU7GmQ0qheuKdGoWMg8Y60/Tp1JweCRUF2jecUB4NZrexNNum7j9PRfPkdRTbgfvhnpmrdlD5MfuahuF5JOKI6ts1ptvmmyKUD7wqnahm3AcZara/MpB6VG52nagwPWicr6HNBtJxRaLxqoUfeHeq7sqnc7YHvUe8KpNc/qtzO0wByE7CrgrIqlQbfkbEtyXfEdJOJZI8c1DowVk3N1q/dTogwMCmz0kijBbcfN1qOclGx2rSjKtHkdarSpvlHFD2HsFshKDNVb22LHgc1pRgKvNKVB5xUJO5EqsVoULVGjUButWlPenFfSlZPkq7o4py97UeLgY5oqsI6KqxXMye3VigGOKq6lG8a5zx3qO21F1425AqaWYXaFcGp0RSg4zv0MGUneAp4Per9kgAG7qaatg4k2nkdjU0ltKoATrSZ0XTNywxE6OrvHt5DKM4NdvD4via0McodZQm3dt+VvqK8+sg4iAkOTVsqHGCSPpXJicHHEWb6HG5ShJo9R8M6PaXOmB2vZMyrhk2goue3IzVO/wDBl1ZStNYyJeQkY8mT5eo6A9K5Xw7q8unSeTvYwtxhj3r0PSdcZkVZGB4OfcetfI4x4rB1XZ3R6dKnRqRWh5Nq9jLYXMqiNhGD909U9jXofwYtTJb394QMl1jH0xn+ta3iCxstVtd2FSZRhZAOnsfUVe+GNh9h0S6i4BFwxyO/SpzDOHiculCStLRfib4XD8mIT6G9LFvkY9h2qFk6CtPyxggdTzVeaLbnAwBXycZ9D2pI848X3t5oGvW9/BJi3mj8qROzlT+hwetdNoOuQa3p6ywyDeOCM8qfQ1znxgkij0e0UsolM25VxyRg5P0rzbQ9Yn0fUUuLZjsbBZM8MO4r6yhlqzDAxqRVprT1seRUxLoYhxfwv8D3NLuSRGE8YV1bBGePrUQJJ4HH92qel38Gr2aXFs4PHzL3B9DWlbW7NhgRketeDOPsm1JWa6HpRakrrU5vx5bwHw9O84mwuNhQ5APbI9K8hEfGTXrnxFtr660d1t0BihPmSKOSR6ivIJZWX6V9vw3f6q9ev3HhZiv3u3QSOPzJwg4q3NaNChck8VHat0fGM1euJhJFtXnivodjmjGMlqZsb7xwOKksId1wWboDTbcbTtPrir0e2I8/Wnc1jFR2IdadorVvLzuPSuPiZ459zA9a7yUJcrkgVi3FlCZCCBihMbQaddJIMk8ite+t9kMcsZ3b+9ZUEEMIKrgA+9b2nqbmwaInlDkVnN8upwYiNpXM+a5aK3w2c1ShvDcTeUoJzWlfQ5IXHQc1BEkdup2L8570RasOE+WnbuSFRCuDyxqrKG2Fu/YUS3DBueaabpehNUkuoqdGa95ojgZgf3vIp7wxTEfKDUbzxsvYGmhiMlG4q7HdF6bF+2s41B2jGfSq1/pzSAFWORUMV3Mp65FX4b0NxIMUtS9CO0tpFQAirLWuBnFW4JkPTGBU7SKydKGwsc/ckoxApkM3GDU+ogBuBVRY26haEcUl7xOx71Ip+Wq0hKrUcM5+61Nk1KZM7gNRS7Vbk4oquYgrPCsb8HihnAwVPNWyAeoyajWBWJxUWNFXurMfBKGjy3BpZLmNMZ5qKW3ZiFXgUq2gkiKk/NU7EwlFO7ZNDKrnK09mYsNuevOKr2lo0LHd0rTiuY1OZ48sMbWQAEfh3pTk0tFcJq8tNSxZ2JlV/Nc+WcGKRfXuCOxq7bSX9kim4T7pwrKcn8q0NN1hIri2XUlXyd2/PlgHHbIrX8QS6Xf2lxKr/O4BGz5cGvncVXlUmozjdMulKau7mVb64ChV2K5HIru/hnNJJo9zMHzE9wyrk+gFeNzyW8QwklxK5/hOBg+9dh4E8XDRIvsV9CDZs5cNEcshPc+orhzHKpzw8vYRu9NPLyO/B4uMaqdR2PbUwQPyplx5cVvJNIQsaAszHsB3rm7vx14dtLTf9vWVtm5UjBJPXj2PHf2rzLxl42bxBtgtle1tUJwC3MmfXHb2r5vA5JicTUtOLjHq2j1sRjqdON07sp/EXV4te1tmgwbWFfLjcE/P33Y/z0rkHtxFCSpY7Wzz6Veww5+8Pai3KzSmIj74K/pX6Th6EKFFUqe0UfP1HKpepJj9E1u+0rVIXsnwGADqeVce4r17RvGOkXiATzC0ucco5wD9DXjdhD++3EfMoNMkYO/PTPT1rz8blVDMJe9o0t1/WpeHxtShpHVdj2DxN4p0i3sJ4reYSXki7FRDnr3LDtXO3PwxmurJJ9Pv45CVBKSrsyfYjNcLGgbkjn1r17QtdlTw9ut/KknVMhH5DY6iuWWEnlFOP1aV7vW/4Gk8QsTK81ax5zcaBdWMjQ3UexkwDjnj1GOtXfD2io+qQrfpuhZ9hUHrziumGs2moTb7+Pyi3C7WIAP17VnahefvWSFCCWVct146GtXmdWrF07WdtzmblGz3RD4n8FxW0B1LR3MkCktJETnAzjcp7iuK1GTy4SR1Ir3uyGLG1gRVMYQIfQjFeL+P9HbTNWnjTH2fIdPoc8fhg1plGZSrSdCq9Vs+53VIcquZWmT74wCear6vvRWKHBFN07EYIB6GrN4vmr9RXvvTUxWpxV5qdyJCA3Aro/BWo3MvnGQ5Velc9qti0dyR2NdV4bsvsehy3D8bjx71NWSUdTCsly2LkurLLdFMZI64qWVhKn3SK5vTX8y9eT3rrPlNvnHahRtsOFLlXuszXAXg9agKI2TuouJcOe9Y+oXxgbCqSD0ppGy21L00KA5zUsaDYNprlpdRuWYYwBW9pcrywqW61aQi/CvBz1qnd3flShfWtFcLjPes+aBZZiW7dKBly1uxt5NXUutwGG4rCkgdQApq5bIyqMnNS0TKfKtS7Id7c8irARNmc1UUYpxlwMUHNJ31RBdAKTiqihnb5RVqVTIfauh8KeH31u78mKRYgv3nIzipq1Y0ouc3ZIILndjASMhRkc0V6L/wgbK7pLqECMrYwUPI9aK4/wC1MJ/P+Zbw87nn4U8gA1dhspPJE23C+vpVa1mXLeZkKopBrPlgwlsxnjnpWlWU23GJyKLZOY41c+ZJkeoqH5A37snb6miIQkAlwyn0NR3BHKxdDWlPs9RKKuW96lOtdb4C0GC+aW+u8NHC2FX39TXBIrIgByT61o2urXFnlIZWSN/vIpwDWWLpVKlJxpOzZtTtGR0ninT3lv5WiCbc8bD0rnrmc2EGfML/AMJB6Zplx4hOPKEDBm+XO6qGpyPOiIQF77R29K5MNhqitGqtCpWXwlU6gPMHy8epq/FMsifKQfpWM8HrU9hE8bE5JFeraxPKmWpXUPhj1q1HF8ikHIasya1ubq4VLeJ5HY4CqCSfpWlYW1yLUvJE+wEgMRxkdRScktCp02o3Q9onQZQ4/GljededoOO9NdY5Y8OMkcgjrTre2ja2DKxEobBXd1HtWU4xe6Mk31L9gJLmRLeCIfaJDhfUk1o6/wCD10jRJL5rtnmj27kK8ZJAPNdT4N0L7Iz3c6hHkUBUIHA6g1p+NNNl1Dw/JbRcedIpPrtXk4/Svmaub8uMjSou0Lq779z18PhOWi5zWrPI9Jt5r6OeRCFggAMjk9MnAwO/NaWkajJaq8K3CkAnBUkYP0NdFBolvpdlZI4WOCctEXY8kt1DH9QfUe9czpmjMNZvtKvoSLtk3xTB8rFhsFiB1z0x1r154mliIS53p/Sv8uvl0MfYym9DWty9zp2ryMoLxRpKCB23gHH51c8NN9rSV5mkCRRfe4PQ8ZPHHFV/B8sjS3NrK7/u4ZIsFQQBkN0Puprb8JxxX17eI7SG0ncPyAhYZ5yBwOcjA6Yrxsa/Yqce1n8v61N6FBycde50umakj2KrHJgqvzcGuM+IMSaktuyyqiqcu59B6Cu58Sw2tlbxXdnCsMcf7t0Xpz90/wBK828VI/2CV7iXy59/lLCV5IxyQfbjP1riyy1TExqw0KxMJwhydTiI5Y5bt/s6FIhwB3x6n3q8px8pFR21sIFzjk1ZRAzDHJr7xbWOSJXutNW5ubVO0jKCQORk816GPD+jjRUgvXuNgX5ViYA49TWRp+i388cMiWcw2MWDMuAQR70y/wBTeyhkiuyUuh8oXHb614GPqVKs4woy1XYiTSfvIzbrQQ2qQw2NuyW0cfSKMszEnI47nH5VrDwlr00Z8jSblUPTfgH9TWz4F1tIZ4Elgkkkc7UZQOPf/PSu61fxLHZQlYNpfGcnt71jPM6+HSpqN2u5VC0le54N4g0DVNFaNtTs5LdZSQpYggkfQ1y+qIDFuHVa7zxjq02u3u9nLRx8L/U1ybWRlnCt9w9a97CzqTpqVVWky5aHKzZVQxVseuK3vDzF4ula91YRSW5jKDAHpTdHsvs0RJHeul6HOq6auS3S5jGOtY7TPAx3HIzW7IAc5yfasW+tJpZCkEbM7ZwAKnmRqppuyJrO7SZvWrxZRyKxbaymgVS6OhI3DIxketaEaOcZBqlqZ1dUXFcNQUz9agVWU0j3Ij+8cUHOlbY19PsluYndXGFGGB4KnsfpXo/w/sZrHT1eQqnmOZCO5HQc15jayh3QxTKyyYR2XjP1HrXqSX8VtahS4WNFG0j04r5vO69RRVJbN/kdWCj77lJ7HR3dxC02WUMcdaK5oaxDMN64YdM0V8xy1Voz0+aD1R5FMsuw+Ufm7+9Z4sZpZMnp3Fa7PleBgUxJdvNfpNrngJu2gkNrsi2dKTySrck1cjlhkGWcD60rNGykIQ1GxmpSvsVZZVjTnrWZJKxnyeKnvHAc89Kxbq4dnwlFzeMbGyZoxJG7DO1gSKkmn89mlXAJ7elYltI2cPnmtGKPjKnijzHYRrg7sMKs20u4gdqakaE4bGakhjUNxj60MqOnQ6jTP3H2T/SD94SRvESDC+eVP1FbsGkpdJeh3bMj+fjady+o9Oc/pWFZ25hhWbmW0k2q6gctnrgeo9a6/R2KvEkUsjAJjzHwpI9CP6e1fN5lWlS9+nLX+n/X/Dnr4amp6NHE6jodzFcgRA+S4LpK+EVgBnnng+1avhzQ5V1OK7MiPb27IwYKR5uepXPoa6PWLO6ewzZZYrcxuqAZBOehHfvWvp8JSOCEtkIxREC++T0rixGcVJULaXd1/X9dy4ZfBT9NTWskM8aZJYdSSu3I+lX54UnWNl6KCMMMdTj+lTrHsUHHzdT71z+t6wLe+aHPzbQ2F5J68Yr5nDN1aystrnXXtCm2zD1aW3ur61sWmaKaF/NVUQOSVHvxz71m3OkgX0F9JLK8kWUDj5XYH1/TP0PrVe/YXN08yWryP/Cg3QzEAf8ALNxw/wBD+tb+nXSX1lie2uYjjPl3CYc47/jXvV5TpJSht1267+dvwMsNGM42e5HBYQx3lvd28KpJIpjuWOS0jFcDpwARzn1+tO8IWjxahqUBTMaSxzxHHIDnJ/DINbFhBskMuAUkPmM2COenOfYCtDRbMl5Jc+Yrts39Cy9QPpzXmVsY/ZyjLXRL7nf8NV6HfDDpTTX9f1uWJ4PtMUkS/wCpYYJP8Xt9K8lntLnxF4ueyVPKSFihHaJAeT9Sf517jDCXhBYggsdoxjA9K5C5so7XXNQurSLfJdSK+YwfTH881OU4/wCre0aXvW08n/X5GWNo+15V0NW0/wCEf8Naf5P2eAfL8zMoLP8AVjXJ2mjafa61dajGY7hZ5N9uAvyoDzgf41R8W6bq135OyxnuMSAMEwcDvx3q7pOoJOxiZdjIACp42npiumMqsaLmqjk5fFr/AE9Tkkoc6i1bsXtWuXdNisdx4Jz0ryjXwzahO20kxueCOSPX3r1KRVefYuXcAttXk+lef6jpl/e3165srgJG5L/Ifk78/hzXpZEoqcru2n6nPjqfMkQ6JrK2y4jEe4jG4nkU7VLu4uoH4lKNyxQgk/jWfFY+TKVaNkP+0MUl4rQhSMgHuK+jWCpqftDy1dx91lS2bAIPapYwN5NQcrL9aswKWcjFd/mXKV6baHYzxUxQLHikhhZ5M/wikuHy+xDnFKpK+iPNScnZFi2sJJbSSeII21gm3PzMT6DvWvpmlRR3Ecol8y4hcSEopKMuAWTpncATntUWlvMkC3Bt0yqrEjgFeAwyeOp5PP0rTtWKtutZZPLuJA7pgeoGD+v514mKxc4c0dv62+49nDYKOknuYPi63jg1ZYhMDEirGgLbtijp07c07WtCeyZIbSGaZmYLllAZm25+Ueh6iuzlgt4Q3mWNvI7ShI38sEqCDnn0AqheoJ7JovLjjigID3ZyXQH7zZ7ccY+lc1DNJfu4rS2/mdlTBL32zzyWBl00XjSRqGk2LET87AdWHtnise4zK1b2s3FveX7vbhltkASJG/hUdv6/jVARL1FfSU3KUby6njTSi7Ii01GhYnJGVrt9AtZdZiMUs/kwZA3Hk/gK47OGCqMt6DvWrYXL2BjyzMUJIXPA/wAa5MdQdWNobkKSTuzqr/T1064NtZ3qyRKOrjBB7jiisB795DvWXr2I6UV5SwNX7W5r9YitjEB7GnBVxVbeGO0HmnhT6mvozBoiuF4OBU9ouyA+tBXp6VIORxSBvQyruGSSQ46UWemCW4ijYhd7Bdx7ZNapAHWoZJwhGz7wORSd7aFRlc7qT4Zae1qht7+cSHqxUFc/SuZ1XwtfaIziYCWAj5Jk6Z9D6V1Om6tqWmmJdQt5bdZQD+8UgEGtebVYr2CSOQq0RJVhXzEcfiqEv3j5l8vzR3ShCS93RnlTwvC0M1o7RXAGQRWpH4iE03/Ez0uymBAA2IY2HHXcOv410Nl4VfUbmXZMsVsv3ZByc84GKzb3wnfmXbawCZh0KMPmI5OM+xFeo8VhajXtJWfrb8TCk6i0sdDpEllfadF5bXUMat5SLIdyoSM4U9+vQ1fstNmjtmeOVI0aTeIhzhgMEg+h9O3NcTEdS0lRFdW80K7txjlUhSR3HofcV1/h/U4b2EKmVmjHzKx6/wCP1rxcww1SknUpu8G/X+v611PWwlSMnyTVmjpbCUvEV7uATjswNaltDH/aEbxDCHacVR0yRWkw2AzDI4wCamluPs8hdQTt5C5/rXzFRNyaR6qktjpGXLqmCQTyR2+tZF/pxlnZiigEYIXq31NW4bmS6skmiBjJ5J2kk/hUFjrkM8rQTqIplOPVX9wf6da5KdOqruCvbciVSnopO1yhFZzIoUjaOvQc+xFRTWrx7XGSF68cn39q6krk8rj8Kp3c0MCMXBBztCkfePtVRxEm9EVy8upkWk4UgZwQfu9vqK3NGGx7p7hkESMHUhv4SoPP41kC1ha6Ekysig7nMYwOT2A5NdEWis2zJtRJIirv0AK9D+v61OIa+FdTohPmjcsXam30hDHxIUVU/wB5uB/OsjVIkTZbW5PlxABsHq2K05ruC5v7GJJQYVUOpHRnxwPwGTWVq1ykGpCDAJYkkg9PxrDDqV7W13Ib6sdp8gWExzuoixjef4R9fSq194ZQyGU7GwNo+QbsemR9aZGFuLZyAfKkUjJGD78VZ03UZ7e3ihaA3GxdsU0koUMPx5Jx3roSnFuVN2fXZfmTNJasWy0PyoUEuNy4Py9vQVeMMVvHJJIY0jHLs5AUfU1i32u67JN5Vnp9laJ086aTzT9Qq4GPqa5nxVoerX0dvLLqk93IMl43wsY/3EHTn1z9a6MPhHWqJYiqop9tfy0/E56k3GN4xuXtR8S6RrV3LpUaHa6/NOQFL9sL/iaybvwNbTxs1nfEccxzrkH2yK4PVLa90y5SZ7eeNgQQzKQDXWaP4hS+s1V5mV1GCGr6uWHlgYr6rJ8j+Z4U6jrX9otTnjpVna3rQ6gxKBgMo3zD1Fb1zoemSNaQ6bK7SS/IHY7j+mK5vxJiSYyW7l5M84Oag0rVZftds0jbdkgIAODwe/pXXP29WCqRn8jlgl8Mtjq9Ks4bHV20TXYUe1uAfs833WDezDnn0PtWL4n8NT+H705DSWkhzFNjr7H0Nelar4etteto5LlZVkTJjZGwUJ5pmk3jT20mla/avcRgbfNKbhIOxOO/06GvIo5xUi1Wjr/PH/25fr/TPZeDglyLTs/0Z5n4Wus6g9pIAySr8oPqOeK6TRLRiudmWClSMdCGar138Prc3S32g6gyPG+4RTDK/TI5rTs7Hy7twflwxZsevp+dLH5hQr3lQe9rrZpo3oUpU9Z9CKW2EsvzxABPn3A84x6VxPjHUFtLA2VqChuSTJuOWZc559O3Su9u/md2UArnv2FTQ2mnX1ksN7axSZGCSgLfgetcWFxUcPONSouZLodGIpucXGLs2fP0u9eRmi3nYtg17nq3hfw/cWPkizEbIp2vHw2ccZPevE/KRZWTupIr7XLs0p49S5E1bufP4nCyo25upat4xIzY4YKSpHYjmtS00ee7sPOyQXyE/wBo1V0+Mou8DIP3j7en41u6dqy22yKcExp90AcU8VXlGVqZwO99Czp/gfUntlZopCTzwyr/ADoq9BqomTepZsnk5/xorgeLqX1lb5E8jf2X96PK7HcZ97dDWuFBGaqRx46CphKUHPSvobFTfMLKdik1X+1BULHpT7iYOuADmqbRF020hxXcQaikr7c1ZtwPMWTeBggjIzVSGwSNt3ergGwYHSpl2NbLoe8+HtUtNY0yOO4QSoVAKsM4/DvTL/wPpk6vJYF7aU8go5K591ry3wvrLae5UnjHy56fSvT7TXIp4cJLtdgDx97/AOv/ADr4nF4Wrgqj9m7L8DthUhUVpnKM174YuJILv5kk4Vwflbn9Diuh8M20qX0r3aFJTHiJCRyONx/UVieLrwXm1GJK8hlPQ+hHvWVB4in0+LT44xtFuJD5g5LBsAj8xRKlVxlFcq953v8A18hUpU6NW76Ho2pKY7ZjIsckfdGIAI/EGuCutS063mElvpohlBPzBhz+VZGr+Jri8TykeQIerM2Sat+DNH/tGeW7uFJgh6Z6M1b4fLfqdCVXFOy7K+v42Ompifb1FGl+n+R1miXj3oj2xtG7cjfwPrmustNJguB5l5clwB/q4h1P1Ncpq8sNrNpa3IZIJZgryKcFOODntWy8Go2MmYX+1W453qcOPqO/4V4tVRupxVk72v69zq5qj03sdnGLOONYo4nK46k1h6ppEdy7PHKFIPQYP51hxeJInXJlRiMg/OOD+NZ134oeOU+SYhETyo6n8R3q6UKi0irM5azjJe/qbOl3OoJqb2PMoUEjnkf/AFqvpak6hNcyzNO6nZsx/qvb1H4VN4Ph2aU2pTrMBcneN43Mq9BjAzg9elT621m1wTGGacoC+OjLnHOT1FeXWqp1nGK8m/PqephISVNc+pV82dXlfbEFzhRk5ZO4PoadqGoNcWvKlmQEEY5YYx0/KqjXEcxVVjaKQ/eUtkH6GmPcnaw2qxVcq5bGfal7O7Ta1R2pqOiLOl3DW8T5jC+SCUYrxkr1Hp6fhVfSIvt2ozSoCFAwZyPvH0X09c0RO7wAXBzK4y4B4z3A9q3rGILbxsCqLtA8tR0P1qpVFTjOy956f5mFaLc4voiNdELFWMrMVJKkk96swaUBnd1960YnbgbeKmx8wU/ePtmvOqVKq0kac6ZnrpiA/dyakSyEcgZeMn5iOTWr5ZHpVDU76z0+Mve3kECDu8gFZwnVcly3uRJxtqV9e0C11m1MV5HvUA7HU/MhPdfQ155b+DbPTNVlOpXb3ManMULDAA7bvU/pWjrHxN0u0Bj0lmvZufukqo+pP9K8r8R+JtTvNUl1K4lVCwA2xk4AHQYr7HKsFmU4S5rxg9r/AKdUeTi3QdurPXZH0WNQv2ZQCOoQAfpXJeKrPR5E32UMUU6nIZetcfp3jINxK6k1LdeIobtljgCvMxwFGDmtYZbiaVVS1OeVWny2PVvAWqLfaSFkOZI2KMCc4x711dtDFHDtRQVz0614R4P8QrouqyGaTNrKR5hHOCP4q9t0vWrC5to5YLmF0YZyGrxM4y+rg6zly3jLXyPUwteNSmtbNE11ZqYmKKF9xXn+t6xBo155VxKpdxkKPvAetdR4l8YaXplqzyXkW7HyRhss5+grwDWby71nWZry7O55Tu46ADoB9K68ky2eKcp1lyw/P0uc+NxCprli9T1ixna9tg0CK6v/ABE8Vt6Tpk6A7mBHUDbwKy/hBaW83hwfvAz+c+R/d6cf59a9EWEQEbQMdRXDj6vsK06EejOmlepCNR7tHNX2m3IXfGIhngg+lebeKfAa2V3HfmYGyuiWBHUN6Njoetez3bB0Ydv5VzsulLqkd1p0pl2yKXiK9FcdzTyzM6uFfNF2vv6CxWGVaHmcp4e0WwjjjLQJNgfxDIH4V21vHZRxD5IkAHcCvPpNYi02SS0mzDcQko6HjBFZV94oJ4SQ4x2r0vq+JxE+bV3OBezpKyPSrn+wPNPnQWxfufKWivGJdbmd8/M3vnFFd6ybFNbsxeJo+RzyFSuQRULzxA/eyapWBLJtJ5FMlt/9JGM819tc82NNPqaGQ4yopMY6DNSbNsYwKkiAx15pXHGF9jU0HwxqesFWtLfMbf8ALR2Cr+ddmngKz0qPzdUkkvJMZEUJCoPYnqfwxXEabq19pr5tnzH12kZFdZp/jmVikc1vlzwACOf0rx8W8ap+78Plv8/+AaOMbW6mXqNutnc7rO0SJHPGQeBnpz1pmpLPG0U6tFHIOoRuCM9qm8Wa5HqGEABccfKelcx5ZkCh3YEdBmijQlWSlL8Tk5bO9zcu9Qkkg2zROzDo6qTmgWck+kSPt3BcuhHp3BrKgLQsGWdxjsprZ06/vLmaO0gTzXkbAXOSameGlh1zU0rLU0UufQztC0efW9TitLcEL96STHCL617JaaXDp2nJZ2ikRgYGepPcmpvDmiwaPZlI0XzpDulcDq3+ArTZcsPavkc1zeWNqKMdIL8X3Po8JhVQheXxMydS0uC9spYLhA0ZQjnt71J4K0mQ+H7Zrl552dc7pT27Ae2KxvHWuxadp9zZxyf6XOmwBTgoD/FXA+GvFWqaJcRQ2d24ty4Bif5kxnsD0/CtcNlmKxeCk4O2t1frprb1/GxlVxdOlWSep7edBs0OUtoVPtGKfDpVvFKMRoOedq81z1l4tYZN1BJJMM5YHAIPTj26VTv/AIgpp8m4W8zsBjDAHP614yweLnLkWp3e2pJc1zvru+SyjTzRtzwqA849fpXO3uoxXG+W6mjSNBuZjxgD+Vea3fjq41W7uAkJWRRndI2evoB0qC2lvdXuIrNpC/mtgKeAPfFd1PJZUdauj6jWMhb3NTqrPWbPVLi5OlrLLDEwUzMpVXP+ye+KmWdoo5zIGaNMHA5Zc+nrWlb6bBp1gltbqAiZ7fePUk/U1PYWuL6OTaAwBzmsp1aV24LTz3NE52SluZUczzSwJCCok4LMuPyroD9rtYAYAJTj7p61ajKPeQxugMituNazzWqMAzoDnB74wOlcVTE2krQv5DnT51a55Tr3i3UUuPJN1c27p1SO2CfmWFZS+LPFElz5VpeyfPhhhF4HucV0PxNvk1OeCz02FPPhOWuG7L/cz2HOaxLW3m0+NDcwl1IDEjG3H1z0zX1mFnSlh41HTV30dn8z5/E1PZScOdtrqbcH/CS3cHnz6lcXJIxsicKAPoMZNeT+KtTu7nVJI7sTq0R2hJgQw9yDXo974mMFqy200SvjAVT/ACrgteu59RaTdIskzgb5GxuIHbNehlcZe2cnTS9NLHL7S9m5NmTZyEOprSuYftEBX1FXPAE0EGovHdRIxYDBcZxjr/n2r2O10yynjXzbeGeI9igyK6sbm/1Sr7J02/O51Qp8yvc+evsCwxkZ2nucc0ya2uLIwGBGCXERdHT+Jeh/LHNe5618ObC8dbvSz5bqcvbSDMcg7j1BrmjZ2+2azuoPKMJfYpH3Seo/EGrhmtKsk4fM5qz9k1dHn1vG0kQzmmPHJCTsZgO+DivaV8BWF5ZWMrNJbymBFcRAYZgOpz3qpqnwzi+y5trss4LEu5HI4wMfnzWEeIsDJ8spWfodU8JW3itDxSebGcqD7mrtlfmCEFkBDDODWtLay6R4rNtbkKrqyKWUNlGQ+tc/dAbdo6cAV6XNCtZJaNJ/ecUo23Om8G+M5tF1UOrslo5w6gZx6HFfQWj+ILHWbESpJlCMhlBIP0P9K+UYYgDk9K6Xw14ivtDfNjMRGTlom5Vv8PrXi5xw/DGfvKOk/wAz0cHinS92Xwn0tNGnO1gSPQ5/Osi9HlkSghWQhhn1rgbL4h2UkKpNbSWspOTInzAHIOffoK6I+L9Fu4g0lxGnGcNg5NfGzynF4Z+/B/df8j144qlJWUkcj8SNP+3A6tJktkRzOhww/utjuO35V5sqsgKsSwHfua77xx4ostQsha6aWYOwLuy7QAOwFcNkYr7/ACOjWhhkqqs1sn2PncwnTdVum73/ADIi0v8ADwKKVpcGivaPP+RnQ25SQFTWgsAYhiORWM91Iv3a19PnLQAv1pM1nFxVySQhRz0rNuLny3yp6VpTbHXmqM9rE68H9aUSoVElYlt7wSKMHBqwJFwGGd3scYrIhj8tsDpV1XCYyabJqO7HtbngxfIfapY53Hyzpn/aFSQzRtwDTpduDjG7tRtsZN9xFg80gRsSScAV6/4A8Mpo1qLi6QNfyjLE/wDLNf7o/rXnnw7McviaIX7RhI1LoGwAz9h/WvbEEhIOQv8AWvj+JsfNWwsdE9X5+R7WWUF/Fl8i0AMYrE8V67baFpjzzMPOYYijH3mbt+Fc74/8UXOnItpYuiXLg7jjJVT0I968mu7y5vLqWS+maWWTq7HmvOyrIJ4lRr1naHbq/wDgHTisdGDcI7mjd3s2pXMt1LKZZZTljVKPY7HY4LL1x2qrJK0MbMn+tXjjvS2V7FcXCmaECf8AvDjP1r7qK9nGyWiPAkm22ek+HNRWaGMSAE42kk9KXxrZo9kZYl5UjOP51z1pd2ywxxLAIG53SBiwkOe4PT8Pxrcu9S8u0eylAeVhkMD8rLjpj1FfMVYOlW5oLr+B3wlzw3Oe0izWVZrgN+9UbZF9fQ16J8P9IKK2oToQx+SLI7dz/SuT8FabPeazFGiBopg0bEN0AwTkdq9tS1WJBHGoVUAQKOgA9K8rO8W4Xpp7/l2PSy6nzRUmjJWPzRlkZOTw3XrV1LQ+WOgkIPTt+NQ6tLFZwbxjfnjjv3JrnE8VTRIQM78/3V/KvBhSqVleB6jlGL1OnvHSwjLJgzgZLHGFHv65ri7O81bXLppWdorNcjbGR8/0xXJ+L/FWozzLp6Ew28/LHO5nHfJNd18PLy3OjW0ZIXK16ksBPB4dVppNy/BHnVcQqtTki2rGX4m0R7TTHudLUpJGNzwtz5nuM964C71G5ktIzDPMYMZRehXsy/ka9z8R25ezPfgqcfoa8NsmNrf3aFC8aucr2Kk/zFevlNVTjJPVx/E8nF0kmmN0XSbi7nJdmliU43L1x24pPF1p/Y0kUcsbDzQWjl4IYd8+hrq9E1iwtZN8bBCeoxR8Qb7S9d8MSW9u4kv4WEkKxqWbPQjj1Ga9GljJ/WFzRdjKFFWu9zzO1nHnhozhgcivV/BviPdBtbDyKOIycbgO31FeLabvE5U5zW7G9zbTo8OQQc9a9TH4GGKgr7o0VTlPedJ8VaXcsqQzCCXODHMNuT6Z6fjVPxlBbXESXaBPMJAY55IryeLUVdy0waOXqeOGrYstWLxbQ6uq9Buzg14MsDKnLmhpYxnXb92auj3KziU20IHTYv8AKoNSjESqOfn+UY9f8iq+kX07aTDcbTNlQQMFWAwM8dx15qXWLtAWKsNixLLvJ4xnB/nXw0oSVVrzPqoaxR5R4ssVXxVps7xtIhXYSh/iBPf1xWxY+FdPPhxLO5hVmGd0wQbtxHJH0zgVtXJS606CWKGJg6KWWRc4bJwfryKVMy+RblmxG26TK438Zz7Cvenjqrpwgm1y/pf/ADOeOFipOT1ueQ64DEl0HsEjkWRIkcJswijHKgY5yuT3Nc7NDJFcBSjrn+Aggg/SvaPF2kbbl5lZPMlUO4k/1a7TwT7Dk47nGeBXCa1q1ha3EkmnKZp5AC97Oxdy2Odo4A+tfW5dmPt4L2cb3/Db+vPseRWoeyleT/4JyqybcA96nmOxM/xdBT5Xe9vPtEu08A/KoUcDjgUkVtJqGpJbQ9emcE47mvYcrK8umpxVEpzSiUnlenRyMetBibuOajPymt0zJonxnmimqx20U7kWMaNGd8MvFWlmKOIxUtqmCc81TdSbskdqk2cuZGsBmMA1G0IA4quLh1wMcUPcMRwKDKzHSIVXjrVbZKevNO8xmbmtC32svP40WHsRaYoVjvq9NgkY61EERgHUbQeozTlwM4NI2UVycwjIWCvG2yUEY+tX47jU7mILLfTjy2LBWlPU9TWdIZNmIyASetQeVcFgJCx/Gs6kFJ6oxjJpaM0ppS0mHfe2MZLZNZtyGa6U9FFdF4Z8LXesRXM9qEDwDGGY/MeuB71k31vLDctFNGyOjYZSOQamnVg26aeq6FRi1qVLhnEW4cMlVROH++vPeuk0HRJdZ1RLNHCCTJdyMhFA5NUPEnh+40HVpLO4wwA3JIOkinoRUqtT9p7G/vWv8ilB25ug3S5YC7q4lGU+Qo2NreuO468V2ugtck2cMNvJdOzbGORtcEjAXuPcGua8KaHPe3kUhiY2obDuOBnHTNe0+CrOKzl3PuJhT92GP3fU/lxXz+eYylSXJuz0sDRcnzbG54X0CDQ4JjDGi3M53y7eQD6A9wKt316LG3YBmlm5JZlHr+FVdW1+CzwqspkIBCRnczc9fYdq4LXdcvJZZFaN0iRirxkYPrjNfFUsPWxc+ap1PcvCki14h1EXUhhRg8fXd3OD+grB1ZxbW7SPtVlxgnnqOgqdFRo/NRGO8fKQO+OM1la5bS3Qt4kG0tlzu7cAc/nXu4WlCMowbsupy4ipLkc1qzDluU1e6aYKE8lCq59PX9aseCtea2BhlfaysWUk8EelbPh/wzAm/wC0u0obgr90V1Ft4f0uGCSOGygjEilSQgzz716WNzDBqHsIptaHm0cLXcnUb3L8PimC70x4pZALgDEa5zvPYVxWmeGtWnvLmeeNbaKSTcu9xuA+gzXY6RpyW1jao8MfnwoE37RnjjOa1FiYkc4FeDHGLDc0aC36vy7Howw/NaUzj9N8DabazebeNJeyk52EbUH4Dr+NdpZ2EUFuVgVYgo+7GoUD8qkjiAHt3rlPGvihdMt2tLB83U6nLqf9WM4/PrioVTFZpVVPmbb+5f5GnLToRcrHkGrxQReIr1bRg9v5zbGHQjNTxJuYZHHpUmiaVJqetR28e7a5yzhSdo9TXqWleCNNtZD9qR7kEcFnxg/QV91is0oZfGNOq23b5nkQoyqtuKPLLuGMR9gT6VXt0NudyMQTXukfhzRo0KC0iCt/Ey8j8TQLLTro3Gl3EMDiDjYyAErjhgR/SvJlxPSl8NNtdfQ2eBdrNrU0PAmpNqXh7T2DRsqpskLkkqQO3vmqfiEG3nkgLO0YX93k5G08kH1HXg1zum2N/wCFjMumXS3EM7gJby/Ku49Du55+mK0b+8lu/Ka5t5be4UFXjk5/EMOCK+aq4aKxEqtJ3g/v+78Dvw9a0VTnpImnDR26S26Y2gfJnAx0/qTUtvcStAFiCuzHeCcfd6/jVBmk2RM1zIFTJaNAMPxgA5p1rOFjdkga4ZUO1AOp/MUnDTudSmndnS2OnSSxNc3BWeSRAxdgPlbqAB0PB5rxPxvYWtr4juYLXlYXww7AkZP5E16t4c8R31zcrpY0y5t2A3GScZVV9c0ybwHoctzLPc/aJ5pXLuTLgMSc9B0FdeXYt5XXk8S9GtErP56Ox5+Lo/W4L2XfqeL20YEY2jAPSvRvAPh2bTVkv7mPZMVDfPxtj65+px09K7LTPD2lWcyw2NrbRTgEh3G5gPXnn0rnfHmrT3MT6T4fikkDBoppQDjkjdj69K9DEZw8y/2aguVPdvt/X3nLTwiwj9rVd30R5FdurXM7J9xpGK/TNVWXca6z/hDtXihMkmnXbqB/yzjz/n8q5y4ge3nZJo3jcdVcEEV9dh69OorU5XPNlre6sQKoAxRTi4FFdehz6kMQwhNUWdFlOetX8HZgVRuLB3O5WwagqLS3JHWNXAklAb0AyBUxtiAMjg8gjoarC1cxbpPmfOCfarcDtGqJyUPrRclkDwkCprNR82D0HNTTLyYwOT3pLeLy1KdT1Jp7lJrkuQXU/kKqjktk0tmPMHmM7b/7vamXcgFzsIBUDn2q3ayICFP4GjqUpNwsOPA6VHI0mRtAFaDRKy5WookHnDdkqCMilKSRhFrqj1r4Q2skWgGabO6V2kAA6gcVS+LHh/Bj1O2T5ywjcKOWB6fj2re8PSyWeh20cULK7Rny+MDB5GT26frVW3e+vvGrpeDEKrvwAdrqMbfrg18UsTbFTrxeqvp5dj03CXs4xcdGX/AHhZdG04S3Cg3kgBlJ52+ij6fzrL8e+Hv7a1HSwTjyZGEjf9M8ZI/QfnXopcR2mGwrEE471zF5MsmoxAE/fI6+q15k8XWVV4lP3tfyO6FKNlT6GdZaLaWaH7NbLCrdVU8U6RJlQjcqAjnaSa0pGTO0HLYzj2qnKy5CjqelcPtZ1HzTd2d6go7GLdxgMWcuzngEAdff2qnJ5is7Hn6nk/j61rXEErMWyFAPGOciqrJnO9Bk5A3LkfWuyE9BSbRAU3JCVkPOC+04K9cBvrjt+lUtSmUywlnO5QRgLk4+gqjrMV3p67xOSrN8m7nmrel2E0+2WQlmbnPoK6uSMYqo3oY+05/3aWo+HWrKCeNH823bAz5qnDe9dhZSJLGGUh1PIZSCD+IqjN4atNSs0ju1fK8qynBU1y2q+HNY8OO9zot5M9oR86gZK+5XofrWXLhcWlCE+Wfns/mJurR96SvHy3+49BaRUUszBVAyc9qytQ1+0thh7iJIypy+/BH0FeSX2vai/mQvdSsjElgDjJ98VmmSSbIIOPevVw/DN9a0/uOaWZ30hE67xN8QxBG9ppRa5zx5s3RR6AdT9TXH6PLe65q4iDGa7uGzl2xk/U1malbEvlPxrqvhPp/m6vLdkxE2+FCOm5st3Hp0617Lw9HLMPKpSWqW76sx9pPETSkeq+CfDq6PZN5qn7ZLjzjkEDHYe1dQieWM9BTogCo4BPrVhVXHzYxX5visVPEVHVqatns06agrIq+cju6BWBUAkleCPb+tcZqEITXVV5SCIwpJbnaCeT9VxWp4rnk0nU9KvbYnazPHIpOVZcDt61zHiGI38RntpfKmAKoP4SvXb7c5/OvQwFJJqd7Rkv8AgHBjp3TglqjXeSC5v9P+yvvInBUZ4IqbxDeQTRq0M6KwJ75zg4J/PNcHpl7dRTIFkSKVQdrO3Q9DXeaBo6ahbLezRgZbEYAwuBxkevOa78bQhQaqzei2/E48HUnN+zgtd2YC3lyECyWr57EHrWv4TvI57uSFiI51GDGfvYrpRpsK5DKNw5rz/wCJiHS2stUsGEUqMUZgcH1B/nXNh5QxsvYR0ctn5noz56MeZapHqdraZB2k/TNWPsxXlhwBya5DwL8QdI1bRomv7+3tNRjGJ45WCZP95c8EGmeJfiLpdpFJHYypdyngMDhPrnvXlvL8ZKu6PI7ry/U6/rNKMFJs0PFXiJNN0oIFRbxwY41XqSe/4DmsPwtGI7ZX81ckEtg5Oa881S5v9Xna6e6jlnHIj+7ge1T6feNalVnuGXKhiidz6D+tfR0snVOjy31e/wDl6HiV8fz1OZbI9o0bX4rqDcjhSpKlCO4NRa5FpOsRMmq2MMwxgSIMsB7HqK8nm1xIC8kch845ACnCr/iaoT+KrntNJuPTnpWsMqqqSdHQyp4xTjaSNzVvh7bPeM+m6jHHbMMhJcll9qK5OTUrmZy8k8jMe5Y0V70KOPjFL2n4ITUHrYyj5Y53CqtzdpGCE5NEVoXBJbao45ok0/eeJQB7ivZPOSinqynbXoWbMgyh+8K2re7hiy6lfKbsRms5dJydxb8F5okRonOEBXbtIPSs5JSRTtI0JbiNlLKpA7EmmRuojeXqq/qayHmcuEd9gPRVFXYwZIzHu5xwPWiL5RclkUgS7szdWOat2wOMZwR0qfSILWS6eG8SXfIuyIocBXJ4Leo9qLq0msbt4LiMpKhwwP8AT2oU05cvU2s0uZF7Rf8AiYXUtmgP2h4nMOT1dRnH4gEV1Pw40trh11O7jWSJCQiN/e9cVzOkQXH2sXljE7SWgFw7KPuAEcn2r2TR7a2jgWO2BjSfM6oTkZbk49OtfPZ7jJ0IOEH8X4d/vVvxPQwNJVpc01saEuowtEkcgKseOTVeC5DXySiMBRlN4btnJ+lZ08sJkZUy5yU+YEcg8/z/ABrn/EMj6bCkRZjPK7INpP3PT6818rh8PzTSW7PUxD5abZ6BqepA2oZG3bzgEHOfSuK1zV7m1hSa3AFwJP4uQPUn8Kp6dq7W9v8AZSd3lHaoA6ev61dsPD9xrEqSXJdUDA+WR1Gf4q6YU4UJc1bZficClOppT3/IZ4fm1fVJpLtpEhtXIBcrlpMdl9B711q2ysmCNw96uReH4IoCF2RxgBflGBwMf0qKeA2+V3vJk5HzYx7V52IxUa87wVl6HpUaTpxs3djRAuOgwOAKpXEILlmHA6VbtxMJEBkaRWLblfGVHXOfbpVDxZfxaRos11KenRc4LHsBU0YynUVOOrZrUkowbfQ5TV3Gu61ZaRbK4kjO+UkYC9P6fzr0e10uK2SNY02qgAA9BivDfCPio6J4hGo3UTTxTBkmUctg8jGfQgV75pGpWurafHd2UiyQyDgg9PY+9elntGthFTpJe4lv5vf/AIBxYCUKjlN/E/yFMSqOKjOAatJGWfGfpU62IK5I5r5vnS3PSujzHxj4EjvGkvtGUR3R+Z7fosn+76H9K8vuIpIpGjdWjkQ7WVhgg+hr6WktiFBU9a4n4g+GY9SsZb62jC38ALMQP9ao6g+pHavrskz+UJLD4h3i9E+q9fL8jzMVg4tOdM8TuQWYbuB61c0rUrnR7jztPcJIRg5GQR9KjwXVjgEjoTyKhUgsd2FYflX3E6cakXGaumeJOq0/dO8sPiZfwxAXNlFNg4JQ7fxrZT4ls4xHp53H+9IBXk9xI0QQqcZOeO9PuZ/NlSOHIBALV5FTIcBN39n+L/zN4ZhWUdzt9f8AFM+u3du0kfkCHhY927PvRp97uEiSZ2+/8640ypE7fPz6H/PFSSahcRK3krvbAHXrmsamVRjFQpKyM3XlJ80t2bVzqC2+qQz7Y5E8wCSPGfMHQ4rufDOtT3viEPCnl2kEJxCDtDjgbiPXv+Fc94N0A3kBmuAhkIyDjOPat3UNKbRbVb7T2AYAeYCeo7kV4+NqUKj+rr4krX6HRQVSmlN7Xu+53kkqSx+bG25GG5T6ivF/i/qEcht7VSTKrGRvpjArv/DeqS3UbrLypBGE+6pwTk+9eK6/K+p6hcXEh+aRyR7DsKOH8vaxUpS+x+v9M7MViE6Sa6nO2Cma8SMdzW1qgDRGMemcU3SbIQNLcP6bR/WqFxNI8jls4Y8V9tbU8hS5peg+yv7hQkRbOw/Ix6qPT6e1dZpNu2ryoyYinX5QQcZP9K4eNiJgcV12gSY+VX2uTkc4zXPioWptx0YqsdLo7W28DSrEsnkBs9Rnke9Y/i7w4uk28czQzBHONynhT6GvQPCGvTBBbaiuFXhXY5NdZfWVlqmnvazIkkEy7SBz/wDq9q+cWPr4er+8d0aQoRmuZaM+dIvIKDLSj8AaKteJdNl0PWJ7GYE7DlGx95T0NFfUwkpxUovRkczWhifbkSUqvKdOe/vV6OaB1GcrXMwh2l5U5rZtY5JVVUUsTwABkmrT5SKtOLNHdCBkTCqk9zCeMlzVrV9Ku9Pgje6t3gLgfI45+v41t/C7RrbVPEJW9iSVYYzIIpBkMc45H41z4jGU6NGVe90uxNDD881E5EqjAsoG496ZEjbsrnivpHVNA03U7LyLmxhaMDgIoVkPqpHSvMtd+GWoWrtNpDfbIeojziUD6dG/D8q8rBcQYfFJ8/uer0+876+AqU/h1OMto0uJgsswglAyshBwT2Ht9a6uLT21vT0hu2jXUYlbDHgjB6N9evGfUdTXH6jbXdo5iuYpInHBWVCp/Wt3RNdtLeeAKrwiNVAErlwSOvzdQD6YI+ldWOVRxVSjq1qv68zPDKCfLU2MVJLq1upYw0kDKSsi5xnHUEdx7V7b4etktrSBxmVlj3Rs67S443Lg9OOn0rnb7TrTV41uIolkc4Z1BGTjoc/T8DXUR3pntfOKMiiTzRHgYxgAj6DFfN5vjfrdKHKrP7Xr+fc9XBUPYzkm9OnoYyzOdn2eBVUXGZC55wQOAR16CsnxR+/v7ZwrB49xTJyC7HC/kATXQzhUfcWIQ/PkjGPU4/OotJtjfal57yNEtuxZHZQAOgGAfxPP5Vx4eooS9pbRJnTio80OVPVieFPAz7Vur6c4PKp6A9/rXotpZW9lEiRgBVGAKgjZYolMsjNj16mqstxJKflG1P514mKxNXF1HOT0Ko0YUI8sTQdkkJ6kDpxxUDW+QWABA7ntUEIkYcdPyFOuUkQebcXOxEGSM4AFc1rO1zdaFSTAkxtCknqOprxz4p65/aGqDT4HBt7Y/MR3fv8Al0rZ8c+PU2zWmiSBpCNpnVsbB/s+/vXmaqdm9yN3ck5ya+4yDKJ05LE1lbsv1PFzDFqS9nB+pYsrL7XIsStsJG7Lc44rpvC+o6z4cmkgQM1lIC7IOVbtwRyp96xPDCJNqsLSy7IFOJAeCR2/A16Z4i1XTrXSIGsnjebOAinlAB/kV6OZ126n1dx5lJfceZTlKN5xdrGpoPj+3ma3F1azqzHazjDgH6Dn9K7UeJdLSEvJdRqu0N83Bwfbr+FeN6Rqmn/ZZgiogbLtsT5jkZwPTmsPUNWKyRvGxMpy2wrjC59fWvnq2Q08RUtTTidlLM6i0nqe53HiTSkO1rtSCcF8fIvHUn0964rX/iJpgiurfTl864YMgk6IDyCffjkGuLtPFYS3dZLBHRgVb5sZ4xXDOgt7k7eEbkV6GWcN0oycsRF6Wtro/uNquYOfuwZqqDEcZyppsibuQM+4qFJjGoH3gfXtRJdBRuhYjsQBk19geJJO+hWkZQdhO5SePY1LENrfu/mf+I9qkEYYiW4jRTjjsx+tMlLFQEUIn86i/YpakdyEyXXPB+YDmrFm6pdQ7wCjHbx2rOlcpIxjJHb2rSt3CxRyOVDetTKnzRsDlyno+jaqNPhyg3ALkhf4gOw96sa34liutKXygsUxjbch5215mupyJJstpW2nrz0p5uJM7pDnA5rwFkadTnl0Z2PF2hZHYeFdZkbfbzumBhgo4P1yO1cvrljJYXrwtsIc702nPynpVRLkJNHJGwVwflK962b+9h1GwaSZo4Lu2XcoPSYdwD6jrXfTwzwtf2kF7kt/J9GZ+19rT5JfEtjJmxHb7fwx61QnJeFwwBUDIwO9WDkjk9DQYwYyD3r1krHLDRnPSSqG56itTT5DJmIH74ypHqKgurMZ+ZOvQ4qW2gMAVydm05GetDV1Y65NNG3pev3sA8p2Eirxh66LTvHN5Yn5Mlc/dbkfnXFTMrZni6OTkAdDTIXZia4quBoVvjiTGbWqPRNQ8bWuoypNdaUksgQJuY+mf8aK4iP7o4orNZXRSsk/vZp7S40LHGwdR8w/EVs6I8dqvmqo3E8ew9qp2Vk1/OIoiinGSxOAo9TUEcwibyi46YXnrTxaVWPLF+pzUrp3Z2cV99uYpfIJ424IbqPTBqn4buINA8XJcLI4tw5jI6khuDn271hQaqls+DINx5FVDcme7nkbjc+evNedh8DJ89KXwSVjplVs1Jbo+m1iz93lSOaRrNRK8oyWYAHJ6AfyrhPht4rjuLSLTJ1YzxDg7slhkdAfrz6V6XGy5xnPtX59jcPWwNWVGf8Aw67n0lCrGtFTiZFxbRTLsnhSTHZ13fzrmtR8M2d2QZNNsEBPZBn8wBXetHG45Aqpc2qMpG4gVnh8ZOk/ddjSVOM90efDQk0xCLOKFY2GGTLNjnqp7dOlAdoyACA/8RJzuHf+lbevT2tlGZLqRYYEPzSOcCuHuda/tG7SXSoWmgBxvdcbh0JA6ivbw6rYqLqS1Xd/5nLVrU6L5DYRU2kZJLE5UnIxV7RtlxcyQOx8s/MwHQn3rn/tsspMcMEizHjLDgVBDqdxo0xjuVTf1DEkBvetVhp1U4x3IrYqFOzex6jaxM4OWVQP4m5rSjtIRhpG3nrXlz/EWwtrZ1eN5JumxWBFcxrPxLv7iMR2kCQnH3y24j6DpXPT4fxteW3KhPMaUY3Tuex+IfEmmaHAXu5hGMcDHJ9gO9eFePPG9/4hkMFqzWum/wBwH5n/AN4/0rl9S1G71C7ea+uJJ5OmXbOPYelRyL5cCsxG709q+qyvh6hgmqk/en+C9DzcTmE63ux0RE5EbBwNxxzmnwXbsGARSR1B4qNJYpQeoYelTQopUsoyO9fRWtsec/Mdb6h820oVU43YPIroktbq6tYZUK7JeVB4JFcxIiYCoCpXrx1r0f4cSW+oGyt7pQz2u7Ge6ivOzKTpU/apXsXTim7GOllJZ3EeYnRCuDtOM98+9Z8lxbu0kbKTk5Bz909x+dd3461GxtUZYzG8/wB0BDkL6V5fcSGOclcHB5zWGXTniIupJW/UU6KUtGWoI3eNliALA52+vtUNzYz3EQKRlSDkb+KWC8VZAsXEhyeanLSzD5pDu9K9SLktEYu8XcjNskaqJpQCOy801ZI0ytsmCerHrTZ0KHI5Pr1oVpSvGM+uKdm9xeYyWCWQbvM5pZnYw5AyR1Ap1zcbLcjgse471Rm82G2DsfnI6A9KteRSTe5HnzI5QY2EiSDr3U1KQHjD/MGBwFJzmm2MbTguXJbGHX096bqdncmEyW7nCDLL6j607Mel7Fu3hYKWTBbsKr3st4inLcey07R5i8Y3HBrTn2mM5wfajYbjZ6mZptysgCPEVf8AvE5Gauzsblli+UKvPTjNUkGJGKDAFR3Mp2kRNiQHGBR1sgcNTSDHJRlGR3z3owf4n49BVWwnkI23WCMcMeDV4CPH3h+dWkZNWZXldzgJwF6ZqIQs33zVvfGDwc/Sjdn7oxSdhpsYI1WNV9KRQqnjFNuJQq9eapLMd/BpI01tY1AeKKrpLletFaXRPLITTbuS2kDwp+84+/8AMv61Hqkr3Eh5Q5P8I7024kcp8zE+1JCFcAPwpPOK5uSN72NJXVrslC20cSN5ZaXbgt7061iITcoAjPT60nKSNFLyD91h3FPeN7cfxH0PUCm73tEUbW1JVvpLGWOSBykyncGU4IxXp/h34kiKGFtXhSWYLsE8RBYL6EfhXkTqZFUnk5qdBtDKEAFcGPy2hjklVWvfqbUMRUoP3GfRUfjXT7uzaSxu7MyAAqs8mwn1DA9PrzVWDx1psriC+c2k5HKhlkX8Cprxrwx4ZufEV+tvDlY15kkJ4Rf8a9Xs/BOmWcIt7KBMA4eVh87H3NfH47KcFgn7NttvtuvV7fgepTxtWouZK35f18zjvHF+3iPWo4bR3Gm2/wDEV25J6n+grtfD+kQ2ulwsqgs4BxjoPSsLW7Ozs7lLexkLNGy7wD055r0B0OAYx8oHQU8fio0sJToUVZP+vxIwkJVq8qlTdGJJLbw3BRbQM3Td9az/ABJo8Wt2PktH5ci8xSD+E/4VtyW/784OTjNX4IsKAR04NeVDFyoSVSm7NHpyw8ZpqR88a5pNzpF15F5EoLDcp6gisohNxbjgdjkV9CeK/DttrFk0Eyqrn/VyAcqe34V4LqGlvZ3ZRYyHjcxyqeoIPOa+7yjNI4+lrpNb/wCZ4OMw31eWmzM4bIk8yb7xOVXvU+cRR5A/eZ3DHaqt9AwundhgHkfSp9/mpGdpUivZWpxMhgCQSzID9TVi3dVYcEK2cjOahu1fzI1wBvbg9Kn8nZE6BgWwevHNU9dAbuUvt2JdrqNmcA9xWhFdvAk/kyMjrjaVOM56isHY4nVXBB3DIrTYZ3EgjIqXFSVmA+S9m2o0h8xi+CWOah1Cbz7hygKqT0qRk2IFcYYNwKSGAs4JpqKWwXEaEhzICfkQ1Jpc9zJbhpZGyD35JFWYwu2Ruq4qosYMyybm46AdKUVcNGrM1RIOjZz7VFKvmZyxCDrSwsznGBjuTUF9NxtXpTlZaIzitSCV2MyEAKg4UscCkdiCRL1zzVUo88i56A10Gi+HrnXb1ordlRB96R+gqZVI0oOU3ZI6aavoULeAI4dOhFO1GASRK7M2wcMoPWres6Tf6BfNbTJvwMgqOHHrVe2vre5BibKSHgqw704zjNKUdUzGcZQldGfaw+WS6sSnYd81amd8BowSPQ05IzHMw/gapoAoY/MpPpVsftHuyMLsgJI5xn8awDG6XO5m5JrU1O9VbkQKenLfWqFwzSZMakkegoiuptT2u+pdcEw5HWq8F0wbac1NZsZIwD1xSPZ4fcBVMJNbMlaYDnNTpOCgINZ0sTk4HGKtJG4jGakiyKt9KxJ6mm2e5hlhg1YkT5SSOapi7WFyMjPpTZvFJmrHG23iimW86vEGB60Ui7IS5OBnrUdsxZwKWJfMQAmmmNo34oscRoyPHs2SE47EdRT7WXeDGWBYdD2NVs7owWHNQSSxw7SSVYnjFJrsRa5fnG1gGi+XPUHnNLGnmzhYxuDEf/qqjNJJcJvRiZBztB4cf41teEbuxs9ctbjUSywRkyBeu5x0B9qxrT9nFzSvboXCN3Zs968F6HH4f0GKNyPtUo8yRsd/T+laNxewqh3EGUg4VTnA/pXnmoeN7Zw7i6Ug9UgGWP1PQVxus+O7xsw2kYt4z+JP19a+PpZdicTN1JrV7tnpyrQglFHTeNdVtbYHOJLstlEQ89e/tXpPh66j1LSre6i+7Igbnt6185GWSXFxM++WTkZ5J9Sa9m+DWpefos2nv/rLZ9wPqrH/ABzU57lfsMGqkdXF6/P/AINjfL6zlUaezOz+zD52xz0qaOIKTx3q2EBDUvkgOW9SM18V7S+h7bVkZ91GHhYEcV4J43Vn8Zao9sgjhDLuBPVtoyfxPNfQdyMLjFfMnjO8F94k1GdZGB85lAPHA4H8q+s4Ti5V5tbW/Nr/ACPIzX+El5ldpLWZyk6gMOMjg1DcWMkY8y2/exgZwvX8R1qrKpkgjZ2VXBI5PUdqjNxLZjLy4x0Hevv0jwLditceY1yPMydq5yavRyLPHgnD9veoF1mOb/XoCehLDBNORbSUARSPExPG4Z5pp2GyGTdFMjOM7SCD1q/PiTy2Uk55FVrhJIlP76N2HUDmnx3FsUVWEiY5wRwPxoeuwn3HX11/pOFRWYAAsfWmwTyEHCIfXillayUbkbLf3QDUsNzDJhEBQnpxTF0JbdAbaQouOvBOeabDGS23ALdz2FWLVd4K4x9akIA+SPgdz61CdtiXK2hBPIFXYnT+daXhfwne+JGuJImWKCAZeRhnnsAO5qgwQDjk17H4FltNO8MJat8k8wMm7HDk9efUdK4MyxM8NRvT+Jm1BRlK0tjyzVtJayW1jkjCTR5jY7cbueD+Vdz4AeGEy2sgQGNd24cZ9ab4skh1DWbZjgRhNq8dxyM1cuLu0kgW7ESJcJhSVGN3Y14+LxLr0Ywmtf1HD3ZNxeiKnxVtVlt7a5j52/KT6g1xtj4Svr+3e+tbdXMIHGcO3HOB3xXT65eRXOkJbs+fmKg+ynNdX4OmCWKxEfwqR7HrTpY+phMNGKWt3v2NFFVaj9Dwu8YmQp2X7w/pUNiCblm7KOp9a7r4laJFpmqy3tntEV0CXjH8D55/A9a4wBPsrKitzwXxxmvo8NXjiKaqR6mEo8r5SrLBYQOZbqTe+cmmvqMckbJaJsUjG7vUc+liZDmb/wAdqvDZPbTNCzBsYORXQi1yvVu5JZybXArUEgxzWcsJSXpV1gPL96rYJLm1JRtY9qZcXCRLzgUlsO9U7+0ku2KxsFA7k8VFyYpdSdpUmhOMVzOpREXJK55rTsUkiLRS8MpwRUOortcHFUdEFYsae5FqgPWimWrAwiikVqX4mCOAOecYqae5iB27SzAc4OBWcfNilVgTkGrihZRlAD7Y6UjjYhv1Vf8AUt0z1qvcSrdEbF2lPU9amkhAByozT47DgOVKHtg0rBoQw7kzg7QPmBq2LtHUAqS3dsU6aNRbnzEAVepDdaihgDMNqHA9TQlfcEx1xK1sIpImO1idwbvUd0/mzgqCQQMVYM8O4xSxhoT0OP1FNay8tfNifzIgOMdR9aQX6snEpQKXGWA2/lXReBfE39heJraeVyto48ucD+6e/wCBwfwrnrUpJGFPaqFwD9tkGQoU8k9BWOIoQxFOVGotGrHTTqeztKL1R9fW9wksSyxuHjdQysDwQelTNJjHcnsK+ZfCvjjWdBQ29vcebbjkQyjco+ncfhW1qnxI1y9VEi8u0fpvjzke4yetfn9ThLFKrywace/+aPdWa0XDmejO/wDiN4wGkRTWcOVu3TKSK33Qe/8AOvn+VnkuXmbJEhyfWtC6d553eVy7uxJZjkmqM88eCI846E+tfZ5XldPLqXJHVvd9zw8Ti5YiV3sQXL+Y6KOiClnmTy1L4Zscg1FjqfWobiF3DMuAAMnmvVOdMgZoS2BHlv0FatrG05UugAReMVU023QODL+VaGpb4rbzYGKFOcj0ot1CV0SpEFB3d6zLqMx3rCInBAJGe9XtOmuJIS9xglj8vHarAiRmJMa56k4oJvYz0jzjeBirtlbQtKHcquOnrmnPsHyoo3UqIN2doz9KVhN6F2IiPcxIxzVUXEZY5cjJ6YoB3B8n5D6VBLGpwyED6ilGIrdzX0u5jWOR1AbY67ty8FTkH+ldzY6lcWjqLeQeQPmC8cZ9j+Fec2T+S6CQ/u3Uo+PfvW7JMzwRndhggU49Rx/hXm46jztEPTU1Nb1lbu/LiNI3AOewz61Sa7LWzpu4zn+tZF+8RQSENuHDA88UW8P7t5PM/dkZAzzj0rm+rRsmaLYlluHmnGw5AHc8ZrsbLWvsps54CGj+ZZF9elefWhZ5Jt2cEgqPQVZM7IGVcg9uetdNfAKajpt+pCm4XSO/8VS215p8sxcMQmee/HA/SvPrydNP0dJJIfMfPRRwjN1/IAVM09zPaoHDbchCR1+laNj4fvNXklgtYphaqpkk84bCcjnrWOGisLDlnLS9zRxdR81jkor7z0/dIE/WnW8O1izHJPJJrdvfCMun2cl1E8RiQgMgfcy/pWSDGJET+HIDc9a9WliadZc1N3LnBw0tYjlCnp1qjeSPGDgE1vLpzSai0ECNLkZUD+tdC3gXU5rL9zHAvmDJLP8A+O+1TVxtClZTklccG2vdVzgdMkeXjFXpIyiYPU81d/sifR7mSHUE8p1PTrn8qfdoJFO3tyK0hUjPWLujKpKzsYxiBZZG6Ywfequo24mUFV254x1rSZQkAVidxPAo+SKIySdF5z/StC4VGZVvZtHHtYEEdjRVlL3zNzt1JooOhNkkkW5iR0rL1Ob7Mh2nDVqmVYo23kcVy11Kb6/2ryuaaRjGN3dl7Rry88wOx82Mdn5relvyELGLB/3qq2sAjiVVGKsGHzFxg4FFjOVm7lCeWe7ADfIoOdq0+Hz3DBpDtHGK0YoCmW4Huajk2EFI87R1Yd6LCv0RC5by8IQMf3ulQwXEyFgsiiQ9AOQaLvZGhZiQB6nk1z8881xNiPKjsBU2RaVzoBdXETElFbv0qJ5WuJGYKVYnJX8KTTnnZdk7BlHG49amW6VPMVoQ+3OGzjNDVxPQSCVllAVHYkAfLV/zgrgcq3uM1kfb3Z8hAoPG0VfiuCyrlefWiwMtxyeYSHAweoxVHUGjEipCACTkgdKszSLDb5XAkb86z4xulJ+83amJInVc4HpQ8ReIhTgHvT5I7hIv3UJdz6dqyoLubcQxPynDLQUnrcknla1YKCCetaltO01n+8XKnisYo1xOSOhP6VvCNQI0jkjVAMYJoCUr7kaSMTgHAFTbyeBmo5JraHjeGP8As80yeUiEPD900iNyzGnzADljUV9I8QCD5S3U+lVbW8CyLlj171a1AfaLgbO6ipbGlqWkx5KheRimkgjBU4p0tqwRWiYggciqyl9+HJwetWnoDiaKx27xKGd42A5yMinqfLXYk8cgHQZwa1JfDc6+GrXWIS8m/d5yY+4oOFYf1rn5U5BxXLCdPEJ8kr2bXo0EqUoP3uupcm3m0ZvJLFTl89hRlWsRJHlAx5HsOtafhYR3EU8FxyCpX8P/AK1Q+KHhgVIbcg4HK46L6Vzr+L7LqmRrsULVv3BkhAIJ4Pt3qOT5uSOP5VDYSCJDtyYwckex61alAJypyD0PqK9DYyd1I1fDE6rdlZeUQbvbPavSrDUre3tEYSgFz847njp/OvItPuDFc7SMZ4P0rXkumV0KsSM5xmvmMzwbq1rnp4aooRNLWbuBrqYwAxwSMfkPPHf/AD71wJGXLL0zxW1rNyZsbJPLK8lvSqVpZm4mjEbbYW6s31r08upqhTcpdTKtU5mdd4VuER5HcqmAoLdSa6C/177LblbeR2dvuqTXGpA0dzHFC4jDk/vW5GK1NZ0K4tNNMou45HYgbj3HqK8ivhqdSupTluKnVcY2icvrFzNezh5JcuOGbOcnNU4pGjY+ZPG0fQ8YNOu7Ywy4ZgWPXb0qFYVb619TSpxjBKGxg/e1Yy4ZVmZiTsA6/wCFUbyVpwqgYXsK1WhEsZjfA7qarXNuI2XGDj0q12LptXM1dPKcecPyoq+6fMeKKqw/aSMDXJpC6omQG4rU0rS0htFkPMh5Jq9eWcE7LkDcKmVhFGqDnHFIOf3bIakZxzUd0GWI7JSh9QadI7Hviq0o/dknk02RFXZiveyRXebmVpBnnntWzBdCeMeUFVe3euf1G1LkuDiobS9Nmdmcr/KktdjqcY7HQzRlziQDPr61VeCNXwBiprG8S6HvTL4AEYODSG4pLREMVw3noqqqx7gCCOcZrVns85wPasxIC67k5PepHvL1EC72AHQ4BP500c0k7jNTiW0ijLLmXPTtS6ZeGW4WNlwuM8VRmeSVf3zlznOW5p1ptSbL8KByRQHQt3U0sDO3EhByO/FT2GoSyMN8ESA+xyahtbpY5MnLnpkjrVjzFlbcxf2xjgUlcBLy7uSh3HywTgKvXFZit1L9uhrTu03jbxvUZH+0KomMNx+lG4IdbnJ3n8BV5iZ8GSNcr0qhIzR4K9x+VNNzOkZwcnPGaYyzcYRctwPQVds7u3jswkq53DoKxYZHmB80c+h71agiXILn8KT1DYnZElztHNX4VZPKJ5bHNUlcKSsQ5NXbdn2KX/h60pAemfDnw9Y+IIZpb8yfusL5anGc9yad4s+HE1lG15ojvdW6/M8DD94g9R/e/nWX4D8RR6PqsTvlLafEcv8AQ/hXvC7XQPGc5GciviM4zDG5bjeeMrwlsnt5o9nB0aOJocrWqPNfCGs/bdNhSVA0keYpVAAwOxx6etcV420iLTtU3WqkW0+WRcfdYHkfT0r1nVdNhs52vrS3RZWYGXA4Yd+PWsvxBbR6laeaIlkYBvKBHAyMZ/DFc+AzOFHFOtTVoS3Xn/wH+BtWwjqUuSXxI4vw9pMkNlKLvbbyxOxKv1bKggVyHiNg2qug+9gYHrXe6XDOli6XqP5+SzBuuQP/AK1Un0yzfUHu5EhIkbmJgW8sAjv2PFe3h8coVZ1Ju/p8jzJYXmklFW0OOvsG3tYLS0jieAYkmDH98c85+nSokJiT98VUZ4VeSf8ACr+qS20l8WsbdYIM4CAkjPrk+tZN3Eok+Vime45P/wBavcotuC6epw1Pek0xTOH3Dfhhzk9RSyS3GwMxC7fXvWVNbtHKTklegb1zWhEXURh/mJ7HtVSgpMpe6tBiSyH76lueuOtXoZpR3YA9R60qMoPPOO1Ejq6kFcg9s1ahHsYylfoRjUzaXcM4QGBSY2cc7W/z2rWm1O41EywpMpYfKCrZVfesiMRu6QmFPKySQBjb7/WqMsOHcwhomB+8vArGphYTfNbU0ja1kQXE91Y3hhushuvPII9RVxmaaIeWdrGs77PeXcqfbZXeKM/LuOT+BrSjVYvmY4bsPSuqN0tRv8SnClyJslyee9adxIPLBK5kPGPeoWdgjccjgHFRQ3PlPulO8r0BofkKz3Q+NZI1xIMt1oqY3NrOfM81Fz2bqKKvTuTzd0c/9rlWbfIxyT09K14rkMoyM1Sjt1nYMw+Ud6uC3WNEkibdE/T1UjqDUWubVeVOyJAA5yDRJGBGc1Tu5WhAK0qzyPHuJ4p3toQovcztQs3mOEJArNk0qZVyBk11cYDL705o+D6U0UqjWhymnmSCQowINPv5JWkXGcdK33t0LZ2jNVjZbrgZHyDmk1rc1VRSRLZq8Npno5HBqgxfedzvmreoTspCR9uKS1WSQZlAAHqOtIz5VLVsqko3Ej498U+OJWk2qPv9CeRTZFEkrPtAHYdqfuaNcqPn6ewNFiBluqyNkbQK0FaKBCSQSOwrO060CK7vnFTTSRL0GcetPYpR5noWfNhuQCT5Ug7mmTRBYsjBcckjuKqJ5cwypG70qSKGUNhMkntSt1E1YhyCoJ59BWlpVpDdSkzIfLAJKKcZPTrXbfD7wppmrRK2pW0sm4E5RyAvNbj+ARo1xLc2zedZA9+Xj+o7ivOqZnRhN03uipU3y3R5frmiS6Zcedaq8kOBuVhynGefb3quqrPCsijg17N4sjsJtDR41TfFGIz6suOR/OvJZLeTSJnhdCYnw6bh/CRxWmDxXt43e5MFd8rY2yIU4ZQOfvVeK+gqoLiNn5G0GnJIRM2OUAziu25pOLSLADdq95+G+qf2h4WSWORvtVqpjlX7wbaOOPcYr56aWYsW3n6V2nw38UtoOq/vP+PWfCyj0PZq8PP8DLGYVqCvKOq8+6OnA1vY1Pe2Z7ZFqcd1LFFMghMik4f16YrCnYW8stuVIjSQMoz2HBA/WtGeE+SsyyRNA5PmAc4HY/rWLcDDt5mMjgc/e/GvgqMIpu2x9KtVcbewxyhpS7BVRWA78joaxksvMjut52RAD5hyRkda2EG+1lXayOvY8gj69xVeGH978rs3zZHGB0r0aNX2cZR/rdM5alBSmpf1tYjsvBFhbwWrXF0WO0koVAHI6/Xniol+GdhPCskl9MG9ABjbn379K6rTIyZt9wPMbbwWOSPYDtW1GqljhePXFYTzjGU27VHd+n9dTP6lRfQ8lk+F12T8l/b+WDldymqGpfDzWLVXmiiS5VRkeS2SfwPNe4vCpj5AFcn4s1+20C3Ls5Mp+5GDyxrqwmf4+rUUIWk30t/kY1cBh4xu9DxW0td24Txuksb7XQgg88AV1Nl4cs54QJxIHbKqVP3ff3rJ1PxI2p3z3lzEqByEwvYDpW3Ya5BGEy45JC7a+nxdXFJRaXK+ttfkeDaCm+3Q5vULEaewVjzuKH6+tZ9rZXVxeFYFLK5xiuo1C3Op6sgHAJ+UMPblvpXYaXBZ6dGqW8IJUct1yfUn1pV84eHoxTV5tFUKDqNtbHGR+EQlrK13fLC6rlY1QnJrkQFR3BX94pxzXqevTSktNIEMhGExxgV5rLHvvZ2H3S5rXKMXVxPN7R3LxFOEPhKsjRoN87gD3rLvryJyqQjCjnPrVjXImllGBwoxWJ5Em4jPSvbSsRTjdXLqJFINx60VWVWUY5op2NeVdjUeQZIThB0AqW0JNuyHsdwqJbdmXJztzyaswgBCxGOKSOVkF3GGi5rMScoCg5xWjfTgRphcZHIqniMjIHNM0inbQdBcHPJq2Lk96oPGR92mhJT9PWmS0asc6E4bGakkcBPlNY6zuCVVR5ff3qdJSOSfl7VLHGN3ZEzeWp3EZNQQyyXEkgAwijH4mms+/kdDUlluWfCoCCOQaLA00SrAEUE9RzUZT1HPWrhRm64HtVa5YQpuY8nge9FrCWpJFtC7OPeobm2V0PQVFFLg5qT7SrShTyvtRfQ2UXFlSCyZZhWslpMQGhUllIOc9KvWT2bbR5TFzx97g16VonhgSxL5ltbQJj5yy7mx16muDE42OHXvLcmpJy0ijF8JX7QxSRRMUYD7oOO+a6y611hYhdxIY849K47xHa2uiXpmsHdmXhwBgYrnpvETj5E4yfutXiTwH1qftobP+mKNWSjyo07y+Rr93Zz5KNkx54zWB4iWa9/0sjO1yDk9VPt9as3cIkt4542zKwwwHc+tN03SbrUL23sLZS9xK+cE9B6k9hXs0acKS5r2sZQV5Jrcz9F0C91q8S209BJIeeWCgD6mvUtM+GltFJbyXt1JOpGZY1XZz6A9a7Xw7oFppNnHDZ27R5wz/NklscnNdDFAoUZiH4mvkMy4kqzm44d8sfxf9eR9DRwUbXqas4X/AIQbQo3RjZ/dGMMxw31qrf8AgLS7kKbaBrYk8PC+4Ee4PSvSDGozwPoe1VpAI85I5/SvIhm2KT5lUd/VnV9WpvRxX3HC6LaanpayWjyx3NquQjch8ehqWY4jO8YIPAPGK6GYESM4HHqaxtXtpSvmwoWJ68cVsq/tp80rJv5DivZrlWw37UNiqCQu3BAH9aZbyxI+Z3EcXdvSsg3Nwj4kt2JH92r2lxnUJQWTagPTrzWsqSim3sJ1k1Zblm78Uabp8iPvnmKnjsD/AI10Ok+I7fUYd9tGzr0yiNgH0yRVddNhRQPLQt6kVo2tuIUAUce1cmInhZU7Rg+bvcilCre8paehS1fVb9LeT7HYs8gHy5cAGvCfF2oX0upO9+HWfOGVhjb7V9CT20cpyc5HbNc94h8N2eqoVvIQzAYR8fMv4135NmVDBS9+G/XqiMTh5VVueHw3YMKSIqMyHdtYZBokmjmhaeNDG4OSqnjNbOv+FbzQnEjIslozECRen0I7GsiKIBmVRlXFfeQrU68PaU3dHz9Sk6c7SVma/h67ZZjK0u5+g3noPrXbWmrJENseCB1BHU15dCHg2vtJAJGK3NFVZ/KWWVo3lPOD91a8nMcFCo3VCnVlT0Wxs+IdWEys271xiuMlmETLhJOecmvS7nwpD9k82zcq/Gd3zcV5/dwy/apFnwXU7eDV5NVo2cab+8K/Ne8jPlKzKSpBY9jxVBIMM25CDWnNEq5BGD70x2VYuuTjvX0G5NOVtjHlAD4oqK4cmU4BxRSOm5tSEXA+UnYOlQyHcBGnTp+FSWsQZPKcbX3cHON9QXkxS5dY0wfug44xUprY41vYpXcm69MeCAgAHvV2NPLhAQAbuTx1qJkWN0dlzLtHJ5AFSwTu29HOVIzz2qim3ayI5EVXG0fKe1OklUwOoXBI60+LYYyXGcHgU+6gUIhXIDdaRal7rMlFJzipBGzREgdKtRIEcKih+eWYU6P70iqMrmmFN+8UbI4kIerlwCqh4ThhUElvI7HYvPbtS25ckpKDuWixqpKWhTn1qdWKLGqkdc81nXFzcTvuckmty6sN53hRmqEluVbbjmmUlFbIsaeN0Q3HLGp/JCSZC1HBG6jpinsZV4BOPpUXQ5JtaF+xQ7vNaQRhTwM8k12lt47usLBc+m3cDivPUDH72TViGFEcSuu4LyB71zV8NCt8auZunLds667uV1KR5IFLhPmlx6elYGoW0M1001syiM9upU96ks9RMGi3aKQHmfaSOuPapf7VjhiAiCKv+wME/WooUXT0WxyPmT0FtIXWILuL4XIxwB9a9Z+GHhlbUS6vd4eScYhBHKoe/wCNeRWWpwy6nam+EjWSyqZVHUrnkV9K6Vf219bxvp7xNFtGzaw4GOBXz3EuJq0KKpQWkt3+nzPVyygpT55bovxQKp3LnA96kePHVqcrnI+eP/aHWiWe3jP72RRxnngV+e3bZ9CkkVSrM3yAnHemPABzJyar3Gv2Xni2tJY5rkgkRowJwOTXNWniyG6iuZ0SSaRZvJWJMFyfYdhnvXbSwlea5lF2JdWCdrm9PbzSjhxGuTnAzn0p8cRJZGGVHBzVvTYZnjEt0MSMMlAchPb3+tX1twuAFwCcmsp1eV8pVlJHP3Oko6EqgX8K830TWGsPHk1nJIGtZZjD7A9j+fFeoeLLs6VpdxqCksIE5TOM187vcu+qi6JAYy+afbnNfUcPYZ4qlVdTVNWXqeVmFRU5RS33PodYeee/SnpkDH61LpFxBf2EFzbsHilUOpqyYOeK+XnJxbUtz0426FJkJ5AwaaSfut3q8Y8HPUUySLPYHFJTQ5R7GVd2KSqdyIw9CM15R418PxaRqBu7ZWS3nOWUL8kbegPvXtO1SO4Nc74w0qPUdEuoCSHKHaVTcc9hj6162U4+WHrpN+69GceLoKrTa6njAEMu1kI+UckAkUWN5DZXRdsHnjjoKihE9uIrIlYpNwV41+8Mn+L3rqvFmm2UVuscEanzB0J5Br7qq0rU56pnzFnF3K1x4huntZRZgIuMM2e30rkp7wXEzMW3P3xVCVJQVYM2xuNgPT2pjZa4BEezHB56104TBQw791GspOe4twZGclSaEgd1+aryBcdKR3C98V6SRPPbRFH7JzzRU7XCZ60Uxc0hmh28kktqruzII2JOec7j/wDWrvJ7a3fS3tBEjLtHIHIPtXIafKkOUTAIBK4HY/5NdBZ3iiywT84z+VeFj4zlJSi9mEZK9mcdqkZhuBkdRgfhRbW+6IsSRnoau3kX2uddqk44zmnSRSWkZUhcryQTkYr16UrxSe5DZnRxuiujckH86lZmkAX+FeBTJ79VcbIQwIwTnrTDeO4CpHHGB3zk1oPUdK626/7Z6D+tQpM3I6UJEGfLsWY9TVmKNFOdo/GmPYjijLtuY4HqaguJC1yzp64FWncnOzp61AqZkAHWmNblqEu8YyuQetQSQfP0q6qPEBhSQaR1zyaSNarskU3xHjipraWLPzEfjSvCXXiqNzbOvI4qHuawd43NkLCwyNoFZWozAyiOL7o64pbSVxGFmjzjuKhnni88kRfN9adjOUpSdkLHExGTUgRd4XIpgd5FJ6fSq0jeW+4E5pXGqT6lyQhHKjoKs6bfz2m4wzSIyHKlWIrM8wvhvWpoeSD2PBolFSVmZvR6HS2vibV2nCjU7tDg8CQnNTHXtRnlPn3U7HP8TkiuXjYpKpB5BrofDBil16xjvSDbPKAxPTFcs8PQpxc+RaeSGpTm+W53/gvQL6Ym/jH2QyxlA6jJkVuvHau88KeDrLRS00cYadurNyfzq3Fc6RaSJG17CsgQuF8wD5R7VoR61ZvZiaOWPyGGVfPUe1fmuYZli8U2kmovpb7l5n0OHw9GilZ3a8/6sX42VPc08ttRnbAGK5W98WabZSnaXllPAA4Fc54y16e/02eKGVokxhxGf4T39646GVVq00muVd3/AJDq4+lSjo7vyMv4m+KF1OU6XYy5toz++YdHYdvoK822biQvJGM49KuSCOKFlDGT/aAxiren6S06rFLJ5SPjIXrj0Jr9FwtOhgKCp09Evx7s+brYiVeblI6P4aeJf7P1OPSZ5SbabO3J4STsPxr2eKVGjyeCO9fPt5pCaZMkv2fAUgpJnPPaut8DeIhJqRh1O7bc5PloThcnrXzuc5fDEt4vD7W1XfzPSwGNslRnv0Z66EVuuPamtbgHjkelU43KYUn5ex9qsJLjHOa+McXF6HvKZDNBzwP8aoThkwVXn3FbJkQ+uaoak6RQtK5CBMksxwMVpSk72G0nqeAfEyH7L4plmjhaIuofJ6Oe5FZQuJzbw3M05wykKvXk1e8Z6nFrutT3FuD5SnapOcnHeubuPN2xRl/3aZ2j0zX65gqEvq1JVFqkvyPksS1KrLl7l+MwhVOQWHr2qKfyycjFUJlKJnJzWe94wYjNejbW5io9jWknCA4rNuLtmOBSxuZRkmpIrNJVdmYjHpTsPRblUGRuc0VK9u6HC8j1ophodNa6RAJhLe3YSST5Y4lbGfap9btrSG0jSzkaGZT+8b7wxT2lQQxNMgDD7rdc1l6nfAg5wCeBmvDpqrUqJyb/AEL93l0IBMRkxHheMj+dKp3ZDd+DmmxOqnKAeYfQUhXyXdpshRyc17EElsYNDIIY5YmQY3odrA+1ElntQsByPWuamvpP7RknQsqs3TPatQ3f2iMATOrYxtJ4NXcfK0WWmgh5eRc+maZHdCbeuNqfXrWPNaNE+4kYPTnpVq38s7Qr7iOWHSjctJFuaTyYvkPJ4FRWl0UbMnzFTUt+EMUbRngmqMDBZmZhlR1FMNEzrbO7hni4Iz71Fcld5xWJbHzWPl/IAcHmtTymEf3sn1pIdSaaQeasaFm6Csq5uTczAoSqA8AU28mdj5Yzs/nTrG3Z5FUDk0eYk3axpxR5RfpVa40/dJuXrVi5eSA/dwB3qKPUAW+ak3c2pU3HVkbW8iR8DpWPeB88g11CXEcmB60yezjlXkDNSbmBY/NDz61o2axybiS3lqcEgc04WYgIQdM5NFvbrBKQJQu7qTyPyp30OOo9Wb/h3RLXVbwW8MNz6ly2Qv1rsofBtgqFBFO0g/iznBrJ8F+JrTRbeS3kRWaRtxlx19q0dV8TvcTB7WRkQj5gp4NeHiKmIdVxjdRM2rK5zus6bcQ3HlXEmGX7suMBh6Gtrwlpc7yKz3kknkjKorHaM9Kxr66+0nzJ5X8pQTk966T4XXqyCR5vutJ/+qscdUqwwjktzTDLmnZ7HUaXogSK5uLz94xG0BuaxRpyWeti1+1jyGG4Ix6eorttavY7a2+YgKSPxrzXXHOqXTzCdIvK4Un19K8fAqdSTlJ7nTiuSCsS+ILGKF2cGJkUkgLxke9W9K1ezitlEqqpPbFcHqLXTSyw7nPy9SeozzWZbX00zmOMcKcDJwT717f1D2kEpS2OKLs7o9F17xFay20ttFEGDjBbpj3rhpYHUGQyjPbHenGGUgeYpCnqTSSRupwzAjtXdgsMqMeWLCU7s7Lwt8QdQ0oCHUAb21xgBzhl+h712Q+KeihGaS3uVAQNkAHnuteKsR/e46cVn3cjHO/Kxjp71zYnh7BYmfPKFn5aHbSx1aC5U7nresfGSEB103T23bvleVsAjHoOhzXH67481nXbJraeZUt2OWSMYzx6+ntXAXLBkPr2qxpVwC+xz14rbC5LgsM06dNXXV6v8S6uJrTjqzStJDHc5bODwak1ZlhtvM7buKRosEEVQ15Ga2jbJwOMV69jz95JlSfUgyYzWf5m4FqpyfewOtKzGNcE0mjeKLsF75b7TWzpV0s0jR92HFcxbwmbJq9bQzW86SoTwapaETidR5eOKKmhZZ4lkHGRRVWMOY1PFltEXZbdivl5we3H9K4q+SLP76SSSUDgKcKDRRXlZfrSVza+pHHqstsihArPjq3aqtxqt1NgOylQcgYoor0RpIr5EnJGCeoq3GrRwhgqluxPYUUUhMb80rfOxJqdAIxwvHeiiqAmGxkCAsuOneo/LILA+tFFITdyeFZBCfLAyTnrT3nuxbMh4J4zmiigd9LEECMB8x6VraZIIW3HnNFFD2Kpq71NWQLKucZBrHvNPUEyJxjmiioR1PYqWs4Y4GcitJLnYVGT8xxRRTa1Mud8tx0rSOGeMAhDVJ7sjO+MZ+tFFWcqd27hp8ktzfRrGQvPpmumSONxL85G3jhe9FFcWJ+IUtzA1LVDJDHbFcCPqf73PWtXwvrMmi3IG3fC/JHpRRVVKEKtL2clozWD5GmjpvFnimLUbK2jgWRJlwQazVZLWaBJGJkAMjd8tj/69FFcNDCwpxjCO2osTNyauVUu3u7mZeFlH3T7elX/AA5oyXN2VlQfKM5B60UVz42o6KagVTgnY2PEGjrDYM55VV7Vwc+UcKeQRkH2oorfJ6kpU2n3Jqq0yMlvLI/hJ4HpSCLKYJyPQ0UV7ROxl3+nOAWhP4Gsu2WSO4+cYPsaKKLGsZtrU6y0k823UnrjBqO/QPauD25oopnNtI5aW3CyE1m3kmXwKKKFudkHoW9JuFQ7WFdBBJG68j9KKKfUzmtSykoiG1Omc0UUUGdj/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Martin Wall/herbslides.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36452=[""].join("\n");
var outline_f35_38_36452=null;
var title_f35_38_36453="Colestipol: Pediatric drug information";
var content_f35_38_36453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colestipol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"    see \"Colestipol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/17/1301?source=see_link\">",
"    see \"Colestipol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colestid&reg;;",
"     </li>",
"     <li>",
"      Colestid&reg; Flavored",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Colestid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1007031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent, Bile Acid Sequestrant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1007055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"      see \"Colestipol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;10 years: Limited studies with doses ranging between 2-12 g/day; the most recent study produced significant lowering of serum cholesterol utilizing either 10 g once daily or 5 g twice daily (Tonstad, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Granules: 5-30 g/day given once or in divided doses 2-4 times/day; initial dose: 5 g 1-2 times/day; increase by 5 g at 1- to 2-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablets: 2-16 g/day; initial dose: 2 g 1-2 times/day; increase by 2 g at 1- to 2-month intervals",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral, as hydrochloride: 5 g/scoop (500 g); 5 g/packet (30s, 90s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg;: 5 g/scoop (300 g, 500 g); 5 g/packet (30s, 90s) [unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg; Flavored: 5 g/scoop (450 g) [contains phenylalanine 18.2 mg/scoop; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg; Flavored: 5 g/packet (60s) [contains phenylalanine 18.2 mg/packet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride [micronized]: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colestid&reg;: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1007059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be administered one at a time, swallowed whole, with plenty of liquid. Do not cut, crush, or chew tablets.   Dry powder or granules should be added to at least 3 ounces (90 mL) of liquid and stirred until completely mixed. Other drugs should be administered at least 1 hour before or 4 hours after colestipol.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5597586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1007032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia; primary prevention of cardiovascular disease in high risk patients; risk factors include: Age &ge;55 years, smoking, hypertension, low HDL-C, or family history of early coronary heart disease; relief of pruritus associated with elevated levels of bile acids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7297703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Colestipol may be confused with calcitriol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, chest pain, edema of hands or feet, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache (including migraine and sinus), lightheadedness, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain and cramping, anorexia, bloating, constipation, cholecystitis, cholelithiasis, diarrhea, dysphagia, esophageal obstruction, flatulence, indigestion, heartburn, hemorrhoids (bleeding), nausea, peptic ulceration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, backache, joint/muscle pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1007035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bile acid sequestering resins or any component; bowel obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5597585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some formulations contain phenylalanine; use with caution in patients with phenylketonuria; may decrease absorption of many orally administered medications; avoid concomitant administration with other orally administered medications",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1007036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May interfere with fat-soluble vitamins (A, D, E, K) and folate absorption.  Chronic use may be associated with bleeding problems due to hypoprothrombinemia from vitamin K deficiency.   May produce or severely exacerbate constipation and fecal impaction may occur. This may be lessened by a gradual increase in dosage, an increased intake of fluids and fiber, or addition of a stool softener.  Avoid accidental inhalation or esophageal distress with colestipol powder and granules; always mix with other fluids prior to ingestion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens).  Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins).  Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: Colestipol may decrease the absorption of Diltiazem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: Colestipol may decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bile Acid Sequestrants may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Colestipol is not absorbed systemically (&lt;0.17%), but may interfere with vitamin absorption; therefore, regular prenatal supplementation may not be adequate. There are no studies in pregnant women; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5597588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum cholesterol (total and fractionated), annual serum levels of fat-soluble vitamins A, D, E, K, and folic acid",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1007050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol is the major precursor of bile acid.  Colestipol binds with bile acids in the intestine  to form an insoluble complex that is eliminated in feces.  This increased excretion of bile acids results in an increased oxidation of cholesterol to bile acid and a lowering of the serum cholesterol. Serum triglyceride levels may increase or remain unchanged with colestipol treatment.  Colestipol is an anion exchange resin and may have a higher affinity for anions other than bile acids.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5597587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lowering of serum cholesterol: ~1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LDL-C reduction: ~19%",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1007052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1007063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/17/1301?source=see_link\">",
"      see \"Colestipol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take granules with 3-4 oz of water or fruit juice. Rinse glass with small amount of water to ensure full dose is taken. Take tablets one at a time. Other medications should be taken 1 hour before or 4 hours after colestipol. You may experience constipation (increased exercise, fluids, fruit, fiber, or stool softener may help).  Report acute gastric pain, tarry stools, or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, &ldquo;Cholesterol in Childhood,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(1 Pt 1):141-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/ 11345978 /pubmed\" id=\" 11345978 \" target=\"_blank\">",
"        11345978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, &ldquo;National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(3 Pt 2):525-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/1538956 /pubmed\" id=\"1538956 \" target=\"_blank\">",
"        1538956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/11368702 /pubmed\" id=\"11368702 \" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Groot PH, Dijkhuis-Stoffelsma R, Grose WF, et al, \"The Effects of Colestipol Hydrochloride on Serum Lipoprotein Lipid and Apolipoprotein B and A-I Concentrations in Children Heterozygous for Familial Hypercholesterolemia,\"",
"      <i>",
"       Acta Paediatr Scand",
"      </i>",
"      , 1983, 72(1):81-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/6407278/pubmed\" id=\"6407278\" target=\"_blank\">",
"        6407278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, \"Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/15358046/pubmed\" id=\"15358046\" target=\"_blank\">",
"        15358046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwarz KB, Goldstein PD, Witztum JL, et al, \"Fat-Soluble Vitamin Concentrations in Hypercholesterolemic Children Treated With Colestipol,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1980, 65(2):243-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/7354970/pubmed\" id=\"7354970\" target=\"_blank\">",
"        7354970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tonstad S, Sivertsen M, Aksnes L, et al, \"Low Dose Colestipol in Adolescents With Familial Hypercholesterolaemia,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1996, 74(2):157-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/8660081/pubmed\" id=\"8660081\" target=\"_blank\">",
"        8660081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tonstad S and Ose L, \"Colestipol Tablets in Adolescents With Familial Hypercholesterolaemia,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 1996, 85(9):1080-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/38/36453/abstract-text/8888922/pubmed\" id=\"8888922\" target=\"_blank\">",
"        8888922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13064 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-3E1552308A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36453=[""].join("\n");
var outline_f35_38_36453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154486\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007031\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007055\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154468\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154454\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007059\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5597586\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007032\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7297703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154526\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007035\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5597585\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007036\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299082\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154463\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277388\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5597588\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007050\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5597587\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007052\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007063\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13064\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13064|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=related_link\">",
"      Colestipol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/17/1301?source=related_link\">",
"      Colestipol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36454="Dynamic hyperinflation in patients with COPD";
var content_f35_38_36454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dynamic hyperinflation in patients with COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36454/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36454/contributors\">",
"     Martin Kohlhaufl, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36454/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36454/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36454/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36454/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/38/36454/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced air trapping is referred to as dynamic hyperinflation. Patients with chronic obstructive pulmonary disease (COPD) are particularly susceptible to dynamic hyperinflation. Common questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What causes dynamic hyperinflation?",
"     </li>",
"     <li>",
"      What are its clinical manifestations?",
"     </li>",
"     <li>",
"      How is it diagnosed?",
"     </li>",
"     <li>",
"      What is the treatment?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology, clinical presentation, diagnosis, and treatment of dynamic hyperinflation in patients with COPD are reviewed here. The diagnosis and treatment of COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volumes remain stable when the tidal volume is completely exhaled prior to the initiation of the next breath. Tidal volume increases during exercise (",
"    <a class=\"graphic graphic_figure graphicRef69862 \" href=\"mobipreview.htm?26/10/26784\">",
"     figure 1",
"    </a>",
"    ). Therefore, maintenance of stable lung volumes requires that expiratory muscles be recruited to elevate pleural and alveolar pressure, increase expiratory flow, and force the increased tidal volume to be completely exhaled prior to the next breath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hyperinflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinflation exists when the end-expiratory lung volume is increased, usually due to an airflow limitation. Hyperinflation acts as a compensatory mechanism. At higher lung volumes, there is decreased airway resistance and increased elastic recoil, resulting in improved expiratory flow. Two types of hyperinflation can be distinguished: static and dynamic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Static",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elastic recoil pressure decreases during expiration, reaching zero at the end-expiratory lung volume. Patients with chronic obstructive lung disease (COPD) have decreased elastic recoil pressure compared to healthy patients; therefore, the elastic recoil pressure falls to zero at a larger end-expiratory lung volume (",
"    <a class=\"graphic graphic_figure graphicRef63226 \" href=\"mobipreview.htm?42/18/43310\">",
"     figure 2",
"    </a>",
"    ). This is referred to as static hyperinflation, which exists at rest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dynamic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to healthy individuals, patients with COPD recruit expiratory muscles and increase their pleural and alveolar pressures during exercise, in an effort to increase expiratory flow and completely exhale the increased tidal volume prior to the next breath. However, the airways of patients with COPD typically compress or collapse when the pleural pressure is positive, thereby preventing increased expiratory flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As a result, exhalation may not be completed prior to the onset of the next breath, causing progressive hyperinflation (",
"    <a class=\"graphic graphic_figure graphicRef63226 \" href=\"mobipreview.htm?42/18/43310\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This is referred to as dynamic hyperinflation; it occurs during exercise and can exist in the presence or absence of static hyperinflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hyperinflation is a compensatory mechanism that increases expiratory flow, it has several disadvantages including: it increases the work of breathing; it places the inspiratory muscles at a mechanical disadvantage due to length-tension effects; and it produces a positive alveolar pressure that must be overcome to initiate a breath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/5\">",
"     5",
"    </a>",
"    ]. The net effect is a marked disparity between the level of inspiratory effort (approaches maximum) and the actual mechanical response of the respiratory system (greatly diminished), which manifests as dyspnea, initially with exertion and later at rest.",
"   </p>",
"   <p>",
"    Dyspnea with exertion is a nonspecific complaint in patients with chronic obstructive pulmonary disease. Additional causes of dyspnea with exertion include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dynamic airway compression",
"     </li>",
"     <li>",
"      Respiratory muscle weakness",
"     </li>",
"     <li>",
"      Increased ventilatory demand due to physiologic dead space, hypoxemia, hypercapnia, early onset lactic acidosis, deconditioning,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor nutrition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The occurrence of dynamic hyperinflation is not clearly predicted by the severity of COPD (based on the reduction in forced expiratory volume in one second), as patients with the most severe disease tend to have less dynamic hyperinflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/7\">",
"     7",
"    </a>",
"    ]. It is possible that the degree of baseline hyperinflation in severe COPD inhibits further dynamic hyperinflation.",
"   </p>",
"   <p>",
"    Thus, a patient with COPD who complains about dyspnea with exertion cannot be assumed to have dynamic hyperinflation; additional diagnostic testing is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of dynamic hyperinflation requires lung volume measurements during exercise. This is time consuming, labor intensive, and technically difficult. Therefore, indirect measures using spirometry are more common. There are two methods of indirect measurement: measurement of inspiratory capacity and comparison of flow-volume loops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inspiratory capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinflation is defined as an elevated end-expiratory lung volume (EELV). Decreased inspiratory capacity (IC) is used as a surrogate measure of increased EELV. This is based upon the assumption that total lung capacity (TLC) is constant; therefore, an increase of the EELV must be accompanied by a decrease of the IC since the sum of the two measures is the total lung capacity (ie, EELV + IC = TLC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During exercise, healthy individuals increase their tidal volume. To insure that the entire tidal volume is exhaled prior to their next breath, they recruit expiratory muscles and increase their expiratory flow, which results in an increased IC and decreased EELV. In contrast, patients with COPD are unable to sufficiently increase their expiratory flow and completely exhale the increased tidal volume prior to the next breath; as a result, the IC decreases and the EELV increases during exercise (",
"    <a class=\"graphic graphic_figure graphicRef63226 \" href=\"mobipreview.htm?42/18/43310\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77593 \" href=\"mobipreview.htm?15/49/16158\">",
"     figure 3",
"    </a>",
"    ). Progressive decrease of IC during exercise is highly suggestive of dynamic hyperinflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Flow-volume loops",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another method compares the maximal flow-volume loop (MFVL) versus the tidal flow-volume loop during exercise (extFVL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/4\">",
"     4",
"    </a>",
"    ]. In healthy individuals, the extFVL and the MFVL are distinct, whereas the flow-volume loops become increasingly similar (ie, there is encroachment of the extFVL on the MFVL) with an increasing EELV as dynamic hyperinflation progresses (",
"    <a class=\"graphic graphic_figure graphicRef63226 \" href=\"mobipreview.htm?42/18/43310\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The MFVL is obtained by spirometry with the patient resting prior to exercise, while the extFVL is obtained at several different work intensities during exercise. Either a single representative extFVL or the mean of two or more extFLVs is plotted within the largest MFVL (",
"    <a class=\"graphic graphic_figure graphicRef63226 \" href=\"mobipreview.htm?42/18/43310\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Since bronchodilation or bronchoconstriction may occur during exercise, additional MFVLs are often obtained during or immediately after exercise. IC is also determined during rest and exercise, and then used to correctly align the extFVL within the MFVL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small decreases in lung volume are often associated with significant clinical improvement, suggesting that hyperinflation is a significant cause of dyspnea in patients with chronic obstructive lung disease (COPD). Most of the pharmacologic agents used to treat COPD decrease static hyperinflation, allowing patients to tolerate even greater dynamic hyperinflation during exercise before experiencing intolerable dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anticholinergic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic agents produce sustained reductions in hyperinflation during rest and exercise, resulting in improved exercise capacity and reduced dyspnea with exertion. This was best illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind, cross-over study, 29 patients with stable COPD performed spirometry and exercise before and one hour after receiving nebulized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (500 mcg) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/14\">",
"       14",
"      </a>",
"      ]. The inspiratory capacity at rest increased 14 percent following ipratropium, consistent with decreased static hyperinflation. This was accompanied by improved exercise endurance and dyspnea during exercise. There were no significant changes in spirometry, exercise endurance, or exertional dyspnea after receiving placebo.",
"     </li>",
"     <li>",
"      A double-blind, parallel-group trial randomly assigned 187 patients with COPD to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      (18 mcg) or placebo once daily for 42 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/5\">",
"       5",
"      </a>",
"      ]. Spirometry, plethysmographic lung volumes, exercise endurance, and exertional dyspnea of the tiotropium group were compared to the placebo group. Tiotropium increased the inspiratory capacity and decreased the end-expiratory lung volume at rest, consistent with decreased static hyperinflation. In addition, tiotropium increased exercise capacity and improved exertional dyspnea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all studies have shown a reduction in dynamic hyperinflation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    . In a study of 29 patients with moderate-severe COPD, tiotropium significantly increased forced expiratory volume in one second (FEV1) and inspiratory capacity (IC), independent of the extent of the lung computed tomography emphysema score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/15\">",
"     15",
"    </a>",
"    ]. Spirometry including IC was measured before and immediately after metronome paced hyperventilation at twice the resting respiratory rate for 20 seconds to induce dynamic hyperinflation. Despite bronchodilation and lower resting lung volume, tiotropium did not abbreviate dynamic hyperinflation, which was also independent of the degree of underlying emphysema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Beta-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-agonists similarly decrease static hyperinflation, allowing greater dynamic hyperinflation during exercise before intolerable dyspnea develops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This was best illustrated by a double-blind, crossover study that randomly assigned 23 patients with COPD to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    (50 mcg) or placebo twice daily for 2 weeks, and then compared spirometry and exercise capacity in the salmeterol group versus the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/17\">",
"     17",
"    </a>",
"    ]. Salmeterol increased the inspiratory capacity during rest and exercise, consistent with decreased static and dynamic hyperinflation. It also increased exercise endurance and decreased dyspnea during exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids alone enhance bronchodilator- mediated improvement of dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/18\">",
"     18",
"    </a>",
"    ]; however, it is unknown whether this observation is due to improvement in dynamic hyperinflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined long-acting beta-agonist plus inhaled glucocorticoid decreases hyperinflation and improves exercise endurance. This was illustrated in a trial of 185 patients with COPD who were randomly assigned to receive placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    alone (50 mcg), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    (250 mcg) plus salmeterol (50 mcg) twice daily for eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/19\">",
"     19",
"    </a>",
"    ]. Compared to placebo, combination therapy increased the inspiratory capacity during rest and exercise, consistent with decreased static and dynamic hyperinflation. It also increased exercise endurance. Static hyperinflation was the only outcome for which combination therapy and salmeterol were compared, with combination therapy demonstrating a greater impact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antioxidant agent N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC) has mucolytic properties when administered by nebulizer. However, nebulized NAC can cause bronchospasm, so oral preparations have been assessed for use in COPD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=see_link&amp;anchor=H15#H15\">",
"     \"Role of mucoactive agents in the treatment of COPD\", section on 'Acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of NAC on lung hyperinflation at rest and after exercise was examined in 24 patients with moderate-to-severe COPD (forced expiratory volume in one second (FEV1) &lt;70 percent of predicted,",
"    <span class=\"nowrap\">",
"     FEV1/forced",
"    </span>",
"    vital capacity (FVC) ratio &lt;0.70, functional residual capacity &gt;120 percent of predicted) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients were randomly assigned to placebo or NAC 1,200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six weeks, followed by a two-week washout period, and then a cross over to alternate therapy for six weeks. Based on increases in inspiratory capacity (IC), FVC, and endurance with NAC, NAC treatment appeared to reduce dynamic hyperinflation, probably due to a reduction in air trapping. However, routine long-term use of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    is not recommended for COPD because of the minimal potential therapeutic benefit, the inconvenience of therapy, and potential side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=see_link&amp;anchor=H15#H15\">",
"     \"Role of mucoactive agents in the treatment of COPD\", section on 'Acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    decreases hyperinflation and increases exercise capacity in a dose-dependent fashion. As an example, 38 patients with COPD received placebo, low-dose, medium-dose, and high-dose theophylline consecutively for two months each [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/21\">",
"     21",
"    </a>",
"    ]. Spirometry, lung volumes, and exercise were performed at the end of each two month treatment period. There was a dose dependent decrease of lung volumes and increase of exercise capacity, accompanied by a modest improvement of dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen therapy is well known to be beneficial in patients with COPD and hypoxemia. It also appears to decrease dynamic hyperinflation, even in patients who are not hypoxemic with exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/22\">",
"     22",
"    </a>",
"    ]. This was best illustrated by an observational study of ten patients with COPD who underwent spirometry and exercise testing while receiving different concentrations of oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/23\">",
"     23",
"    </a>",
"    ]. Compared to room air, hyperinflation was progressively reduced when breathing 30 and 50 percent oxygen. There was no additional reduction of hyperinflation when the patients breathed 75 or 100 percent oxygen. Similarly, a randomized trial demonstrated faster resolution of dynamic hyperinflation following exercise among patients who received oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Heliox",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of helium decreases turbulence within medium and large airways and increases expiratory flow. A crossover trial randomly assigned ten patients to breath room air (ie, 21 percent oxygen), hyperoxia (40 percent oxygen), normoxic helium (21 percent oxygen plus 79 percent helium), or hyperoxic helium (40 percent oxygen plus 60 percent helium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/25\">",
"     25",
"    </a>",
"    ]. All three gases improved exercise duration and dyspnea compared to room air, although only the helium-containing gases improved the inspiratory capacity during exercise (ie, decreased dynamic hyperinflation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rehabilitative exercise training generally yields the greatest improvement in exercise tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/22\">",
"     22",
"    </a>",
"    ]. At least part of this improved exercise capacity is due to reduced dynamic hyperinflation. An observational study evaluated dynamic hyperinflation in 24 patients with COPD following a seven week training program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/26\">",
"     26",
"    </a>",
"    ]. Inspiratory capacity dropped less precipitously and exercise capacity increased following the training program, suggesting that dynamic hyperinflation was less, although still present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lung volume reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume reduction can be performed surgically (LVRS) or bronchoscopically (BLVR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea relief following LVRS has also been shown to correlate well with reduced dynamic hyperinflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bronchoscopic",
"    </span>",
"    &nbsp;&mdash;&nbsp;BLVR using endobronchial valves prolongs exercise time by reducing dynamic hyperinflation. In an observational study, 19 patients with advanced COPD, who received unilateral valve insertion, were evaluated with spirometry, lung volumes, and exercise before and four weeks after BLVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36454/abstract/30\">",
"     30",
"    </a>",
"    ]. BLVR increased exercise capacity and decreased end-expiratory lung volume, during rest and exercise, compared to baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD) is the most common disease in which hyperinflation occurs. Static hyperinflation exists at rest and is predominantly due to decreased elastic recoil. Dynamic hyperinflation is induced by exercise and is primarily due to impaired expiratory flow. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hyperinflation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyspnea with exertion is the most common manifestation of dynamic hyperinflation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct diagnosis of dynamic hyperinflation requires lung volume measurements during exercise. Due to the technical difficulties of measuring lung volumes during exercise, spirometric techniques are more commonly used. Progressive decrease of the inspiratory capacity during exercise,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      similarity of the exercise and maximal flow-volume loops suggest dynamic hyperinflation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapies commonly used in the management of COPD that have been shown to improve static",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dynamic hyperinflation include anticholinergic drugs, beta-agonists,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , supplemental oxygen, pulmonary rehabilitation, and lung volume reduction. We recommend treatment of the underlying COPD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"       \"Management of stable chronic obstructive pulmonary disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12\">",
"       'Beta-agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Anticholinergic drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Theophylline'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Oxygen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that supplemental oxygen be administered to patients with COPD and dynamic hyperinflation, even if exercise-induced hypoxemia is absent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     MacNee W. Pathophysiology of acute exacerbations of chronic obstructive pulmonary disease. In: Acute exacerbations of chronic obstructive pulmonary disease. Lung Biology in Health and Disease, vol 183, Siafakas NM, Anthonisen NR, Georgopoulos D (Eds), 2004. p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/2\">",
"      Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/3\">",
"      Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Recenti Prog Med 1990; 81:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/4\">",
"      Johnson BD, Beck KC, Zeballos RJ, Weisman IM. Advances in pulmonary laboratory testing. Chest 1999; 116:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/5\">",
"      Decramer M. Respiratory muscle interaction during acute and chronic hyperinflation. Monaldi Arch Chest Dis 1993; 48:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/6\">",
"      Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/7\">",
"      Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest 2010; 137:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/8\">",
"      Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/9\">",
"      Younes M, Kivinen G. Respiratory mechanics and breathing pattern during and following maximal exercise. J Appl Physiol 1984; 57:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/10\">",
"      Johnson BD, Reddan WG, Seow KC, Dempsey JA. Mechanical constraints on exercise hyperpnea in a fit aging population. Am Rev Respir Dis 1991; 143:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/11\">",
"      Johnson BD, Saupe KW, Dempsey JA. Mechanical constraints on exercise hyperpnea in endurance athletes. J Appl Physiol 1992; 73:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/12\">",
"      Babb TG, Viggiano R, Hurley B, et al. Effect of mild-to-moderate airflow limitation on exercise capacity. J Appl Physiol 1991; 70:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/13\">",
"      Johnson BD, Scanlon PD, Beck KC. Regulation of ventilatory capacity during exercise in asthmatics. J Appl Physiol 1995; 79:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/14\">",
"      O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/15\">",
"      Gelb AF, Taylor CF, Cassino C, et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther 2009; 22:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/16\">",
"      O'Donnell DE, Fl&uuml;ge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/17\">",
"      Bellamy D, Hutchison DC. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. Br J Dis Chest 1981; 75:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/18\">",
"      Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc 2006; 3:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/19\">",
"      O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/20\">",
"      Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/21\">",
"      O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/22\">",
"      Casaburi R, Porszasz J. Reduction of hyperinflation by pharmacologic and other interventions. Proc Am Thorac Soc 2006; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/23\">",
"      Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/24\">",
"      Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004; 59:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/25\">",
"      Eves ND, Petersen SR, Haykowsky MJ, et al. Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/26\">",
"      Porszasz J, Emtner M, Goto S, et al. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/27\">",
"      Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/28\">",
"      Martinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/29\">",
"      Laghi F, Jubran A, Topeli A, et al. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. Am J Respir Crit Care Med 1998; 157:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36454/abstract/30\">",
"      O'Donnell DE, Webb KA, Bertley JC, et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 1996; 110:18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1459 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36454=[""].join("\n");
var outline_f35_38_36454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hyperinflation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Static",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dynamic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inspiratory capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anticholinergic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Beta-agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Heliox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lung volume reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Surgical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bronchoscopic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1459|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/10/26784\" title=\"figure 1\">",
"      Rest and exercise flow volume loop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/18/43310\" title=\"figure 2\">",
"      Healthy and COPD flow volume loops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/49/16158\" title=\"figure 3\">",
"      Lung volumes exercise COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34648?source=related_link\">",
"      Role of mucoactive agents in the treatment of COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36455="Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status";
var content_f35_38_36455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36455/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36455/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36455/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/38/36455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with lung cancer depends upon the cell type (non-small cell versus small cell), tumor stage, molecular characteristics, and an assessment of the patient's overall medical condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with stage I, II, or III non-small cell lung cancer (NSCLC) are generally treated with curative intent using surgery, radiation therapy (RT), or a combined modality approach that may also include chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). In contrast, patients with advanced NSCLC are frequently treated with palliative intent using systemic therapy. This includes patients who present with stage IV disease and those who relapsed following prior definitive treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age and comorbidity may limit the ability to deliver therapy for advanced NSCLC. The median age of patients with newly diagnosed NSCLC in developed countries is approximately 68 years, and up to 40 percent are aged &ge;70 years at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, patients with a borderline or poor performance status (ie, ECOG performance status &ge;2 [ (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    )] or Karnofsky Performance Status (KPS) &le;70 [ (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 3",
"    </a>",
"    )]) comprise 30 to 40 percent of patients with advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/2\">",
"     2",
"    </a>",
"    ]. Such patients have often either been excluded from or are underrepresented in clinical trials.",
"   </p>",
"   <p>",
"    The development of agents that target specific pathways involved in the development or progression of NSCLC has provided an alternative to chemotherapy and has led to a personalized approach to the treatment of advanced NSCLC. Targeted agents tend to be better tolerated and may have an important role in older patients and those with significant comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic therapy in elderly and poor performance status patients with advanced NSCLC is discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272523920\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY VERSUS TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of metastatic NSCLC should be individualized based upon molecular and histologic features of the tumor. If feasible, patients should have tumor assessed for the presence of a driver mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is then guided by the results of these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without a driver mutation are generally treated with cytotoxic chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a driver mutation are generally treated initially with targeted therapy that inhibits the abnormal pathway (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      for those with a sensitizing EGFR mutation,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      for those with an ALK fusion oncogene). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some instances, systemic treatment may be required before the results of genotype testing are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/3\">",
"     3",
"    </a>",
"    ]. In this situation, systemic chemotherapy is indicated. When the results of genotype testing become available, the treatment plan should be reassessed (",
"    <a class=\"graphic graphic_algorithm graphicRef86712 \" href=\"mobipreview.htm?39/0/39950\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTEMIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential toxicity with cytotoxic chemotherapy can pose special concerns in elderly and borderline or poor performance status patients with advanced NSCLC. However, phase III trials demonstrated that chemotherapy can provide substantial clinical benefits, including improved overall survival, for older patients and those with ECOG performance status 2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initially, the safety and toxicity concerns in these patients were addressed by using single agent chemotherapy rather than combination regimens. However, more recent data suggest that combination regimens may be advantageous in patients thought to be able to tolerate such therapy.",
"   </p>",
"   <p>",
"    The use of systemic chemotherapy in elderly patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363162897\">",
"    <span class=\"h2\">",
"     Single agent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In appropriately selected elderly patients and those with borderline performance status (PS 2), single agent chemotherapy can improve overall survival without adversely impacting quality of life (QOL) compared with best supportive care (BSC) for advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/4\">",
"     4",
"    </a>",
"    ]. The most extensive data are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , although other agents may also have a role in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363162787\">",
"    <span class=\"h3\">",
"     Vinorelbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of chemotherapy to prolong survival without impairing quality of life (QOL) in patients with advanced NSCLC was demonstrated in the phase III Elderly Lung Cancer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     Vinorelbine",
"    </a>",
"    Italian Study (ELVIS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/4\">",
"     4",
"    </a>",
"    ]. In the ELVIS trial, 161 patients aged &ge;70 years were randomly assigned to vinorelbine plus BSC or BSC alone. Approximately 25 percent of patients were performance status 2 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    had a significantly better median survival than those managed with BSC alone (28 versus 21 weeks, hazard ratio [HR] for death 0.65, 95% CI = 0.45-0.93). Toxicity-related symptoms associated with chemotherapy were counterbalanced by significantly fewer lung cancer-related symptoms, and the chemotherapy group had higher scores on QOL scales.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    appears to be at least as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    . In a Japanese phase III trial, 182 patients aged &ge;70 years were randomly assigned to docetaxel or vinorelbine for four cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/5\">",
"     5",
"    </a>",
"    ]. Almost all patients were performance status 0 or 1.",
"   </p>",
"   <p>",
"    Key results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      had a significantly higher response rate and longer progression-free survival compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      (23 versus 10 percent and 5.5 versus 3.1 months, respectively).",
"     </li>",
"     <li>",
"      The difference in overall survival was not statistically significant (median 14.3 versus 9.9 months, HR for death 0.78, 95% CI 0.56-1.09).",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      resulted in greater improvement in appetite and fatigue.",
"     </li>",
"     <li>",
"      Severe neutropenia was significantly more common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (83 versus 69 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weekly administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    may be a less toxic alternative than an every three week schedule, based upon studies using docetaxel as second line therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=see_link&amp;anchor=H3#H3\">",
"     \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\", section on 'Docetaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Other single agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other contemporary agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) have significant single agent activity in previously untreated patients with advanced NSCLC. Although the efficacy of these agents in elderly and poor performance status patients has not been demonstrated in randomized trials, such agents may be useful in some patients who are not candidates for combination therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Active single agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the treating physician thinks that the patient is able to tolerate combination chemotherapy, our general approach is to use platinum-based chemotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for nonsquamous NSCLC). Older guidelines from the American Society of Clinical Oncology and a European experts panel did not definitively address the question of combination versus single agent chemotherapy for patients with advanced NSCLC who are either elderly or have a poor performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized trials have been conducted specifically in older patients and those with ECOG performance status 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. These trials have yielded conflicting results on the potential benefit of platinum-based doublet regimens compared with single agent therapy, which are illustrated by the results of the two largest trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French Intergroup study (IFCT-0501) randomly assigned 451 patients with advanced NSCLC to a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      for four cycles or to single agent therapy with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients from both arms were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      after failure on their initial regimen. Patients were aged 70 to 89 years; approximately 30 percent of these were performance status 2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At a median follow-up of 30 months, overall survival was significantly prolonged with combination chemotherapy compared to single agent chemotherapy (median 10.3 versus 6.2 months, HR 0.64, 95% CI 0.52-0.78, and one-year survival 45 versus 25 percent). Progression-free survival was also significantly prolonged (6.0 versus 2.8 months, HR 0.51, with one-year progression-free survival 13 versus 2 percent).",
"     </li>",
"     <li>",
"      Treatment was generally well tolerated with both combination and single agent chemotherapy. Grade 3 or 4 neutropenia was more common with the combination compared with monotherapy (48 versus 12 percent). Ten deaths (4.4 percent) in the combination arm were attributed to treatment, compared with three (1.3 percent) in the monotherapy group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomly assigned 698 patients to single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      , or a non-platinum combination of gemcitabine plus vinorelbine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/10\">",
"       10",
"      </a>",
"      ]. All patients were &ge;70 years old and 20 percent were performance status 2. The combination regimen did not significantly improve the objective response rate or median survival compared to vinorelbine or gemcitabine (21 versus 18 and 16 percent and 30 versus 36 and 28 weeks, respectively). Quality of life was similar in all three arms, although combination treatment was more toxic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525780428\">",
"    <span class=\"h2\">",
"     Chemotherapy plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is questionable in elderly and poor performance status patients since more severe toxicity may offset the benefit from an increase in antitumor activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence from subset analyses and retrospective data suggest that caution is needed when using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in elderly or borderline performance status patients with advanced NSCLC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The E4599 trial treated good performance status patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/13\">",
"       13",
"      </a>",
"      ]. The overall incidence of severe or fatal (grade 3 to 5) toxicity in patients aged &ge;70 years was significantly higher (87 versus 61 percent) in those receiving bevacizumab compared with chemotherapy alone, and treatment-related deaths were more frequent (6.3 versus 2.6 percent). The addition of bevacizumab resulted in a statistically nonsignificant trends toward a higher response rate and longer progression-free survival compared with carboplatin plus paclitaxel alone (29 versus 17 percent and median 5.9 versus 4.9 months, respectively), but overall survival was not significantly different (median 11.3 versus 12.1 months). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779210#H525779210\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Carboplatin paclitaxel'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The AVAiL trial treated good performance status patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/14\">",
"       14",
"      </a>",
"      ]. The efficacy in patients aged &ge;65 years was similar to the younger cohort, with statistically significant improvements in progression-free survival for the lower dose of bevacizumab (7.5",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      The differences in overall survival were not statistically significant. No important differences in toxicity were seen when this group was compared with younger patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779217#H525779217\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Cisplatin gemcitabine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An observational study, based upon SEER data, analyzed 1500 patients aged &ge;65 years treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in 2006 and 2007 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/15\">",
"       15",
"      </a>",
"      ]. There was no significant difference in overall survival with and without bevacizumab (median survival 9.7 versus 8.9 months, one-year survival probability 39.6 versus 40.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138417267\">",
"    <span class=\"h1\">",
"     TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a driver mutation is present in the tumor, targeted therapy may provide a higher likelihood of disease control with an improved toxicity profile compared with chemotherapy. As such, targeted therapy may be particularly appropriate for elderly patients and those with a borderline or poor performance status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     EGFR mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients whose tumors contain a characteristic mutation in the epidermal growth factor receptor (EGFR), an EGFR tyrosine kinase inhibitor (TKI) is preferred for initial therapy, based upon results in studies limited to patients selected for the presence of this mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EGFR TKIs as initial therapy for advanced NSCLC in elderly and poor performance status patients were originally studied in unselected populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. These trials failed to demonstrate an overall survival advantage compared with chemotherapy.",
"   </p>",
"   <p>",
"    Single agent EGFR TKIs can have a particularly dramatic benefit in very elderly and poor performance status patients whose tumors contain a sensitizing mutation in EGFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/19\">",
"     19",
"    </a>",
"    ]. As an example, in a Japanese study, 30 patients with previously untreated, advanced NSCLC and an EGFR mutation were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    (250",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36455/abstract/20\">",
"     20",
"    </a>",
"    ]. Partial or complete responses were observed in 19 of 29 evaluable patients (66 percent). Among the 22 patients with a performance status &ge;3, 15 (68 percent) improved to a performance status &le;1. The median progression-free survival, median overall survival, and one-year survival rates for the entire cohort were 6.5 months, 18 months, and 63 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272524038\">",
"    <span class=\"h2\">",
"     ALK fusion oncogene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the ALK fusion oncogene conferred sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    , a specific inhibitor of the anaplastic lymphoma kinase (ALK) tyrosine kinase, in phase II and III studies. Although the trials with crizotinib contained only a limited number of elderly patients, this approach is preferred for the initial treatment of these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older age and a poor performance status increase the risk of serious toxicity associated with systemic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The choice of treatment should consider the patients overall medical condition and age, as well as the molecular and histologic features of the tumor. (See",
"      <a class=\"local\" href=\"#H272523920\">",
"       'Chemotherapy versus targeted therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"       \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For elderly or borderline performance status patients (ECOG PS 2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      )) whose tumor does not contain an EGFR mutation or the ALK fusion oncogene and who are candidates for systemic therapy, we recommend cytotoxic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Our general approach is to use a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -based doublet if the treating physician thinks that the doublet therapy will be tolerated. Single agent chemotherapy may be an alternative for patients who cannot tolerate combination chemotherapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For elderly patients or poor performance status whose tumor contains an EGFR mutation, we recommend treatment with an EGFR tyrosine kinase inhibitor (TKI) rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients whose tumor does not contain an EGFR mutation but who refuse chemotherapy or are unlikely to tolerate even single agent therapy, an EGFR TKI (erlotinib, gefitinib) may be considered, but the benefit is unlikely to be meaningful. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'EGFR mutation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For elderly or poor performance status patients whose tumors contain the ALK fusion oncogene, we recommend initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H272524038\">",
"       'ALK fusion oncogene'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=see_link&amp;anchor=H11#H11\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Crizotinib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Surveillance Epidemiology and End Results database. file://seer.cancer.gov/ (Accessed on September 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/2\">",
"      Lilenbaum RC, Cashy J, Hensing TA, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 2008; 3:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/3\">",
"      Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 2012; 30:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/4\">",
"      Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/5\">",
"      Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24:3657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/6\">",
"      Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/7\">",
"      Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/8\">",
"      Abe T, et Al. Randomized phase III trial comparing weekly docetaxel-cisplatin combination with triweekly docetaxel alone in elderly patients with advance non-small cell lung cancer: An intergroup tiral of JCOG0803/WJOG4307L. J Clin Oncol 2011; 29:478s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/9\">",
"      Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/10\">",
"      Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/11\">",
"      Lilenbaum R, Villaflor VM, Langer C, et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 2009; 4:869.",
"     </a>",
"    </li>",
"    <li>",
"     Lilenbaum R, et al. A randomized phase III trial of single agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 (suppl: abstract #7506). J Clin Oncol 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/13\">",
"      Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/14\">",
"      Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010; 5:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/15\">",
"      Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012; 307:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/16\">",
"      Crin&ograve; L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26:4253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/17\">",
"      Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients &gt; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/18\">",
"      Lee SM, Rudd R, Khan I, et al. TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy (abstract #7504). J Clin Oncol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/19\">",
"      Langer CJ. The \"lazarus response\" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 2009; 27:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36455/abstract/20\">",
"      Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27:1394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4606 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36455=[""].join("\n");
var outline_f35_38_36455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272523920\">",
"      CHEMOTHERAPY VERSUS TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTEMIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363162897\">",
"      Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H363162787\">",
"      - Vinorelbine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Other single agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525780428\">",
"      Chemotherapy plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1138417267\">",
"      TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EGFR mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H272524038\">",
"      ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4606|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?39/0/39950\" title=\"algorithm 1\">",
"      Initial approach to patients with newly diagnosed NSCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 3\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=related_link\">",
"      Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36456="Urine output and residual renal function in renal failure";
var content_f35_38_36456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urine output and residual renal function in renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36456/contributors\">",
"     Anthony Bleyer, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36456/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36456/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/38/36456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the glomerular filtration rate (GFR) is very low in patients with end-stage renal disease, the urine output is variable, ranging from oliguria to normal or even above normal levels. These findings are related to the fact that the urine output is determined, not by the GFR alone, but by the difference between the GFR and the rate of tubular reabsorption. If, for example, a patient with advanced acute or chronic renal failure has a GFR of 5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (versus the normal of 140 to 180",
"    <span class=\"nowrap\">",
"     L/day),",
"    </span>",
"    the daily urine output will still be 1.5 L if only 3.5 L of the filtrate is reabsorbed.",
"   </p>",
"   <p>",
"    It had been thought that tubular damage impaired the ability to reabsorb sodium and water, thereby contributing to the maintenance of an adequate urine output in this setting. However, it seems more likely that volume expansion (due to initial sodium retention) and a urea osmotic diuresis (as the daily urea load is excreted by fewer functioning nephrons), due in part to solute intake, play a more important role in the persistent urine output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, water intake (which usually determines the urine output via changes in the secretion of antidiuretic hormone [ADH]) plays relatively little role in regulating the urine output in advanced renal disease. These patients can neither dilute nor concentrate the urine normally; the range of urine osmolality that can be achieved may vary from a minimum of 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    to a maximum of 300",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    compared with 50 to 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The net effect of this ADH-resistance is that variations in ADH release in response to changes in water intake have relatively little effect on the urine output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL IMPORTANCE OF RESIDUAL RENAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of residual renal function in patients with end-stage renal disease has important clinical manifestations. This includes adverse effects upon volume control and patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the remaining GFR may only be 4 to 5",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      in patients begun on maintenance dialysis, this is sufficient to make a significant contribution to the removal of potential uremic toxins since filtration is continuous, as opposed to the 12 hours per week that the patient is undergoing hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Continued urine output also facilitates the regulation of fluid and electrolyte balance and may enhance nutritional status and survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/7,9-12\">",
"       7,9-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluid removal is an essential function of the kidney and the one most identifiable by patients. The amount of urine output in dialysis patients equates to fluid that does not need to be removed with dialysis (either peritoneal or hemodialysis). In hemodialysis, decreasing fluid removal with each dialysis treatment decreases the possibility of intradialytic hypotension, which can lead to myocardial stunning, ischemia, and increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link&amp;anchor=H441018086#H441018086\">",
"       \"Hemodynamic instability during hemodialysis: Overview\", section on 'Clinical significance'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In peritoneal dialysis, the need to remove less fluid allows for the use of dialysate with a lower glucose concentration, decreasing the caloric intake from peritoneal dialysis and also decreasing the toxicity of glucose and glucose intermediates to the peritoneal membrane [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/12/18632?source=see_link&amp;anchor=H6#H6\">",
"       \"Peritoneal dialysis solutions\", section on 'Low molecular weight agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among peritoneal dialysis and hemodialysis patients, the beneficial effect of continued residual renal function on survival is clear, as shown in the CANUSA study, a large study of Canadian and US peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/15\">",
"     15",
"    </a>",
"    ], the Netherlands Cooperative Study of the Adequacy of Dialysis (Necosad) study, a study of 1800 hemodialysis and peritoneal dialysis patients, and others. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore, one should adopt measures aimed at preserving residual renal function among peritoneal and hemodialysis patients and improving endogenous fluid removal through increased urine volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECT OF DIALYSIS MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both volume expansion and the high urea load per nephron are rapidly reversed by dialysis (of any form), which removes sodium, water, and urea. Therefore, it is not surprising that many patients have a marked reduction in, or even cessation of, urine output when dialysis is instituted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/1\">",
"     1",
"    </a>",
"    ]. This observation has raised the question of whether dialysis itself worsens or delays recovery of residual renal function in patients with chronic renal failure. This issue is unresolved in acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peritoneal and hemodialysis may have different effects on residual renal function. This is discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemodialysis versus peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons that are incompletely understood, the loss of residual renal function appears to occur more rapidly with hemodialysis than with peritoneal dialysis (PD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/8,16-19\">",
"     8,16-19",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 279 hemodialysis and 243 PD patients, loss of residual renal function was greater in hemodialysis patients than PD patients, with PD patients on average having a 30 percent higher residual GFR than hemodialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a retrospective study of 811 hemodialysis and 1032 PD patients, PD patients had a 65 percent lower risk of oliguria (self-reported urine volume less than 200",
"      <span class=\"nowrap\">",
"       mL/d)",
"      </span>",
"      at one year of follow-up compared with hemodialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is important to note that many of the studies addressing this issue are older, and at the time modern hemodialytic techniques such as volumetric control, ultrapure water, and biocompatible membranes were not in use. Residual renal function has also been studied extensively in the peritoneal dialysis population but there have been few studies in the hemodialysis population.",
"   </p>",
"   <p>",
"    Potential reasons for differences in loss of residual renal function with hemodialysis include intermittent hypotension and activation of nephrotoxic inflammatory mediators during treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In one study of 522 patients initiating either peritoneal dialysis or hemodialysis, predictors of the rate of decline in residual renal function at baseline included a higher diastolic blood pressure and increased proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/19\">",
"     19",
"    </a>",
"    ]. Over time, decreases in residual renal function were associated with hypotension with hemodialysis and dehydration episodes with peritoneal dialysis. Relatively higher renal function was consistently observed with peritoneal dialysis, which increased over time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another possible explanation for the different effect upon residual renal function is that volume expansion with continuous peritoneal dialysis may help to preserve renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/19,20,22\">",
"     19,20,22",
"    </a>",
"    ]. In one study that examined volume control versus the use of antihypertensive agents for control of hypertension in hemodialysis patients with a baseline urine production of approximately 1600",
"    <span class=\"nowrap\">",
"     mL/day,",
"    </span>",
"    urine output dropped by only 12 percent during treatment with antihypertensive medications, but with the use of volume removal, urine output decreased to less than 200",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/22\">",
"     22",
"    </a>",
"    ]. Blood pressure control improved and left ventricular mass decreased significantly with volume removal.",
"   </p>",
"   <p>",
"    As mentioned above, newer hemodialytic techniques may result in a slower rate of decline of residual renal function. In one study, the loss of residual renal function was similar in a comparison of 175 patients receiving continuous ambulatory peritoneal dialysis versus 300 patients dialyzed with ultrapure water, bicarbonate buffer, and high-flux polysulphone membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While it appears that residual renal function decline is more rapid in hemodialysis patients, the loss of residual renal function is only one of many factors in the decision regarding which dialysis modality should be used for the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is suggestive evidence that the institution of maintenance hemodialysis alone may accelerate nephronal injury in the few nephrons that are still functioning at the onset of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/23\">",
"     23",
"    </a>",
"    ], resulting in a progressive fall in the residual glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/8,16-19\">",
"     8,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of the hemodialysis procedure may affect the rate of loss of function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodialysis with biocompatible membranes may better preserve residual renal function compared with bioincompatible membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26902?source=see_link\">",
"       \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most of the studies in this area have suffered from methodologic flaws or small sample sizes. In a prospective, multicenter, randomized study of 159 incident hemodialysis patients who were assigned to dialysis with high-flux membranes or low-flux bioincompatible membranes, there was no statistical difference in the rate of change of renal function, although the residual renal function at the start of the study was quite low (approximately 1",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      the bio-incompatible membrane group and 0.7",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      in the control group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective randomized study of 20 dialysis patients who were dialyzed with either cellulose or polysulfone membranes, there was better preservation of residual renal function in the polysulfone group at one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The possible role of the hemodialysis dialysate was addressed in a study in which 30 patients initiating hemodialysis were randomly assigned to dialysis using either conventional or ultrapure dialysate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/29\">",
"       29",
"      </a>",
"      ]. Residual renal function in the ultrapure group was significantly higher at 24 months (4.3 versus 2.5",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      Markers of inflammation, such as C-reactive protein, were also significantly lower among these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3383?source=see_link\">",
"       \"Ultrapure dialysate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As mentioned above, the loss of residual renal function was similar in a comparison of 175 patients receiving continuous ambulatory peritoneal dialysis versus 300 patients dialyzed with ultrapure water, bicarbonate buffer, and high-flux polysulphone membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these findings suggest that the use of biocompatible membranes (which is already in place in most dialysis centers) and the use of ultrapure water may decrease the risk of loss of residual renal function, though definitive data in this area is lacking. Avoiding hypotension during hemodialysis treatments appears beneficial in preserving residual renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although earlier studies suggested that automated forms of peritoneal dialysis (APD) might be associated with a more rapid decline in residual renal function, more recent students have found minimal effect of PD modality on the loss of residual renal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective nonrandomized study evaluated residual renal function after six months of dialysis among 18 patients treated with nightly intermittent peritoneal dialysis (NIPD), continuous cycler peritoneal dialysis (CCPD), or continuous ambulatory peritoneal dialysis (CAPD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/30\">",
"       30",
"      </a>",
"      ]. The average renal clearance prior to the initiation of dialysis among patients in each group was approximately 4.0",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. The loss of residual renal function was significantly less among patients treated with CAPD (+0.01",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per month) than among those treated with NIPD or CCPD (-0.29 and -0.34",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per month, respectively).",
"     </li>",
"     <li>",
"      A second prospective study assessed the loss of renal function at six months and one year among 18 patients beginning treatment with CAPD and 18 starting intermittent dialysis (12 treated with CCPD and six with NIPD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/31\">",
"       31",
"      </a>",
"      ]. The loss of function was significantly higher in the group undergoing intermittent dialysis compared with the continuous dialysis group: -0.28 versus -0.10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at six months and -0.26 versus -0.13",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at one year, respectively.",
"     </li>",
"     <li>",
"      In a single-center retrospective study of 70 CAPD and 114 APD patients, modality choice did not affect change in residual renal function over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Cochrane Database systematic review, published in 2007, showed no association between modality and loss of residual renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/33\">",
"       33",
"      </a>",
"      ]. However, this study only analyzed three early trials.",
"     </li>",
"     <li>",
"      In a prospective study of 647 dialysis patients (505 CAPD and 78 APD), APD was associated with a nearly two-fold higher risk of losing residual renal function during the first year, which persisted after adjusting for multiple variables. This study did not adjust for the multiple comparisons performed in the analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 179 CAPD and 441 APD patients from the United States, with mean survival on therapy of 1407 days in CAPD patients and 1616 days in APD patients, there was no significant difference in residual renal function decline over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, studies are conflicting and show that different peritoneal dialysis modalities likely have limited effect on the decline in residual renal function over time. Modality choice at this time should not be determined by risk of loss of residual renal function according to a particular peritoneal dialysis modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7291615\">",
"    <span class=\"h1\">",
"     FACTORS THAT MAY AFFECT RESIDUAL RENAL FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7291631\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics appear beneficial in increasing urine and sodium excretion but do not affect residual renal function. Residual renal function was prospectively evaluated among 61 peritoneal dialysis patients randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    (250",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or no furosemide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/36\">",
"     36",
"    </a>",
"    ]. At 6 and 12 months, urine volume was significantly higher in the group receiving the diuretic, but the clearance of both creatinine and urea had declined at a constant rate in both groups. The furosemide dose that was used in this study was much higher than that usually considered by most nephrologists, and may be associated with side effects in dialysis, including pseudoporphyria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21111?source=see_link&amp;anchor=H1008808#H1008808\">",
"     \"Pseudoporphyria\", section on 'Hemodialysis and peritoneal dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diuretics are likely to decrease the need for volume removal with either form of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/7\">",
"     7",
"    </a>",
"    ]. Therefore, they should be considered in peritoneal dialysis patients to help prevent the need for high glucose exchanges and in hemodialysis patients to minimize interdialytic weight gain and the requirement for large-volume ultrafiltration which is associated with cramping, hypotension, and myocardial stunning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. There are no carefully controlled studies to advise on dosage or choice of diuretics. A Dialysis Outcomes and Practice Pattern Study (DOPPS) suggested that there is marked variability in the use of loop diuretics between different facilities, ranging from 9 percent in the U.S. to 21 percent in Europe and 48 percent in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/7\">",
"     7",
"    </a>",
"    ]. In this observational study, diuretic usage was associated with lower interdialytic weight gain, lower risk of hyperkalemia, and a non-significant trend towards lower mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7291688\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preservation of residual renal function among those undergoing peritoneal dialysis may be enhanced by the administration of an ACE inhibitor. This was shown in a study of 60 patients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/38\">",
"     38",
"    </a>",
"    ]. The average residual glomerular filtration at one year was significantly higher among those given ramipril (1.72 and 0.64",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ).",
"   </p>",
"   <p>",
"    Similar benefits in terms of preserving residual renal function have been observed with an angiotensin II receptor blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/39\">",
"     39",
"    </a>",
"    ]. In a randomized two-year controlled study of 34 Japanese peritoneal dialysis patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    maintained residual renal function (3.2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    at baseline to 4.3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) and total clearance (42.1 to 48.3",
"    <span class=\"nowrap\">",
"     L/week",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ); compared with the control group, residual renal function decreased (5.9 to 2.8",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) and total clearance declined (47.1 to 31.4",
"    <span class=\"nowrap\">",
"     L/week",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ). Significant differences between the two groups in terms of renal function were noted at two-year study end.",
"   </p>",
"   <p>",
"    In part, these findings led the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    work group for peritoneal dialysis adequacy to recommend the use of ACE inhibitors or angiotensin II receptor blockers to help preserve residual renal function in those who require antihypertensive medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. They suggest that such agents should also be considered for nephrotection among normotensive peritoneal dialysis patients. However, at present, there is not enough evidence to recommend the use of these agents in normotensive patients, unless they have other specific indications for these medications (such as heart failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7291695\">",
"    <span class=\"h2\">",
"     Biocompatible peritoneal dialysis solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/42\">",
"     42",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] studies have suggested that more biocompatible peritoneal dialysis solutions preserve residual renal function. In a prospective trial of 91 peritoneal dialysis patients randomly assigned to conventional lactate-buffered peritoneal dialysate or to Balance (a neutral pH solution with low glucose degradation products), GFR in the Balance group did not change over a 12-month period whereas GFR in the conventional dialysate group decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/42\">",
"     42",
"    </a>",
"    ]. Another prospective open-label randomized trial of 91 patients showed that at 24 months, the GFR was twofold higher in the biocompatible fluid group compared with the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/45\">",
"     45",
"    </a>",
"    ]. However other studies showed no difference in GFR associated with biocompatible solutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. As an example, in a prospective randomized controlled study, residual renal function was compared in 61 patients receiving standard peritoneal dialysate (Dianeal or Staysafe) versus 57 patients who received Balance or another biocompatible solution, Physioneal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/43\">",
"     43",
"    </a>",
"    ]. No difference in residual renal function was observed at 3 and 12 months. In a more recent one-year study, 185 incident peritoneal dialysis patients with residual renal function were assigned to receive either a conventional solution or a neutral pH, lactate-buffered, low GDP Balance solution in plasticizer-free bags. Although there was no statistical difference in the primary outcome of slope of renal functional decline, the biocompatible group had a significantly longer time to anuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that aminoglycosides are nephrotoxic, it is generally believed that aminoglycosides should be used with caution to preserve residual renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a number of studies have found no effect of aminoglycoside use on the decline of residual renal function. As an example, residual renal function was determined at baseline and at follow-up in 70 PD patients who received aminoglycosides for peritonitis, 61 individuals with peritonitis who did not receive antibiotics, and 74 control patients without peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/47\">",
"     47",
"    </a>",
"    ]. There was no significant difference in the rate of renal function decline between groups. The lack of effect of aminoglycosides was also observed in a retrospective analysis of 1412 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/48\">",
"     48",
"    </a>",
"    ]. The change in residual renal function over time was similar in 1075 patients who received empiric aminoglycosides for peritonitis as compared with 339 who did not.",
"   </p>",
"   <p>",
"    Another study of 102 patients who received either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    and netilmicin or cefazolin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    showed no differences in residual renal function between groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus limited data suggest that the risk of loss of residual renal function from short-term use of aminoglycosides for peritonitis is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Iodinated radiocontrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodinated radiocontrast agents can cause acute tubular necrosis, possibly leading to the loss of residual renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, three studies that prospectively evaluated the effect of contrast on residual renal function found no loss of function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, residual renal function was evaluated at baseline and two weeks after contrast administration in 36 peritoneal dialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/50\">",
"       50",
"      </a>",
"      ]. Thirty-six control patients also underwent determination of residual renal function two weeks apart. Studies were performed with adequate prehydration and minimal contrast usage (mean urinary volume 104 mL). No differences were found between baseline and follow-up residual renal function and urine volume in those receiving contrast, and results were not statistically different from controls.",
"     </li>",
"     <li>",
"      In a second study of 10 peritoneal dialysis patients who received non-ionic hypo-osmolar contrast media, residual renal function was measured on days 1 through 7, day 10, and day 30 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/51\">",
"       51",
"      </a>",
"      ]. There was a mild decline in mean renal clearance on day 6, but clearance subsequently increased back to baseline by day 30.",
"     </li>",
"     <li>",
"      One study showed no difference in the rate of loss of residual renal function at six months in 42 patients who were given approximately 100 mL of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      contrast compared with 45 patients who did not receive contrast [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these studies, it is prudent to avoid radiocontrast agents in dialysis patients, if possible. The primary alternative to iodinated radiocontrast media is imaging with gadolinium-based MR imaging or the use of noncontrast imaging studies. However, among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7291755\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of N-acetylcysteine may help to preserve residual renal function. This was suggested by a pilot study in which oral N-acetylcysteine was administered at a dose of 1200 mg daily for four weeks to ten peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/53\">",
"     53",
"    </a>",
"    ]. There was a trend toward improvement from baseline in residual renal function, with an increase in mean urea and creatinine clearance, urine volume, and residual renal",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    These results are interesting, but the study is limited by the lack of a control group and small patient numbers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7291762\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors may affect residual renal function. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated baseline uric acid levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Repeated episodes of peritonitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/55,56\">",
"       55,56",
"      </a>",
"      ] although this was not confirmed in all studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Peripheral vascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Larger body mass index [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increasing age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher baseline GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Initiation of dialysis after renal transplant failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36456/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The loss of residual renal function in patients with end-stage renal disease has important clinical manifestations. This includes adverse effects upon volume control and patient survival. Among both peritoneal dialysis and hemodialysis patients, continued residual renal function is associated with improved survival. We therefore suggest the adoption of measures aimed at preserving residual renal function among peritoneal dialysis patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) and hemodialysis patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Survival'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"       \"Adequacy of peritoneal dialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"       \"Kt/V and the adequacy of hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both volume expansion and the high urea load per nephron are rapidly reversed by dialysis of any form. Therefore, many patients have a marked reduction in, or even cessation of, urine output when dialysis is instituted. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effect of dialysis modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Residual renal function may be better maintained in patients on peritoneal dialysis patients compared with hemodialysis. However, comparison studies may not account for modern techniques in hemodialysis &ndash; such as biocompatible membranes, ultrapure dialysate, and volumetric control &ndash; that may result in preservation of renal function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hemodialysis versus peritoneal dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diuretics do not improve glomerular filtration rate (GFR), but may significantly increase urine output. Such increases in urine output will result in a reduced need for ultrafiltration with hemodialysis and a reduced need for high glucose exchanges in peritoneal dialysis. The use of diuretics may benefit individuals on dialysis with residual renal function. (See",
"      <a class=\"local\" href=\"#H7291631\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme inhibitors may preserve residual renal function and may be of benefit especially in patients with cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H7291688\">",
"       'Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/1\">",
"      Yeh BP, Tomko DJ, Stacy WK, et al. Factors influencing sodium and water excretion in uremic man. Kidney Int 1975; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/2\">",
"      Danovitch GM, Bourgoignie J, Bricker NS. Reversibility of the \"salt-losing\" tendency of chronic renal failure. N Engl J Med 1977; 296:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/3\">",
"      Feinfeld DA, Danovitch GM. Factors affecting urine volume in chronic renal failure. Am J Kidney Dis 1987; 10:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/4\">",
"      Tannen RL, Regal EM, Dunn MJ, Schrier RW. Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 1969; 280:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/5\">",
"      Bargman JM, Golper TA. The importance of residual renal function for patients on dialysis. Nephrol Dial Transplant 2005; 20:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/6\">",
"      Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/7\">",
"      Bragg-Gresham JL, Fissell RB, Mason NA, et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 2007; 49:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/8\">",
"      Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int Suppl 1993; 40:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/9\">",
"      Suda T, Hiroshige K, Ohta T, et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 2000; 15:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/10\">",
"      Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/11\">",
"      Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/12\">",
"      Szeto CC, Wong TY, Chow KM, et al. Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003; 18:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/13\">",
"      Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/14\">",
"      Krediet RT, Zweers MM, van Westrhenen R, et al. What can we do to preserve the peritoneum? Perit Dial Int 2003; 23 Suppl 2:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/15\">",
"      Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/16\">",
"      Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/17\">",
"      Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/18\">",
"      Misra M, Vonesh E, Van Stone JC, et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/19\">",
"      Jansen MA, Hart AA, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/20\">",
"      Lameire N, Van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Perit Dial Int 1997; 17 Suppl 2:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/21\">",
"      McKane W, Chandna SM, Tattersall JE, et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/22\">",
"      Gunal AI, Kirciman E, Guler M, et al. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail 2004; 26:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/23\">",
"      Ogata K. Clinicopathological study of kidneys from patients on chronic dialysis. Kidney Int 1990; 37:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/24\">",
"      McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 1997; 29:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/25\">",
"      Caramelo C, Alc&aacute;zar R, Gallar P, et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/26\">",
"      Lang SM, Bergner A, T&ouml;pfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 2001; 21:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/27\">",
"      Hakim RM, Wingard RL, Husni L, et al. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/28\">",
"      Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/29\">",
"      Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/30\">",
"      Hiroshige K, Yuu K, Soejima M, et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 1996; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/31\">",
"      Hufnagel G, Michel C, Queffeulou G, et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/32\">",
"      Holley JL, Aslam N, Bernardini J, et al. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int 2001; 21:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/33\">",
"      Rabindranath KS, Adams J, Ali TZ, et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev 2007; :CD006515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/34\">",
"      Michels WM, Verduijn M, Grootendorst DC, et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/35\">",
"      Cnossen TT, Usvyat L, Kotanko P, et al. Comparison of outcomes on continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis: results from a USA database. Perit Dial Int 2011; 31:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/36\">",
"      Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/37\">",
"      van Olden RW, van Meyel JJ, Gerlag PG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol 1992; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/38\">",
"      Li PK, Chow KM, Wong TY, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/39\">",
"      Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/40\">",
"      K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 2006; 47(Supp 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/41\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/42\">",
"      Kim S, Oh J, Kim S, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/43\">",
"      Fan SL, Pile T, Punzalan S, et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/44\">",
"      Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/45\">",
"      Kim S, Oh KH, Oh J, et al. Biocompatible peritoneal dialysis solution preserves residual renal function. Am J Nephrol 2012; 36:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/46\">",
"      Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/47\">",
"      Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/48\">",
"      Badve SV, Hawley CM, McDonald SP, et al. Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrol Dial Transplant 2012; 27:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/49\">",
"      Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/50\">",
"      Moranne O, Willoteaux S, Pagniez D, et al. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 2006; 21:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/51\">",
"      Dittrich E, Puttinger H, Schillinger M, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients--a prospective study. Nephrol Dial Transplant 2006; 21:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/52\">",
"      Janousek R, Krajina A, Peregrin JH, et al. Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study. Cardiovasc Intervent Radiol 2010; 33:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/53\">",
"      Feldman L, Shani M, Efrati S, et al. N-acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study. Perit Dial Int 2011; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/54\">",
"      Park JT, Kim DK, Chang TI, et al. Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Nephrol Dial Transplant 2009; 24:3520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/55\">",
"      Shin SK, Noh H, Kang SW, et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/56\">",
"      Tian SL, Tian XK, Han QF, et al. Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients. Perit Dial Int 2012; 32:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/57\">",
"      Singhal MK, Bhaskaran S, Vidgen E, et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/58\">",
"      Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis 2009; 53:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36456/abstract/59\">",
"      Madar H, Korzets A, Ori Y, et al. Residual renal function in peritoneal dialysis after renal transplant failure. Perit Dial Int 2010; 30:470.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1941 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36456=[""].join("\n");
var outline_f35_38_36456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL IMPORTANCE OF RESIDUAL RENAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECT OF DIALYSIS MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemodialysis versus peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7291615\">",
"      FACTORS THAT MAY AFFECT RESIDUAL RENAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7291631\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7291688\">",
"      Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7291695\">",
"      Biocompatible peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Iodinated radiocontrast agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7291755\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7291762\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/12/18632?source=related_link\">",
"      Peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21111?source=related_link\">",
"      Pseudoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3383?source=related_link\">",
"      Ultrapure dialysate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36457="Prevention and management of tympanostomy tube otorrhea in children";
var content_f35_38_36457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and management of tympanostomy tube otorrhea in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36457/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/38/36457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanostomy tube otorrhea may occur immediately after tube insertion from an existing infection in the middle ear (acute otitis media, AOM), or later, with subsequent middle ear infections or infectious processes in the ear canal.",
"   </p>",
"   <p>",
"    The prevention and management of tympanostomy tube otorrhea in children will be discussed here. An overview of tympanostomy tube placement and medical care of children with tympanostomy tubes, otitis media with effusion, and treatment and prevention of acute otitis media are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=see_link\">",
"     \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22153?source=see_link\">",
"     \"Otitis media with effusion (serous otitis media) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42857?source=see_link\">",
"     \"Acute otitis media in children: Prevention of recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tympanostomy tube otorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanostomy tube otorrhea (TTO, also called post-tympanostomy tube otorrhea, PTTO), is defined as active drainage through an existing tympanostomy tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1\">",
"     1",
"    </a>",
"    ]. Early-onset TTO occurs within two weeks of tube placement, while late-onset TTO occurs more than two weeks after tube placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Chronic or persistent TTO usually refers to otorrhea of &ge;6 to 8 weeks' duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Recurrent TTO refers to distinct episodes of TTO between which the otorrhea clears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic suppurative otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic suppurative otitis media (CSOM) is defined as purulent otorrhea that lasts for longer than six weeks despite treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1\">",
"     1",
"    </a>",
"    ]. It may result from an unresolved or complicated AOM with perforation of the tympanic membrane or from a preexisting perforation that occurred spontaneously or after extrusion or removal of a tympanostomy tube. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H111861298#H111861298\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Chronic suppurative otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION OF TYMPANOSTOMY TUBE OTORRHEA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Early-onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 20 percent of children who undergo placement of tympanostomy tubes develop otorrhea during the early post-operative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of early post-operative otorrhea is not affected by surgical technique or preparation of the ear canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative risk of early post-operative otorrhea is increased among children younger than two years of age, and children with inflamed middle-ear mucosa, mucoid effusion, and bacterial pathogens in the ear canal or middle-ear effusion at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Bacterial pathogens are identified in about 30 percent of middle-ear effusions that are cultured at the time of tube insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of prophylactic eardrops during the post-operative period may decrease the incidence of early otorrhea and tube occlusion. This was demonstrated in a meta-analysis of randomized trials of topical antimicrobial prophylaxis against purulent otorrhea after tympanostomy tube insertion in which prophylactic treatment resulted in an 85 percent reduction in post-operative otorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/8\">",
"     8",
"    </a>",
"    ]. The beneficial effect of prophylaxis is most pronounced when effusion is present at the time of tube insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/9\">",
"     9",
"    </a>",
"    ]. It is independent of the eardrop used (eg, saline, antibiotic eardrop with or without steroid,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/22/35168?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/54/3940?source=see_link\">",
"     sulfacetamide-prednisolone",
"    </a>",
"    eye drops) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/9-14\">",
"     9-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has not approved any medications for prevention of tube otorrhea after tympanostomy tube insertion. In addition, there is a lack of consensus among otolaryngologists regarding the need for prophylaxis to prevent early-onset tube otorrhea, which drops are most effective and least harmful, and what dosing regimen should be used.",
"   </p>",
"   <p>",
"    The decision regarding the provision of prophylaxis is usually made by the operating otolaryngologist. We suggest that eardrops be administered in the post-operative period to prevent early-onset otorrhea after tympanostomy tube placement in children. The author uses",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/22/35168?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    (three drops three times per day for three days) since it is inexpensive, effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/10\">",
"     10",
"    </a>",
"    ], contains no antibiotics, and is not ototoxic in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/15\">",
"     15",
"    </a>",
"    ]. The drops are discontinued if they cause stinging. Other regimens, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , may be equally effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Late-onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of children who undergo placement of tympanostomy tubes have at least one episode of late-onset TTO while the tube remains in place (",
"    <a class=\"graphic graphic_picture graphicRef64324 \" href=\"mobipreview.htm?0/41/671\">",
"     picture 1",
"    </a>",
"    ), and 7 percent develop recurrent TTO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2\">",
"     2",
"    </a>",
"    ]. Published rates of TTO range from 4 to 83 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,16-18\">",
"     2,16-18",
"    </a>",
"    ]. The wide range is not surprising considering that the various studies followed children of different ages, used different measures to define otorrhea, and observed the children for different periods of time. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective review of 246 children with tympanostomy tubes, late-onset TTO occurred in 50 percent of children after a median of 4.8 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17\">",
"       17",
"      </a>",
"      ]. Multiple episodes of TTO were reported in 22 percent, with three or more discrete episodes in 9 percent, and six or more episodes in 1.6 percent.",
"     </li>",
"     <li>",
"      Another prospective study followed 173 children aged 6 to 36 months of age who underwent tympanostomy tube placement for persistent middle-ear effusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/16\">",
"       16",
"      </a>",
"      ]. Children were followed until tube extrusion (a median of 14 months with a range of 19 days to 39 months): 75 and 83 percent of patients had at least one episode of TTO by 12 and 18 months, respectively. The mean number of episodes per child increased with the duration of tube placement: 0.8 in the first 6 months, 1.5 in the first 12 months, 2 in the first 18 months, and 2.8 in the first 24 months. The median duration of otorrhea was 10 days (range 3 to 131 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants and young children with tubes inserted to control recurrent episodes of AOM are more likely than older children to experience late-onset otorrhea than children with tubes inserted for otitis media with effusion (OME, chronic otitis media) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/6\">",
"     6",
"    </a>",
"    ]. In temperate climates, TTO occurs most often during the winter months in young children and the summer months in older children, coinciding with upper respiratory infection season and swimming season, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prevention of AOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of recurrent TTO in young children during the winter months involves the same measures used to control recurrent AOM in infants and young children. These measures include hand washing and immunization against Streptococcus pneumoniae and influenza (Streptococcus pneumoniae immunization is part of the universal immunization schedule for infants and young children in the United States; influenza vaccination is currently recommended for all children aged six months and older) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. When feasible, withdrawal from day care should have a positive effect. The effect of prophylactic antibiotics in the prevention of TTO has not been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42857?source=see_link\">",
"     \"Acute otitis media in children: Prevention of recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Water precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of late-onset otorrhea in older children has largely focused on measures to avoid water entry into the ear canal during bathing or swimming (eg, the use of ear plugs or swimming caps). Such measures make empiric sense given that most TTO in older children occurs during the summer swimming season. However, the need for water precautions in children with tympanostomy tubes is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1,23-25\">",
"     1,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little evidence that water precautions prevent TTO. In meta-analyses of studies of swimming in children with tympanostomy tubes, the rates of otorrhea were similar in swimmers and nonswimmers, in children who swam with and without ear protection, and in children who used eardrops after swimming and those who used ear protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these findings suggest that water precautions do not prevent otorrhea, the impact of the type and location of water activity on otorrhea is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/23\">",
"     23",
"    </a>",
"    ]. The lack of benefit of water precautions may be related to the relatively low concentration of bacteria in well-chlorinated swimming pools (compared to lakes, ponds, rivers, oceans, bath water) or the failure of ear plugs to exclude water from the ear canal during submersion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little water is likely to enter the middle ear during bathing (unless the head is dunked), showering, or surface swimming, but may enter the ear if the head is submerged (eg, swimming under water at a depth of more than four to six feet, diving, head dunking in a bath) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/18,32-35\">",
"     18,32-35",
"    </a>",
"    ]. The risk of water entry into the middle ear is theoretically increased when the water is mixed with soap or shampoo because these agents decrease the surface tension of water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1,18\">",
"     1,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of consensus among otolaryngologists regarding the need for water precautions in children after tympanostomy tube placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Decisions regarding water precautions are usually made by the otolaryngologist in conjunction with the child's parents. We suggest that children who have tympanostomy tubes wear ear plugs during all types of water exposure. Routine use of ear plugs may help to ensure that the ear plugs are used during exposure to contaminated water. We also suggest that children with tympanostomy tubes avoid diving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACUTE TYMPANOSTOMY TUBE OTORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute tympanostomy tube otorrhea (TTO) in children refers to TTO that lasts less than six to eight weeks. It usually results from acute otitis media following an upper respiratory infection, or from the introduction of contaminated water from the ear canal into the middle ear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children two years and younger, acute TTO is usually caused by the same pathogens that cause AOM in children without tubes (eg, Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17,36-38\">",
"     17,36-38",
"    </a>",
"    ]. Pseudomonas aeruginosa and Staphylococcus aureus are more prevalent in older children with TTO induced by water penetration, or when TTO persists despite an oral antibiotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17,36,39\">",
"     17,36,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H16#H16\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated acute TTO is unknown. In anecdotal experience, many episodes resolve spontaneously within several days of onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/40\">",
"     40",
"    </a>",
"    ]. Similarly, viral myringitis (tympanic membrane erythema without purulent infection) and early AOM may abort spontaneously without drainage because the tube provides middle ear ventilation. Thus, active therapy for AOM may be withheld pending the presence of otorrhea in the tube orifice or in the external auditory canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute TTO in children depends upon the age of the child, the clinical status, and the most likely pathogens. The most common interventions include topical antibiotic eardrops or systemic antibiotics. These may be used alone or in combination. Ototopical drops usually contain specific antibiotics with or without corticosteroids. Daily suctioning is also recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1,41\">",
"     1,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of interventions for acute TTO concluded that the available data do not permit identification of the safest and most effective treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/41\">",
"     41",
"    </a>",
"    ]. It is not clear that oral antimicrobial therapy is better than placebo in the absence of daily suctioning of the middle ear through the tube, that oral is better than topical therapy (or vice versa), or that topical or systemic corticosteroids provide any long-lasting benefit. Studies published subsequently have been limited by methodologic flaws and thus have not changed the conclusions of the Cochrane review.",
"   </p>",
"   <p>",
"    A protocol for controlling acute TTO was devised by clinicians at the Otitis Media Research Center in Pittsburgh. It is based upon the microbiology of otorrhea in different clinical situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17\">",
"     17",
"    </a>",
"    ]. The protocol is time tested, highly effective, and cost conscious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In addition, Canadian guidelines for the treatment of TTO, developed by a panel of general otolaryngologists, pediatricians, and family physicians, were published in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/44\">",
"     44",
"    </a>",
"    ]. The recommendations for therapy summarized here and outlined in the sections that follow are predominantly based upon the Pittsburgh Otitis Media Research Center protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest oral or parenteral antimicrobial therapy for acute TTO in infants and children with systemic infection or occlusion of the auditory canal, and for children with TTO who are immunocompromised [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1,40,42,44\">",
"       1,40,42,44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Systemic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest topical antimicrobial therapy for acute TTO in immunocompetent infants and children without systemic symptoms, occlusion of the auditory canal, or auricular cellulitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/37,40,42\">",
"       37,40,42",
"      </a>",
"      ]. Observation is also an option for such patients since many of these episodes resolve spontaneously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,43\">",
"       2,43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Topical therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest combination systemic and topical therapy for children with acute TTO and associated auricular cellulitis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Associated cellulitis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that acute TTO in ill-appearing infants and older children with systemic infection or severe symptoms (eg, fever, lethargy, severe ear pain, copious otorrhea, associated upper respiratory symptoms) be treated with oral or parenteral antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. We also suggest systemic antimicrobial therapy for TTO in immunocompromised children and TTO associated with occlusion of the auditory canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1,40,42,44\">",
"     1,40,42,44",
"    </a>",
"    ]. We suggest high dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    divided twice daily) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (with high dose amoxicillin) as empiric therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ill-appearing infants may have concomitant systemic infection (eg, pneumonia, bacteremia) for which topical therapy has no effect. The antibiotic should have activity against the common pathogens of acute otitis media (eg, S. pneumoniae, M. catarrhalis, H. influenzae).",
"   </p>",
"   <p>",
"    In children with TTO complicated by occlusion of the auditory canal, the ability of topical therapy to reach the middle ear may be compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/3\">",
"     3",
"    </a>",
"    ]. Empiric antimicrobial therapy in such cases should be based upon the most likely pathogens based upon the age of the child. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathogens'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the child fails to respond with resolution of visible otorrhea within five days, we suggest the addition of an antibiotic eardrop with activity against P. aeruginosa and S. aureus. If possible, before the eardrops are prescribed, the ear canal should be cleaned with 8 French suction catheter and the discharge sent for culture and sensitivities. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Topical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If otorrhea persists three to five days after the addition of topical therapy, referral to a pediatric otolaryngologist is warranted for a thorough cleaning of the tube orifice and culture of the middle-ear fluid. Management of persistent otorrhea is discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Chronic tympanostomy tube otorrhea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefits of oral therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    compared to placebo were evaluated in a randomized trial in 79 children (aged 6 to 72 months) with tympanostomy tubes and acute TTO of &lt;48 hours' duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/45\">",
"     45",
"    </a>",
"    ]. All patients underwent daily suctioning of middle-ear fluid through the tympanostomy tube. Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanate was associated with shorter duration of otorrhea (three versus eight days), increased resolution of otorrhea (82 versus 41 percent), and shorter duration of bacterial growth in middle-ear fluid (one versus eight days). However, daily suction of middle-ear fluid may have contributed to a better outcome in patients who received antibiotics, limiting the generalizability of this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest topical antimicrobial therapy for TTO in immunocompetent children without systemic or respiratory symptoms, auricular cellulitis, or occlusion of the auditory canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. Observation is also an option for such patients since many of these episodes resolve spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,43\">",
"     2,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natural history'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Observation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical efficacy of topical antimicrobial therapy has been suggested in pilot studies and comparative trials with orally administered",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. However, the results of such studies must be interpreted with caution. Most were carried out or funded by pharmaceutical companies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In addition, there are concerns about bias in patient selection (older children, unusual pathogens) and study design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/41,43\">",
"     41,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aminoglycoside antibiotic eardrops have been an important part of the treatment of draining ears since the 1970s. Topical aminoglycosides are highly effective against biofilm-forming microorganisms (eg, Pseudomonas aeruginosa, S. aureus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/51\">",
"     51",
"    </a>",
"    ]. Antimicrobial drops containing aminoglycosides have a long history of safe use in humans with draining ears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/52-54\">",
"     52-54",
"    </a>",
"    ] despite the established ototoxicity of aminoglycosides (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/39/22129?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) when instilled directly into the uninfected middle ears of laboratory animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/55\">",
"     55",
"    </a>",
"    ]. A retrospective study showed no increased risk of sensory neural hearing loss in children with nonintact ear drums (tympanic perforations and tympanostomy tubes) when prescribed a single course of neomycin ear drops. A significant increase in risk was observed with two, but not three, courses of these drops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/35/37424?source=see_link\">",
"     Ofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/11/37042?source=see_link\">",
"     ciprofloxacin-dexamethasone",
"    </a>",
"    are the only topical antimicrobials approved by the US Food and Drug Administration (FDA) for treating otorrhea with a nonintact TM. In contrast to oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , these agents provide activity against P. aeruginosa. However, topical antibiotics have no systemic effect and cannot be used to treat concomitant systemic infection. Fluoroquinolone drops are preferred by some, given their broad antimicrobial spectrum, lower risk of ototoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], lower rate of contact dermatitis, and twice-per-day dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/3,12,40,44,57\">",
"     3,12,40,44,57",
"    </a>",
"    ]. However, fluoroquinolone drops are much more expensive than aminoglycoside drops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/40,54\">",
"     40,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial of 68 children &lt;10 years of age with acute TTO without comorbidities compared the efficacy of topical or oral antibiotics versus topical saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/59\">",
"     59",
"    </a>",
"    ]. Therapy was started five to six days after onset of otorrhea on average. Treatment failure rates after seven days of therapy were lowest in the topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    group (23 percent), compared with oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (70 percent) or topical saline (58 percent). However, there were several limitations to this study. First, the topical saline was not a true control group because the ears were irrigated under pressure, which can be an effective treatment. Second, low dose amoxicillin was used, which would be anticipated to be infective in over half of the patients treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the use of a corticosteroid-containing antibiotic drop when treating acute TTO with topical therapy. The addition of a corticosteroid to the antibiotic preparation helps to control granulation tissue involving the tympanic membrane and middle ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/40,49\">",
"     40,49",
"    </a>",
"    ] and may improve the efficacy of the antibiotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/63\">",
"     63",
"    </a>",
"    ]. A potential disadvantage is that corticosteroid preparations are more viscous and may leave a dry residue in the ear canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/64\">",
"     64",
"    </a>",
"    ]. Corticosteroid-containing quinolone drops are very expensive and are not included in many insurance company formularies for this reason.",
"   </p>",
"   <p>",
"    Antibiotic eardrops work well when instilled into a thoroughly cleaned ear with a patent tympanostomy tube. It is less clear whether they work when applied over a collection of pus from a rapidly discharging AOM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In an observational study using an in vitro model, eardrops instilled into a clean external ear canal did not consistently pass through the tympanostomy tube; entry into the middle ear was facilitated by application of slight tragal pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the child fails to respond with resolution of visible otorrhea after three to five days of topical therapy, a trial of oral antimicrobial therapy or referral to a pediatric otolaryngologist for cleaning of the tube orifice and culture of the middle-ear fluid may be warranted. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Systemic therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Chronic tympanostomy tube otorrhea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of eardrops &mdash; Ideally, the ear canal should be cleaned with suction or repeated cotton swabbing before instilling drops. Having the child lie down with the affected ear up for a few moments promotes penetration. The optimal number of drops has not been established. According to the package inserts, the dose for",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/35/37424?source=see_link\">",
"       ofloxacin",
"      </a>",
"      is five drops and for",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/11/37042?source=see_link\">",
"       ciprofloxacin-dexamethasone",
"      </a>",
"      is four drops.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation without topical or oral therapy is an option for acute TTO in immunocompetent children without systemic or respiratory symptoms, auricular cellulitis, or occlusion of the auditory canal, since many of these episodes resolve spontaneously. However, topical therapy should be given if the otorrhea does not resolve within one week. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natural history'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Topical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Associated cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with acute TTO complicated by auricular cellulitis be treated with a combination of systemic and topical therapy. If possible, culture of the drainage should be obtained before antibiotic therapy is initiated. Empiric therapy should include oral antibiotics with activity against S. aureus and S. pneumoniae in addition to topical antibiotics. Placing a porous wick in the inflamed ear canal may facilitate entry of the ototopical drop if the canal is occluded by secondary otitis externa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathogens'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CHRONIC TYMPANOSTOMY TUBE OTORRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic TTO refers to otorrhea that persists for six to eight weeks with or without initial treatment with an ototopical antimicrobial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oral antibiotics. It develops in approximately 4 percent of patients after placement of tympanostomy tubes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common cause of refractory TTO in children treated with topical agents is inadequate penetration of the drops because of inspissated or accumulated debris in the ear canal. Most such cases resolve promptly after thorough cleaning, suctioning of the tube, and application of a steroid-antibiotic topical drop for five to seven days.",
"   </p>",
"   <p>",
"    Prolonged use of any topical antimicrobial, particularly broad-spectrum fluoroquinolones, may result in fungal overgrowth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Children with fungal overgrowth present with thick fungal debris and clogged, itchy, or painful ears (",
"    <a class=\"graphic graphic_picture graphicRef60112 \" href=\"mobipreview.htm?41/44/42702\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Community-acquired methicillin-resistant S. aureus (CA-MRSA) and multiple-drug-resistant Streptococcus pneumoniae are other potential causes of TTO refractory to the usual antimicrobial therapy described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'CA-MRSA strains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otorrhea persisting despite aural toilet, dry ear precautions, and intensive medical management may be caused by granulation tissue (",
"    <a class=\"graphic graphic_picture graphicRef79646 \" href=\"mobipreview.htm?19/40/20096\">",
"     picture 3",
"    </a>",
"    ); an occult cholesteatoma; or unusual pathogens such as Candida albicans, Actinomyces, or Aspergillus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/68,69,72,73\">",
"     68,69,72,73",
"    </a>",
"    ]. Referral to an otolaryngologist is warranted in such patients to prevent the development of serious sequelae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42808?source=see_link\">",
"     \"Cholesteatoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential causes of chronic or recurrent TTO include immune deficiency (particularly when associated with other upper and lower respiratory tract infections) and adenoidal hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with chronic TTO should be referred to their otolaryngologist. It is desirable to directly suction the tube orifice under magnification to obtain material for culture and to ensure adequate cleaning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/74\">",
"     74",
"    </a>",
"    ]. If this is impossible because of equipment limitations or an apprehensive child, drying the ear canal with multiple cotton applicators or suctioning with a short flexible 8 French catheter are alternative ways to clear debris and permit entry of eardrops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend obtaining bacterial culture and sensitivities of the purulent drainage in the ear canal in cases of refractory otorrhea; most laboratories report common fungi on routine culture. Culture is particularly important for detection of resistant organisms (eg, CA-MRSA) or fungal overgrowth after prolonged antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Antimicrobial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that antimicrobial therapy for refractory otorrhea be based upon culture and susceptibility results. In case series, fungal TTO has been successfully treated with thorough cleaning under binocular microscopy and application of topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/58/34720?source=see_link\">",
"     clotrimazole",
"    </a>",
"    solution; some patients require multiple treatments",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic antifungal therapy (oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    for seven days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful eradication of refractory TTO caused by CA-MRSA has been reported with two regimens: oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    with topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or cortisporin otic drops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/70\">",
"     70",
"    </a>",
"    ]; and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    otic drops (not available in the United States) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/71\">",
"     71",
"    </a>",
"    ]. The author has successfully treated several children who had CA-MRSA otorrhea with oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/75\">",
"     75",
"    </a>",
"    ]. Linezolid is available as a palatable oral suspension, but it is expensive. Parenteral antimicrobial therapy is warranted in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Antimicrobial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Removing a tympanostomy tube is occasionally necessary to stop refractory otorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2,16,76\">",
"     2,16,76",
"    </a>",
"    ]. Bacterial biofilms can form on mucosal surfaces and implanted prostheses, including tympanostomy tubes (",
"    <a class=\"graphic graphic_picture graphicRef69293 \" href=\"mobipreview.htm?6/23/6512\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/77\">",
"     77",
"    </a>",
"    ]. These bacterial aggregates are resistant to therapy with systemic antibiotics and to standard culture methods.",
"   </p>",
"   <p>",
"    Evaluation for possible immune deficiency may be warranted in children with TTO caused by unusual pathogens, refractory chronic TTO, or frequent TTO in association with other upper and lower respiratory tract infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients, TTO is brief, painless, and non-recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17\">",
"     17",
"    </a>",
"    ]. Chronic TTO develops in approximately 4 percent of patients after placement of tympanostomy tubes, and recurrent TTO in 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tympanostomy tube otorrhea (TTO) is defined as active drainage through an existing tympanostomy tube. Early-onset TTO occurs within two weeks of tube placement. Late-onset TTO occurs more than two weeks after tube placement. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a lack of consensus among otolaryngologists regarding prophylaxis for early-onset tube otorrhea. We suggest that eardrops be administered in the postoperative period to prevent early-onset otorrhea after tympanostomy tube placement in children (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A variety of agents can be used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Early-onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of recurrent TTO in infants and young children involves the same measures used to control recurrent AOM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42857?source=see_link\">",
"       \"Acute otitis media in children: Prevention of recurrence\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevention of late-onset TTO in older children centers on measures to avoid water entry into the ear canal. We suggest that children who have tympanostomy tubes wear ear plugs during all types of water exposure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Routine use of ear plugs may help to ensure that the ear plugs are used during exposure to contaminated water. We also suggest that children with tympanostomy tubes avoid diving. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Water precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children two years and younger, TTO is usually caused by Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenza; in older children, TTO is usually caused by Pseudomonas aeruginosa and Staphylococcus aureus. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acute tympanostomy tube otorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest systemic antimicrobial therapy for TTO in infants and children with systemic infection or occlusion of the auditory canal and for children with TTO who are immunocompromised (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). High dose",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (75 to 100",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      divided twice daily) or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      (with high dose amoxicillin) is typically used as empiric therapy. Daily suctioning is also advised. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest topical antimicrobial therapy for TTO in immunocompetent children without systemic symptoms, occlusion of the auditory canal, or auricular cellulitis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Observation is also an option for well patients since some of these episodes resolve spontaneously. We suggest the use of a corticosteroid-containing fluoroquinolone drops where available (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Daily suctioning is also advised. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Topical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with refractory TTO should be referred to their otolaryngologist. We recommend that antimicrobial therapy for refractory otorrhea be based upon culture and sensitivity results (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Chronic tympanostomy tube otorrhea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/1\">",
"      Oberman JP, Derkay CS. Posttympanostomy tube otorrhea. Am J Otolaryngol 2004; 25:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/2\">",
"      Kay DJ, Nelson M, Rosenfeld RM. Meta-analysis of tympanostomy tube sequelae. Otolaryngol Head Neck Surg 2001; 124:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/3\">",
"      Myer CM 3rd. Post-tympanostomy tube otorrhea. Ear Nose Throat J 2001; 80:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/4\">",
"      Scott BA, Strunk CL Jr. Posttympanostomy otorrhea: the efficacy of canal preparation. Laryngoscope 1992; 102:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/5\">",
"      Giebink GS, Daly K, Buran DJ, et al. Predictors for postoperative otorrhea following tympanostomy tube insertion. Arch Otolaryngol Head Neck Surg 1992; 118:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/6\">",
"      Debruyne F, Jorissen M, Poelmans J. Otorrhea during transtympanal ventilation. Am J Otol 1988; 9:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/7\">",
"      Sutton DV, Derkay CS, Darrow DH, Strasnick B. Resistant bacteria in middle ear fluid at the time of tympanotomy tube surgery. Ann Otol Rhinol Laryngol 2000; 109:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/8\">",
"      Garcia P, Gates GA, Schechtman KB. Does topical antibiotic prophylaxis reduce post-tympanostomy tube otorrhea? Ann Otol Rhinol Laryngol 1994; 103:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/9\">",
"      Poetker DM, Lindstrom DR, Patel NJ, et al. Ofloxacin otic drops vs neomycin-polymyxin B otic drops as prophylaxis against early postoperative tympanostomy tube otorrhea. Arch Otolaryngol Head Neck Surg 2006; 132:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/10\">",
"      Kumar VV, Gaughan J, Isaacson G, Szeremeta W. Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction. Laryngoscope 2005; 115:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/11\">",
"      Kocaturk S, Yardimci S, Yildirim A, Incesulu A. Preventive therapy for postoperative purulent otorrhea after ventilation tube insertion. Am J Otolaryngol 2005; 26:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/12\">",
"      Morpeth JF, Bent JP, Watson T. A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea. Int J Pediatr Otorhinolaryngol 2001; 61:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/13\">",
"      Charnock DR. Early postoperative otorrhea after tympanostomy tube placement: a comparison of topical ophthalmic and otic drops. Ear Nose Throat J 1997; 76:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/14\">",
"      Hester TO, Jones RO, Archer SM, Haydon RC. Prophylactic antibiotic drops after tympanostomy tube placement. Arch Otolaryngol Head Neck Surg 1995; 121:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/15\">",
"      Daniel SJ, Akinpelu OV, Sahmkow S, et al. Oxymetazoline ototoxicity in a chinchilla animal model. Otolaryngol Head Neck Surg 2012; 146:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/16\">",
"      Ah-Tye C, Paradise JL, Colborn DK. Otorrhea in young children after tympanostomy-tube placement for persistent middle-ear effusion: prevalence, incidence, and duration. Pediatrics 2001; 107:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/17\">",
"      Mandel EM, Casselbrant ML, Kurs-Lasky M. Acute otorrhea: bacteriology of a common complication of tympanostomy tubes. Ann Otol Rhinol Laryngol 1994; 103:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/18\">",
"      Pringle MB. Grommets, swimming and otorrhoea--a review. J Laryngol Otol 1993; 107:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/19\">",
"      Niemel&auml; M, Pihakari O, Pokka T, Uhari M. Pacifier as a risk factor for acute otitis media: A randomized, controlled trial of parental counseling. Pediatrics 2000; 106:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/20\">",
"      Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006; 118:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/21\">",
"      Ozgur SK, Beyazova U, Kemaloglu YK, et al. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatr Infect Dis J 2006; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/22\">",
"      Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otitis media in children. Cochrane Database Syst Rev 2006; :CD004401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/23\">",
"      Isaacson G, Rosenfeld RM. Care of the child with tympanostomy tubes: a visual guide for the pediatrician. Pediatrics 1994; 93:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/24\">",
"      Basu S, Georgalas C, Sen P, Bhattacharyya AK. Water precautions and ear surgery: evidence and practice in the UK. J Laryngol Otol 2007; 121:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/25\">",
"      Poss JM, Boseley ME, Crawford JV. Pacific Northwest survey: posttympanostomy tube water precautions. Arch Otolaryngol Head Neck Surg 2008; 134:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/26\">",
"      Lee D, Youk A, Goldstein NA. A meta-analysis of swimming and water precautions. Laryngoscope 1999; 109:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/27\">",
"      Carbonell R, Ru&iacute;z-Garc&iacute;a V. Ventilation tubes after surgery for otitis media with effusion or acute otitis media and swimming. Systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol 2002; 66:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/28\">",
"      Goldstein NA, Mandel EM, Kurs-Lasky M, et al. Water precautions and tympanostomy tubes: a randomized, controlled trial. Laryngoscope 2005; 115:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/29\">",
"      Smelt GJ, Monkhouse WS. The effect of bath water, sea water and swimming pool water on the guinea pig middle ear. J Laryngol Otol 1985; 99:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/30\">",
"      Marks NJ, Mills RP. Swimming and grommets. J R Soc Med 1983; 76:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/31\">",
"      Robson WL, Leung AK. Swimming and ear infection. J R Soc Health 1990; 110:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/32\">",
"      Hebert RL 2nd, King GE, Bent JP 3rd. Tympanostomy tubes and water exposure: a practical model. Arch Otolaryngol Head Neck Surg 1998; 124:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/33\">",
"      Morgan NJ. Penetration of water down the external auditory meatus to the tympanic membrane. J Laryngol Otol 1987; 101:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/34\">",
"      Pashley NR, Scholl PD. Tympanostomy tubes and liquids--an in vitro study. J Otolaryngol 1984; 13:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/35\">",
"      Wang MC, Liu CY, Shiao AS. Water penetration into middle ear through ventilation tubes in children while swimming. J Chin Med Assoc 2009; 72:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/36\">",
"      Schneider ML. Bacteriology of otorrhea from tympanostomy tubes. Arch Otolaryngol Head Neck Surg 1989; 115:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/37\">",
"      Granath A, Rynnel-Dag&ouml;&ouml; B, Backheden M, Lindberg K. Tube associated otorrhea in children with recurrent acute otitis media; results of a prospective randomized study on bacteriology and topical treatment with or without systemic antibiotics. Int J Pediatr Otorhinolaryngol 2008; 72:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/38\">",
"      Roland PS, Parry DA, Stroman DW. Microbiology of acute otitis media with tympanostomy tubes. Otolaryngol Head Neck Surg 2005; 133:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/39\">",
"      Fliss DM, Dagan R, Meidan N, Leiberman A. Aerobic bacteriology of chronic suppurative otitis media without cholesteatoma in children. Ann Otol Rhinol Laryngol 1992; 101:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/40\">",
"      Schroeder A, Darrow DH. Management of the draining ear in children. Pediatr Ann 2004; 33:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/41\">",
"      Vaile L, Williamson T, Waddell A, Taylor G. Interventions for ear discharge associated with grommets (ventilation tubes). Cochrane Database Syst Rev 2006; :CD001933.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenfeld R, Isaacson G. Tympanostomy tube care and consequences. In: Evidence-based otitis media, Rosenfeld RM, Bluestone CD (Eds), BC Decker, Ontario 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/43\">",
"      Isaacson G. Why don't those ear drops work for my patients? Pediatrics 2006; 118:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/44\">",
"      Daniel SJ, Kozak FK, Fabian MC, et al. Guidelines for the treatment of tympanostomy tube otorrhea. J Otolaryngol 2005; 34 Suppl 2:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/45\">",
"      Ruohola A, Heikkinen T, Meurman O, et al. Antibiotic treatment of acute otorrhea through tympanostomy tube: randomized double-blind placebo-controlled study with daily follow-up. Pediatrics 2003; 111:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/46\">",
"      Goldblatt EL, Dohar J, Nozza RJ, et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngol 1998; 46:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/47\">",
"      Wintermeyer SM, Hart MC, Nahata MC. Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea. Otolaryngol Head Neck Surg 1997; 116:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/48\">",
"      Force RW, Hart MC, Plummer SA, et al. Topical ciprofloxacin for otorrhea after tympanostomy tube placement. Arch Otolaryngol Head Neck Surg 1995; 121:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/49\">",
"      Roland PS, Dohar JE, Lanier BJ, et al. Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis media with otorrhea through tympanostomy tubes. Otolaryngol Head Neck Surg 2004; 130:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/50\">",
"      Dohar JE, Antonelli PJ, Poole MD. Tympanostomy tube otorrhea: treating the first infection. Highlights of a roundtable discussion sponsored by Alcon Laboratories, Inc.; Oct. 16, 2004; Fort Worth, Texas. Ear Nose Throat J 2005; 84:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/51\">",
"      Eckert R, Brady KM, Greenberg EP, et al. Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother 2006; 50:3833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/52\">",
"      Rakover Y, Keywan K, Rosen G. Safety of topical ear drops containing ototoxic antibiotics. J Otolaryngol 1997; 26:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/53\">",
"      Alper CM, Dohar JE, Gulhan M, et al. Treatment of chronic suppurative otitis media with topical tobramycin and dexamethasone. Arch Otolaryngol Head Neck Surg 2000; 126:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/54\">",
"      Berenholz LP, Burkey JM, Farmer TL, Lippy WH. Topical otic antibiotics: clinical cochlear ototoxicity and cost consideration. Otolaryngol Head Neck Surg 2006; 135:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/55\">",
"      Roland PS, Rybak L, Hannley M, et al. Animal ototoxicity of topical antibiotics and the relevance to clinical treatment of human subjects. Otolaryngol Head Neck Surg 2004; 130:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/56\">",
"      Winterstein AG, Liu W, Xu D, Antonelli PJ. Sensorineural hearing loss associated with neomycin eardrops and nonintact tympanic membranes. Otolaryngol Head Neck Surg 2013; 148:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/57\">",
"      Daniel SJ, Munguia R. Ototoxicity of topical ciprofloxacin/dexamethasone otic suspension in a chinchilla animal model. Otolaryngol Head Neck Surg 2008; 139:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/58\">",
"      Lemke LE, McGee DH, Prieskorn DM, et al. Safety of ciprofloxacin and dexamethasone in the guinea pig middle ear. Arch Otolaryngol Head Neck Surg 2009; 135:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/59\">",
"      Heslop A, Lildholdt T, Gammelgaard N, Ovesen T. Topical ciprofloxacin is superior to topical saline and systemic antibiotics in the treatment of tympanostomy tube otorrhea in children: the results of a randomized clinical trial. Laryngoscope 2010; 120:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/60\">",
"      Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010; 304:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/61\">",
"      Greenberg D, Hoffman S, Leibovitz E, Dagan R. Acute otitis media in children: association with day care centers--antibacterial resistance, treatment, and prevention. Paediatr Drugs 2008; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/62\">",
"      Hoberman A, Paradise JL, Rockette HE, et al. Treatment of acute otitis media in children under 2 years of age. N Engl J Med 2011; 364:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/63\">",
"      Roland PS, Anon JB, Moe RD, et al. Topical ciprofloxacin/dexamethasone is superior to ciprofloxacin alone in pediatric patients with acute otitis media and otorrhea through tympanostomy tubes. Laryngoscope 2003; 113:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/64\">",
"      Discussion: Incidence of otorrhea in children with ventilating tubes. Pediatr Infect Dis J 2001; 20:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/65\">",
"      Arnold DJ, Bressler KL. Permeability of tympanotomy tubes to ototopical preparations. Otolaryngol Head Neck Surg 1999; 121:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/66\">",
"      Hebert RL 2nd, Vick ML, King GE, Bent JP 3rd. Tympanostomy tubes and otic suspensions: do they reach the middle ear space? Otolaryngol Head Neck Surg 2000; 122:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/67\">",
"      Rosenfeld RM, Brown L, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2006; 134:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/68\">",
"      Cohen SR, Thompson JW. Otitic candidiasis in children: an evaluation of the problem and effectiveness of ketoconazole in 10 patients. Ann Otol Rhinol Laryngol 1990; 99:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/69\">",
"      Schrader N, Isaacson G. Fungal otitis externa--its association with fluoroquinolone eardrops. Pediatrics 2003; 111:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/70\">",
"      Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005; 131:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/71\">",
"      Hwang JH, Tsai HY, Liu TC. Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol 2002; 122:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/72\">",
"      Shelton C, Brackmann DE. Actinomycosis otitis media. Arch Otolaryngol Head Neck Surg 1988; 114:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/73\">",
"      Hall PJ, Farrior JB. Aspergillus mastoiditis. Otolaryngol Head Neck Surg 1993; 108:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/74\">",
"      Supance JS, Bluestone CD. \"How I do it\"--otology and neurotology. A specific issue and its solution. Medical management of the chronic draining ear. Laryngoscope 1983; 93:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/75\">",
"      Isaacson G, Aronoff SC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol 2008; 72:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/76\">",
"      Luxford WM, Sheehy JL. Myringotomy and ventilation tubes: a report of 1,568 ears. Laryngoscope 1982; 92:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36457/abstract/77\">",
"      Post JC. Direct evidence of bacterial biofilms in otitis media. Laryngoscope 2001; 111:2083.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6295 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36457=[""].join("\n");
var outline_f35_38_36457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tympanostomy tube otorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic suppurative otitis media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION OF TYMPANOSTOMY TUBE OTORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Early-onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Late-onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prevention of AOM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Water precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACUTE TYMPANOSTOMY TUBE OTORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Associated cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CHRONIC TYMPANOSTOMY TUBE OTORRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6295|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/41/671\" title=\"picture 1\">",
"      Tube otorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/44/42702\" title=\"picture 2\">",
"      TT granulation tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/40/20096\" title=\"picture 3\">",
"      TT fungal overgrowth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/23/6512\" title=\"picture 4\">",
"      TT bacterial biofilm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36458="Overview of medical care in adults with diabetes mellitus";
var content_f35_38_36458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of medical care in adults with diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36458/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36458/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/38/36458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/38/36458/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/38/36458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of diabetes among adults in the United States ranges from 4.4 to 17.9 percent (median 8.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/1\">",
"     1",
"    </a>",
"    ]. However, because of the associated microvascular and macrovascular disease, diabetes accounts for almost 14 percent of US health care expenditures, at least one-half of which are related to complications such as myocardial infarction, stroke, end-stage renal disease, retinopathy, and foot ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous factors, in addition to directly related medical complications, contribute to the impact of diabetes on quality of life and economics. Diabetes is associated with a high prevalence of affective illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/4\">",
"     4",
"    </a>",
"    ] and adversely impacts employment, absenteeism, and work productivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This review will provide an overview of the medical care for patients with diabetes (",
"    <a class=\"graphic graphic_table graphicRef63002 \" href=\"mobipreview.htm?36/36/37452\">",
"     table 1",
"    </a>",
"    ). Detailed discussions relating to screening, evaluation, and treatment of the individual complications of diabetes are discussed separately. Guidelines from the American Diabetes Association for health maintenance in diabetics are published yearly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]. Consensus recommendations for the management of glycemia in type 2 diabetes were published in 2006 and updated in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION FOR DIABETIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity from diabetes is a consequence of both macrovascular disease (atherosclerosis) and microvascular disease (retinopathy, nephropathy, and neuropathy). In type 2 diabetes, disease onset is insidious, and diagnosis is often delayed. As a result, diabetic microvascular complications may be present at the time of diagnosis of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/9\">",
"     9",
"    </a>",
"    ], and their frequency increases over time (",
"    <a class=\"graphic graphic_figure graphicRef58736 \" href=\"mobipreview.htm?2/16/2318\">",
"     figure 1",
"    </a>",
"    ). The progression of these complications can be slowed, but probably not stopped, with interventions such as aggressive management of glycemia, laser therapy for retinopathy, and administration of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) for nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Routine eye examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes are at increased risk for visual loss, related both to refractive errors (correctable visual impairment) and to retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Screening for diabetic retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of laser photocoagulation surgery in preventing loss of vision is the major reason to screen regularly for diabetic retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Panretinal photocoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for the type and frequency of routine eye examinations vary, based upon the type of diabetes mellitus and the presence of specific eye findings (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]. Serial examinations are indicated because of the increased incidence of retinopathy over time in patients with either type 1 or type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef70042 \" href=\"mobipreview.htm?24/45/25309\">",
"     figure 2",
"    </a>",
"    ). Screening for diabetic retinopathy is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Correctable visual impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study using data from the National Health and Nutrition Examination Survey (NHANES) in the US found that 11 percent of patients aged 20 years and older with diabetes had visual impairment (visual acuity",
"    <span class=\"nowrap\">",
"     &lt;20/40",
"    </span>",
"    in their best eye with glasses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/10\">",
"     10",
"    </a>",
"    ]. The impairment was correctable with an adequate corrective prescription for glasses or contact lenses in over two-thirds of the patients. These data indicate the need for visual acuity and refractive error assessment in addition to dilated eye examinations for retinopathy in diabetic patients to reduce injury risk and improve quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Routine foot examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foot problems due to vascular and neurologic disease are a common and important source of morbidity in diabetic patients. Systematic screening examinations for neuropathic and vascular involvement of the lower extremities and careful inspection of feet may substantially reduce morbidity from foot problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the American Diabetes Association recommend performing a comprehensive foot examination annually on patients with diabetes to identify risk factors predictive of ulcers and amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]. The comprehensive foot examination can be accomplished in the primary care setting and should include inspection, assessment of foot pulses, and testing for loss of protective sensation, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a visual inspection of the feet at each routine visit. The skin should be assessed for integrity, especially between the toes and under the metatarsal heads. The presence of erythema, warmth, or callus formation may indicate areas of tissue damage. Bony deformities, joint mobility, and gait and balance should also be assessed.",
"     </li>",
"     <li>",
"      Screen for peripheral artery disease by asking about a history of claudication and assessing the pedal pulses. Consider obtaining an ankle brachial index as many patients with peripheral artery disease are asymptomatic. The presence of peripheral artery disease also suggests a high likelihood of cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"       \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Test for loss of protective sensation using a Semmes-Weinstein 5.07 (10-g) monofilament at specific sites to detect loss of sensation in the foot (",
"      <a class=\"graphic graphic_figure graphicRef52481 \" href=\"mobipreview.htm?33/55/34687\">",
"       figure 3",
"      </a>",
"      ), plus any one of the following: vibration using a 128-Hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold with a biothesiometer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation of the diabetic foot\", section on 'Screening tests for peripheral neuropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advice for prophylactic foot care should be given to all patients (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/38/43618?source=see_link\">",
"       \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoid going barefoot, even in the home.",
"     </li>",
"     <li>",
"      Test water temperature before stepping into a bath.",
"     </li>",
"     <li>",
"      Trim toenails to shape of the toe; remove sharp edges with a nail file. Do not cut cuticles.",
"     </li>",
"     <li>",
"      Wash and check feet daily.",
"     </li>",
"     <li>",
"      Shoes should be snug but not tight and customized if feet are misshapen or have ulcers.",
"     </li>",
"     <li>",
"      Socks should fit and be changed daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who may have neuropathy, based on abnormal results from a microfilament and one other test, or who have callus or other foot deformities should be referred to clinicians with expertise in diabetic foot care (podiatrist, nurse, diabetes foot clinic, or other, depending on available local resources).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening for increased urinary albumin excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased urinary protein excretion is the earliest currently used clinical finding of diabetic nephropathy. The routine urine dipstick, however, is a relatively insensitive marker for proteinuria, not detecting protein until excretion exceeds 300 to 500",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal rate of albumin excretion is less than 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     mcg/min);",
"    </span>",
"    persistent values between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    in a patient with diabetes is called persistent albuminuria (historically called microalbuminuria) and is usually indicative of diabetic nephropathy (unless there is some coexistent renal disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/11\">",
"     11",
"    </a>",
"    ]. Values above 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    are considered to represent overt proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Albumin excretion may be tested by screening with either a specifically sensitive dipstick or a laboratory assay on a spot urine sample, to determine an albumin-to-creatinine ratio. Increased urinary albumin excretion is defined as an albumin-to-creatinine ratio &ge;30",
"    <span class=\"nowrap\">",
"     mcg/mg",
"    </span>",
"    creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]. Abnormal results should be repeated at least two or three times over a three- to six-month period because of the large number of false positives that can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/13\">",
"     13",
"    </a>",
"    ]. Establishing the diagnosis of increased urinary albumin excretion requires the demonstration of a persistent (at least two abnormal tests) elevation in albumin excretion. Fever, exercise, heart failure, and poor glycemic control are among the factors that can cause transient microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of effective therapy for diabetic nephropathy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) is the rationale for yearly screening of all patients with either type 1 or type 2 diabetes for increased albumin excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening for increased urinary albumin excretion can be deferred for five years after the onset of disease in patients with type 1 diabetes because increased albumin excretion is uncommon before this time; some recommend that screening should begin at diagnosis in patients with type 2 diabetes because many have had diabetes for several years before diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal therapy of diabetic nephropathy continues to evolve. In patients with type 1 diabetes who have increased urinary albumin excretion or overt nephropathy, ACE inhibitors both lower urinary protein excretion and slow the rate of disease progression (",
"    <a class=\"graphic graphic_figure graphicRef80409 graphicRef60878 \" href=\"mobipreview.htm?32/58/33710\">",
"     figure 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/15\">",
"     15",
"    </a>",
"    ]. It seems reasonable, therefore, to institute therapy with an ACE inhibitor or angiotensin receptor blocker (ARB), even if the patient is normotensive, in those patients who have increased urinary albumin excretion or overt nephropathy. Since these drugs do not completely prevent progression, additional interventions may be required, the most important of which is maintenance of strict glycemic control. Similar considerations apply to patients with type 2 diabetes. The treatment of increased urinary albumin excretion is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Screening for coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes have an increased risk for atherosclerosis due both to diabetes and to the frequent presence of other risk factors. Furthermore, diabetic patients with CHD are more likely to be asymptomatic or have atypical symptoms than nondiabetic patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Silent ischemia and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the frequency of silent ischemia, however, it has not been proven that identifying asymptomatic disease or providing early intervention will improve outcomes in this population. In addition, CHD risk factors (dyslipidemia, hypertension, smoking, positive family history of early coronary disease, and presence of increased urinary albumin excretion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ] do not predict the likelihood of having ischemic findings on stress testing or coronary angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the American Diabetes Association guidelines recommend annual assessment of risk criteria to identify patients who might benefit from interventions such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , ACE inhibitors, and statin therapy, but no longer recommend that these criteria be used to identify patients for stress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trial data to support the routine performance of exercise stress testing in asymptomatic patients with diabetes who are planning to begin an exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]. The vast majority of patients, particularly those with a sedentary lifestyle, are encouraged to begin a gentle exercise program and to gradually progress to a more vigorous program as tolerated. In addition, all CVD risk factors should be treated. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Blood pressure control'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Dyslipidemia'",
"    </a>",
"    below.) Thus, exercise testing is not necessary for most patients. However, it may be indicated for asymptomatic individuals at high risk for CHD (eg, evidence of peripheral or carotid atherosclerotic vascular disease, renal disease, abnormal resting electrocardiogram, multiple diabetes complications). The decision to perform stress testing prior to beginning an exercise program should be individualized.",
"   </p>",
"   <p>",
"    We do not typically perform exercise stress testing in asymptomatic patients as long as they are beginning a gentle exercise program with gradual progression as tolerated. However, the increased risk for asymptomatic coronary artery disease in those with diabetes and other risk factors suggests that an exercise tolerance test be considered prior to changing exercise levels in patients with diabetes who also have peripheral or carotid or coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/20/18761?source=see_link\">",
"     \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of diabetic patients with known CHD is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41289?source=see_link\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REDUCING THE RISK OF MACROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men and women with diabetes are at increased risk for developing and dying from cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Compared with nondiabetics, men and women with diabetes have decreased life expectancy (six to eight years less). At the time of diagnosis of type 2 diabetes, many patients already have one or more risk factors for macrovascular disease (obesity, hypertension, dyslipidemia, smoking) and many have evidence of overt atherosclerosis (past myocardial infarction, ischemic changes on electrocardiogram, or peripheral vascular disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/9,21,22\">",
"     9,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of modifiable risk factors for coronary heart disease were identified in a cohort of over 3000 type 2 diabetics from the United Kingdom Prospective Diabetes Study (UKPDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/23\">",
"     23",
"    </a>",
"    ]. Estimated hazard ratios from this study for the upper third relative to the lower third were 2.3 for serum LDL cholesterol, 0.6 for serum high-density-lipoprotein (HDL) cholesterol, 1.5 for hemoglobin A1C, 1.8 for systolic blood pressure, and 1.4 for smokers.",
"   </p>",
"   <p>",
"    These and other observations suggest that a substantial reduction in cardiovascular mortality could be achieved by smoking cessation, aggressive treatment of hypertension and dyslipidemia, and possibly daily low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef58014 \" href=\"mobipreview.htm?20/57/21406\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Multifactorial risk factor reduction'",
"    </a>",
"    below.) With regard to cardiovascular disease risk reduction among patients with type 2 diabetes, the benefit of good blood pressure control has been confirmed, whereas benefit from strict glycemic control has not been conclusively demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/25\">",
"     25",
"    </a>",
"    ]. Among patients with type 1 diabetes, the",
"    <span class=\"nowrap\">",
"     DCCT/EDIC",
"    </span>",
"    study demonstrated long-term benefit of intensive glycemic management on cardiovascular outcomes, reducing fatal and nonfatal heart disease and stroke by 57 percent compared with conventional diabetes management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survey in the United States found that the prevalence of cigarette smoking was higher among diabetic patients than nondiabetic subjects, even after adjusting for age, sex, race, and educational level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/27\">",
"     27",
"    </a>",
"    ]. Over 25 percent of newly diagnosed diabetic patients were smokers. A meta-analysis of many of the cardiovascular risk reduction trials showed that cessation of smoking had a much greater benefit on survival than most other interventions (",
"    <a class=\"graphic graphic_figure graphicRef58014 \" href=\"mobipreview.htm?20/57/21406\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/24\">",
"     24",
"    </a>",
"    ]. These findings suggest that discontinuation of smoking is one of the most important aspects of therapy in diabetic patients who smoke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5189?source=see_link\">",
"     \"Smoking and cardiovascular risk in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The merits of daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in patients with macrovascular disease are widely accepted. A meta-analysis from the Antithrombotic Trialists' Collaboration of randomized trials of antiplatelet therapy for the secondary prevention of cardiovascular disease in high-risk patients showed that aspirin produced statistically significant and clinically important reductions in the risk of subsequent myocardial infarction (MI), stroke, and vascular death among a wide range of high-risk patients (acute MI or ischemic stroke, unstable angina, prior MI or stroke, peripheral artery disease, and other high-risk groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the subset of patients with diabetes, there was a nonsignificant 7 percent decrease in serious cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, in The Primary Prevention Project,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was associated with a nonsignificant 10 percent reduction in total cardiovascular events in the subset of patients with diabetes (RR 0.89, 95% CI 0.62-1.26) compared with a 30 percent reduction in nondiabetic subjects (RR 0.69, 95% CI 0.53-0.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These trials suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may be less effective in the prevention of cardiovascular events in patients with diabetes. Trials that assess the benefit of daily aspirin therapy specifically in patients with diabetes show the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Early Treatment of Diabetic Retinopathy Study (ETDRS), patients with diabetes with and without cardiovascular disease were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (650 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/30\">",
"       30",
"      </a>",
"      ]. The relative risk among all aspirin-treated patients was 0.91 (99% CI 0.75-1.11) for death and 0.83 (99% CI 0.66-1.04) for fatal and nonfatal myocardial infarction.",
"     </li>",
"     <li>",
"      In a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for the prevention of cardiovascular disease in 2539 Japanese patients with type 2 diabetes (no history of atherosclerotic heart disease), patients were randomly assigned to low-dose aspirin (80 to 100 mg daily) or to a nonaspirin group. After a median follow-up of 4.4 years, there were 13.6 and 17.0 cardiovascular events per 1000 person-years in the aspirin and nonaspirin groups, respectively (HR for primary composite endpoint of any cerebrovascular, coronary, or peripheral vascular atherosclerotic event 0.80 [95% CI 0.58-1.10]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The lower than expected event rate in this trial decreased the power of the analysis to assess the primary composite outcome or individual outcomes, such as fatal and nonfatal coronary events. In addition, the generalizability of this study to Western populations with higher cardiovascular risk is unknown.",
"     </li>",
"     <li>",
"      In the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial, 1276 UK adults with type 1 or type 2 diabetes with asymptomatic peripheral artery disease (ankle brachial pressure index of &le;0.99) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (100 mg daily) plus an antioxidant, aspirin alone, antioxidant alone, or double placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/32\">",
"       32",
"      </a>",
"      ]. During a median 6.7 years of follow-up, there were 116 and 117 fatal and nonfatal cardiovascular events in the aspirin and nonaspirin groups, respectively (HR for primary composite endpoint of death from coronary heart disease or stroke, nonfatal myocardial infarction or stroke, or above-ankle amputation for critical limb ischemia 0.98, 95% CI 0.76-1.26).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, trials in patients with diabetes do not show a significant benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of cardiovascular events. However, both the Japanese trial and ETDRS suggest benefit. Larger trials with longer follow-up are required to clarify this issue. Two large trials investigating the role of aspirin for the prevention of cardiovascular events in patients with diabetes are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the main adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is bleeding. The United States Physicians' Health Study found a nonsignificant trend toward an increase in hemorrhagic stroke and an increased risk of gastrointestinal bleeding in those who took aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/35\">",
"     35",
"    </a>",
"    ]. In the Japanese trial described above, there was no difference in the incidence of hemorrhagic stroke (0.4 and 0.2 events per 1000 person-years in those assigned to the aspirin and nonaspirin groups, respectively). However, gastrointestinal and retinal bleeding occurred more commonly in the aspirin group, and four patients in the aspirin group required transfusion.",
"   </p>",
"   <p>",
"    In a population-based cohort study examining the incidence of gastrointestinal and intracranial bleeding in patients with and without diabetes taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the incident rate of major bleeding was similar in those with and without diabetes (5.5 and 5.8 per 1000 person-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/36\">",
"     36",
"    </a>",
"    ]. The presence of diabetes itself increased the incidence of major bleeding. In the absence of aspirin use, the incidence rate of major bleeding was 5.35 and 3.32 per 1000 person-years in those with and without diabetes. These data suggest that treatment with aspirin only marginally increases the risk of bleeding in patients with diabetes. If this finding is due to reduced efficacy of aspirin in suppressing platelet function in patients with diabetes, it may explain why aspirin is less effective in the primary prevention of cardiovascular events in patients with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon these data, the American Diabetes Association and American Heart Association recommend the following approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6,37\">",
"     6,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (75 to 162",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is recommended for secondary prevention in diabetic patients with a history of myocardial infarction, vascular bypass, stroke or transient ischemic attack, peripheral vascular disease, claudication, or angina.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (75 to 162",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is recommended for primary prevention in any patient with diabetes at increased cardiovascular risk (10 year risk &gt;10 percent), which would include most men &gt;50 years and women &gt;60 years who have at least one additional cardiovascular risk factor (eg, cigarette smoking, hypertension, obesity, albuminuria, dyslipidemia, or a family history of coronary heart disease). The ADA recognizes that the evidence to support this recommendation is weak.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is not recommended for diabetic patients under the age of 30 years due to a lack of evidence of benefit, and aspirin is contraindicated under the age of 21 years because of an increased risk of Reye's syndrome.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is recommended for patients with cardiovascular disease and documented",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      allergy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link&amp;anchor=H36#H36\">",
"       \"Secondary prevention of cardiovascular disease\", section on 'Antithrombotic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In spite of these recommendations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use in patients with diabetes is quite low: 74 and 38 percent in patients with or without cardiovascular disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a common problem in type 1 and especially in type 2 diabetes. The American Diabetes Association recommends measuring blood pressure at every routine diabetes visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. Early and effective treatment of blood pressure is important, both to prevent cardiovascular disease and to minimize the rate of progression of diabetic nephropathy and retinopathy.",
"   </p>",
"   <p>",
"    Among patients with diabetes, there is moderate evidence supporting a goal blood pressure less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in all patients and weaker evidence supporting a goal blood pressure less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg. These issues and the choice of antihypertensive drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid abnormalities are common in patients with diabetes mellitus, and undoubtedly contribute to the increase in risk of cardiovascular disease. The American Diabetes Association (ADA) recommends screening for lipid disorders at least annually in diabetic patients, and more often if needed to achieve goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. Adults with low-risk lipid values (LDL &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    HDL &gt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.3",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    and triglycerides &lt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may be screened every two years.",
"   </p>",
"   <p>",
"    The ADA recommends lifestyle intervention (diet, weight loss, increased physical activity) to improve the lipid profile in all patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]. In patients with clinical cardiovascular disease (CVD) or over age 40 years with other CVD risk factors, statin therapy should be added to lifestyle intervention regardless of baseline lipid levels. For patients without clinical CVD and under age 40 years, statin therapy can be considered in addition to lifestyle intervention if LDL cholesterol remains above 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or in those with multiple CVD risk factors. In individuals without overt cardiovascular disease, the goal LDL is &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    whereas in patients with overt CVD, a lower LDL goal (&lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    is an option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]. Triglyceride levels &lt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and HDL levels &gt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for men and &gt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for women are preferable.",
"   </p>",
"   <p>",
"    The optimal therapy of dyslipidemia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ACCORD Lipid trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    has been suggested to reduce the risk of macrovascular complications, independently of its effects on glycemic control. However, this effect is far from established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/40\">",
"     40",
"    </a>",
"    ]. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H11#H11\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'UKPDS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Multifactorial risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of multiple risk factor intervention to reduce coronary risk in type 2 diabetes was demonstrated in the relatively small Steno-2 trial of 160 subjects with microalbuminuria who were randomly assigned to either conventional therapy or an intensive therapy regimen, which included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced dietary fat",
"     </li>",
"     <li>",
"      Light to moderate exercise",
"     </li>",
"     <li>",
"      Smoking cessation",
"     </li>",
"     <li>",
"      Tight glycemic control (target A1C &lt;6.5 percent with intensive therapy)",
"     </li>",
"     <li>",
"      Tight blood pressure control (target",
"      <span class=\"nowrap\">",
"       &lt;140/85",
"      </span>",
"      mmHg for most of the study and",
"      <span class=\"nowrap\">",
"       &lt;130/80",
"      </span>",
"      mmHg for the last two years)",
"     </li>",
"     <li>",
"      Angiotensin converting enzyme (ACE) inhibitor therapy regardless of blood pressure",
"     </li>",
"     <li>",
"      Lipid-lowering therapy (target total cholesterol &lt;190",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.9",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      for most of the study and &lt;175",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.5",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      for the last two years; target fasting serum triglyceride &lt;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"     </li>",
"     <li>",
"      Vitamin C, vitamin D, folate, and chrome picolinate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The attained differences between the two groups revealed significantly greater improvements with intensive therapy in glycemic control (A1C -0.5 versus +0.2 percent with conventional therapy), blood pressure control",
"    <span class=\"nowrap\">",
"     (-14/12",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     -3/8",
"    </span>",
"    mmHg), and total cholesterol (-50 versus -3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [-1.3 versus -0.08",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    At a mean of 7.8 years, patients on intensive therapy had a significant reduction in the primary aggregate end point of cardiovascular death, nonfatal MI, coronary artery bypass grafting, percutaneous coronary intervention, stroke, amputation, or peripheral vascular surgery (18 versus 38 percent, HR 0.47, 95% CI 0.22-0.74). Significant reductions were also seen in progression of nephropathy, retinopathy, and autonomic neuropathy.",
"   </p>",
"   <p>",
"    After the intervention study ended, 130 remaining patients participated in an observational follow-up study (5.5 years), during which time all participants were encouraged to follow intensive multifactorial treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/42\">",
"     42",
"    </a>",
"    ]. At the end of the follow-up period, A1C values were similar in the groups previously assigned to intensive and conventional therapy (7.7 and 8.0 percent, respectively). Blood pressure, body mass index (BMI), and fasting serum cholesterol and triglycerides were also similar.",
"   </p>",
"   <p>",
"    During the entire follow-up period (13.3 years), there were fewer deaths (30 versus 50 percent) in the intensive therapy group (hazard ratio for death 0.54, 95% CI 0.32-0.89). Intensive therapy was also associated with a lower risk of cardiovascular deaths (HR 0.43, 95% CI 0.19-0.94), which was a predefined secondary endpoint. Progression of diabetic retinopathy, nephropathy, and autonomic neuropathy occurred less frequently in the intensive group. These results suggest a sustained benefit of multifactorial risk reduction.",
"   </p>",
"   <p>",
"    In spite of evidence that aggressive risk factor reduction lowers the risk of both micro- and macrovascular complications in patients with diabetes, the vast majority of patients do not achieve recommended goals for A1C, blood pressure control, and management of dyslipidemia. It is notable that only one patient in the observational Steno study described above reached all five treatment goals at the end of follow-up. Thus, renewed efforts to implement multifactorial risk factor reduction strategies early in the course of type 2 diabetes are necessary. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Adequacy of care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GLYCEMIC CONTROL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Monitoring and target A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective, randomized clinical trials such as the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Kumamoto Study have demonstrated that intensive therapy aimed at lower levels of glycemia results in decreased rates of retinopathy, nephropathy, and neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Every 1 percent drop in A1C was associated with improved outcomes and there was no threshold effect. These benefits have to be weighed against an increased risk of severe hypoglycemia associated with intensive therapy (particularly in type 1 diabetes). Although the goal of the intensive interventions in these studies was normoglycemia, with an A1C less than 6.1 percent, the average A1C achieved in the intensive therapy groups of these trials was around 7 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H2#H2\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Hyperglycemia and Microvascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of tight glycemic control for protection against cardiovascular disease in diabetes has been established in the",
"    <span class=\"nowrap\">",
"     DCCT/EDIC",
"    </span>",
"    study for type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/26\">",
"     26",
"    </a>",
"    ]. However, trials examining the effects of intensive therapy (achieved A1C levels of approximately 6.5 compared with 7.5 percent) on cardiovascular disease in patients with long-standing type 2 diabetes had either no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/47\">",
"     47",
"    </a>",
"    ] or were associated with higher overall and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, the trials in type 2 diabetes that achieved A1C levels of approximately 6.5 percent had lower microvascular disease but either no better or worse cardiovascular effects. These trials are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H9#H9\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Macrovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data, the American Diabetes Association recommends the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aim to achieve normal or near normal glycemia with an A1C goal of &lt;7 percent. More stringent goals (ie, a normal A1C, &lt;6.5 percent) can be considered in individual patients. Less stringent treatment goals (eg, &lt;8 percent) may be appropriate for patients with a history of severe hypoglycemia, patients with limited life expectancies, older adults, and individuals with comorbid conditions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/42/682?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of type 2 diabetes mellitus in the elderly patient\", section on 'Glycemic targets'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obtain an A1C at least twice yearly in patients who are meeting treatment goals and who have stable glycemic control, and quarterly in patients whose therapy has changed or who are not meeting glycemic goals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy in type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major components to nonpharmacologic therapy of blood glucose in type 2 diabetes (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Intensive lifestyle modification'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary modification",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Weight reduction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to improving glycemic control, these changes in lifestyle also slow progression of impaired glucose tolerance to overt diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .) Diet and exercise are important components of therapy in patients with type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical treatment of obese patients with diabetes results in the largest degree of sustained weight loss and, in parallel, the largest improvements in blood glucose control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .) Pharmacotherapy for weight loss may also be used for patients with type 2 diabetes, but may not be effectively sustained due to side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy for type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) issued a 2006 consensus statement for the management of glycemia in type 2 diabetes, which has been updated regularly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/7,8,50\">",
"     7,8,50",
"    </a>",
"    ]. Because of the difficulty in achieving and sustaining goal glycemia and significant weight loss, the consensus group concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy should be initiated concurrent with lifestyle intervention at the time of diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The therapeutic options for patients who fail initial therapy with lifestyle intervention and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are to add a second oral or injectable agent, including insulin, or to switch to insulin (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"mobipreview.htm?19/63/20467\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the initial response to therapy, the natural history of most patients with type 2 diabetes is for blood glucose concentrations and A1C to rise over time (",
"    <a class=\"graphic graphic_figure graphicRef81706 \" href=\"mobipreview.htm?17/5/17502\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/43,51\">",
"     43,51",
"    </a>",
"    ]. The UKPDS suggested that worsening beta cell dysfunction with decreased insulin release was primarily responsible for disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/51\">",
"     51",
"    </a>",
"    ]. More severe insulin resistance or decreased compliance with the dietary regimen also may contribute to progression.",
"   </p>",
"   <p>",
"    Type 2 diabetic patients often need large daily doses of insulin (&gt;65 units per day, and often much more) to achieve acceptable glycemic control. Most patients with type 2 diabetes can be treated with one or two daily injections, in contrast to patients with type 1 diabetes for whom intensive insulin therapy with multiple daily injections is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER ASPECTS OF HEALTH MAINTENANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Routine health maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential exists for the clinician to overlook health maintenance not specifically targeted at diabetes, given the intensity and complexity of care required for prevention and treatment of complications in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested an increased risk of cancer in patients with diabetes, possibly related to the coincident obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 10-year prospective study of 98,000 Japanese persons aged 40 to 69, the hazard ratio (HR) for any cancer among men with diabetes was 1.27 (95% CI 1.14-1.42) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/53\">",
"       53",
"      </a>",
"      ]. In comparison, the association of cancer risk and diabetes for women was only borderline (HR 1.21, 95% CI 0.99-1.47).",
"     </li>",
"     <li>",
"      In a prospective cohort study of 64,000 Swedish men and women aged 29 to 61, rising levels of fasting and post oral glucose challenge glucoses were associated with an increase in cancer risk for women in the highest quartile versus lowest quartile of fasting glucose (RR 1.26, 95% CI 1.09-1.47) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/54\">",
"       54",
"      </a>",
"      ]. The most common cancers associated with high glucose values were pancreatic, endometrial, and melanoma. There was no significant increased risk in men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diabetes mellitus and insulin resistance may also be associated with an increased risk of colon cancer, hepatocellular carcinoma, renal cancer, bladder cancer, and pancreatic cancer, although causation is not well established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link&amp;anchor=H640028522#H640028522\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective study of over 700,000 Canadian women aged 50 to 67 years, including 69,168 with diabetes, found that women with diabetes, despite having more frequent clinician visits, were less likely to have a mammogram within a two-year period than non-diabetics (odds ratio [OR] 0.68, 95% CI 0.67-0.70) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/57\">",
"     57",
"    </a>",
"    ]. This is of concern because in some but not all studies, women with type 2 diabetes had a slightly higher risk of breast cancer than non-diabetic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with type 2 diabetes also have an increased risk of cancer mortality. In a systematic review of individual patient data from 97 prospective studies (820,900 patients), adults with diabetes compared with those without had an increased risk of death from cancer (HR 1.25, 95% CI 1.19-1.31) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/20\">",
"     20",
"    </a>",
"    ]. The increased risk of death was associated specifically with cancers of the liver, pancreas, ovary, colorectum, lung, bladder, and breast. In addition, the relative risk was substantially reduced when A1C levels were considered in multivariate analyses, consistent with a direct effect of hyperglycemia on cancer risk.",
"   </p>",
"   <p>",
"    Elevated serum alanine aminotransferase (ALT) concentrations occur commonly in patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Although the etiology may be multifactorial, nonalcoholic fatty liver disease rather than cancer is a common cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Dental screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal disease is a common complication of diabetes and itself contributes to poor glycemic control. Severe periodontal disease was shown to be an independent risk factor for mortality from ischemic heart disease and nephropathy in one longitudinal study of Pima Indians with type 2 diabetes (RR 3.6, 95% CI 1.1-9.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/61\">",
"     61",
"    </a>",
"    ]. Annual dental examination is recommended in both dentate and non-dentate diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/62\">",
"     62",
"    </a>",
"    ]. In a 2004 US survey, 67 percent of respondents with diabetes reported a dental visit in the preceding 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diabetes mellitus should receive influenza vaccination yearly and pneumococcal vaccination, repeating the pneumococcal vaccine once after age 65 years if the initial vaccination was prior to age 65. The hepatitis B vaccination should be given to unvaccinated adults with diabetes mellitus who are ages 19 to 59 years. For older patients with diabetes, vaccination can be administered at the discretion of the treating clinician based upon the risk of acquiring hepatitis B virus and the likelihood of an adequate immune response to vaccination. This recommendation is based on outbreaks of hepatitis B in patients who were undergoing assisted blood glucose monitoring, a subsequent analysis of the risk of acquiring HBV among all diabetics in the United States, and a cost-effectiveness analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/63\">",
"     63",
"    </a>",
"    ]. Tetanus and diphtheria vaccinations should also be updated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Women of childbearing age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraception and pregnancy planning should be discussed with all diabetic women who are premenopausal. For women who do not wish to become pregnant, ADA guidelines state that the selection of a contraceptive method for an individual patient should use the same guidelines that apply to women without diabetes. Guidelines from the American College of Obstetricians and Gynecologists (ACOG) are more cautious and recommend \"on theoretical concerns\" that use of oral contraception be limited to nonsmoking diabetic women who are younger than 35 years and are without hypertension, nephropathy, retinopathy, or other vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .) We recommend that the most reliable method of contraception be used, when not contraindicated by other health concerns, because the risk of unplanned pregnancy is significant.",
"   </p>",
"   <p>",
"    For women with diabetes who are contemplating pregnancy, prepregnancy counseling and planning is important. Prior to pregnancy, glycemic control should be optimized, and both ACE inhibitor and statin medications should be discontinued (",
"    <a class=\"graphic graphic_table graphicRef79625 \" href=\"mobipreview.htm?35/33/36380\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ADEQUACY OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive data suggesting large benefits with preventive and treatment strategies, and despite increasing media attention, there has been little improvement in diabetes management in the US.",
"   </p>",
"   <p>",
"    Surveys of patients aged 18 to 75 years with diabetes, comparing the US NHANES databases for 1988 to 1994 and 1999 to 2002, indicate that glycemic control has improved only minimally (nonsignificant decrease in proportion of patients with A1C &gt;9 percent, no change in mean A1C, increase in patients with A1C between 6 and 8 percent), and blood pressure distribution has remained unchanged. Improvements were seen in the proportion of patients with LDL cholesterol &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ; and receiving annual influenza vaccination, lipid testing, eye examination, and foot examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/65\">",
"     65",
"    </a>",
"    ]. About 20 percent of patients in 1999 to 2002 had A1C &gt;9 percent, 33 percent had blood pressure",
"    <span class=\"nowrap\">",
"     &gt;140/90",
"    </span>",
"    mm, and 40 percent had LDL cholesterol &gt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;3.4",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Even when patients are achieving goals for individual components of diabetes care, the proportion of patients who are simultaneously at goal for all measured targets is low. In a study of 80,000 diabetic patients receiving care in a VA system, only 4 percent were simultaneously at ADA goal for A1C, LDL cholesterol, and blood pressure, though rates for individual targets ranged from 23 to 41 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, small improvements in diabetes management and cardiovascular risk factor reduction have decreased cardiovascular and all-cause mortality rates in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/67\">",
"     67",
"    </a>",
"    ]. Data from the National Health and Nutrition Examination Surveys (NHANES I, II, III), however, suggest that mortality rates are decreasing in diabetic men but not in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/68\">",
"     68",
"    </a>",
"    ]. The reason for this discrepancy is unknown but may be related to gender differences in the pathophysiology of coronary artery disease, less accurate diagnosis of CVD in women, and disparities in access to care and targeting of risk factor reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, the majority of diabetic patients are",
"    <strong>",
"     not",
"    </strong>",
"    receiving recommended levels of healthcare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/69-74\">",
"     69-74",
"    </a>",
"    ], particularly patients under age 45 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/75\">",
"     75",
"    </a>",
"    ] and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Even when recommended screening data are obtained, rates of medication adjustment to address abnormal results are low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several reasons for the large discrepancy between what should be done and what is being done:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of acute and chronic disease &mdash; Traditional medical practice is organized to respond quickly to acute patient problems, but does not adequately serve the needs of those with a chronic illness such as diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical inertia &mdash; Failure to make adjustments in a therapeutic regimen in response to an abnormal clinical result has been termed \"clinical inertia\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/80\">",
"       80",
"      </a>",
"      ]. Multiple factors may be contributory: lack of awareness of therapeutic goals, reluctance to treat asymptomatic conditions, concern about patient's pill burden, time limitations, or attention to acute medical issues that take priority over risk factor management [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/81\">",
"       81",
"      </a>",
"      ]. In one study of modifications in therapy for various cardiovascular risk conditions, medication adjustments were made for 66 percent of patients whose A1C level was &gt;8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lack of an organized system for care &mdash; Outcomes are better when diabetic patients are seen in the context of organized programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]. One study, as an example, examined the five-year mortality of 3288 patients with diabetes who received medical care exclusively from generalists and of 4200 patients who received care from generalists and also had examinations in a diabetes clinic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/83\">",
"       83",
"      </a>",
"      ]. The relative risk of all-cause mortality was 0.82 for patients who received care from both diabetes clinics and generalists as compared with those who received care only from generalists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Who should take care of the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of diabetic patients (greater than 90 percent) receive their care from primary care providers. A major unresolved controversy is the place of the generalist and the specialist in the treatment of patients with type 2 diabetes. Studies comparing care by specialists and generalists have generated conflicting findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large observational study (the Medical Outcomes Study) found little advantage for patients under the care of endocrinologists, when compared with family practitioners, except for improved foot care and lower infection risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. Overall functional status at four years and mortality at seven years were similar.",
"     </li>",
"     <li>",
"      A retrospective study of 112 patients (primarily type 2 diabetes) at a Veteran Administration Medical Center found that patients seen in a diabetes clinic, compared with those seen in a general medicine clinic, were more likely to have had an eye examination and A1C test in the past year (73 versus 52 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/86\">",
"       86",
"      </a>",
"      ]. However, the mean A1C value (9.7 percent) in the two clinics was similar and suboptimal.",
"     </li>",
"     <li>",
"      Lower risks of neuropathy and nephropathy were reported in association with specialist care for type 1 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult to distinguish how much of the difference in care is due to expert knowledge or to the application of a systematic and organized approach. In one study, although diabetes-specific tests were performed more often in a diabetes clinic, diabetic patients were more likely to get inquiries about the presence of cardiac symptoms if they received their care in a general internal medicine clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These reports have generated much discussion and disagreement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/88\">",
"     88",
"    </a>",
"    ], and the place of the specialist remains unsettled. Other strategies for improving the routine care of diabetic patients are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Strategies to improve diabetes primary care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several approaches have been tried in order to improve the care of diabetic patients within a primary care setting. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Diabetes miniclinics\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Better organization and delivery of patient education [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/91,92\">",
"       91,92",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Structured behavioral intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/93,94\">",
"       93,94",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Management by nurse specialists under the supervision of a diabetologist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multidisciplinary disease management programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/97-99\">",
"       97-99",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal intervention strategy to improve diabetes care in the primary care setting has not been established, and the effects of intervention may be short-lived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Processes of care (performance of retinal examination, foot exam, A1C measurements, lipid testing, nephropathy screening, flu vaccination,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy) may be more readily improved by disease management interventions than intermediate outcomes (blood pressure control, lipid control, or A1C level) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis reviewing 66 publications of trials evaluating the impact of 11 different strategies for improving diabetes care found study limitations and likely publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/38/36458/abstract/102\">",
"     102",
"    </a>",
"    ]. Strategies incorporating team changes (expanded roles for non-MD clinicians and shared care) or case management programs (multidisciplinary coordinated care for patient scheduling and follow-up) were most effective. Across all trials, the mean A1C reduction was 0.42 percent (95% CI 0.29-0.34) over a median of 13 months follow-up. A1C improvement was greatest for strategies that allowed medication dose adjustments without awaiting clinician approval.",
"   </p>",
"   <p>",
"    Several organizations are encouraging adherence to routine standards of care for diabetic patients by auditing charts, or by asking for data on random samples of diabetic patients. The most comprehensive set of diabetes measures was launched by the American Diabetes Association (ADA), cosponsored by the National Committee for Quality Assurance. Individual providers or groups of providers may apply to receive recognition that they are delivering a certain standard of diabetes care. Recognition requires review of the medical chart, laboratory data, and a patient survey and measures eye, foot, and renal care; cardiac risk reduction; glycemic control; and patient satisfaction (",
"    <a class=\"graphic graphic_table graphicRef51147 \" href=\"mobipreview.htm?29/1/29723\">",
"     table 4",
"    </a>",
"    ). Further information is available through the",
"    <a class=\"external\" href=\"file://www.ncqa.org/tabid/139/Default.aspx\">",
"     National Committee for Quality Assurance",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=see_link\">",
"       \"Patient information: The ABCs of diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"       \"Patient information: Treatment for type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/34/11810?source=see_link\">",
"       \"Patient information: Diabetic retinopathy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morbidity from diabetes involves both macrovascular (atherosclerosis) and microvascular disease (retinopathy, nephropathy, and neuropathy). Interventions can limit end organ damage and are the focus of care for the diabetic patient. Monitoring recommendations for patients with diabetes are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef63002 \" href=\"mobipreview.htm?36/36/37452\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation for diabetic complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Reducing the risk of macrovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of cardiovascular morbidity is a major priority for patients with diabetes, especially type 2. Smoking cessation is essential for patients who smoke. Cardiovascular morbidity can also be significantly reduced with aggressive management of hypertension, cholesterol (goal LDL less than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 162",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in patients with or at high risk for cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Reducing the risk of macrovascular disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycemic control can minimize risks for retinopathy, nephropathy, and neuropathy in both type 1 and type 2 diabetes, and has been shown to decrease the risk for cardiovascular disease for type 1 diabetes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glycemic control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A1C goal is &lt;7 percent for most patients; more stringent control (A1C &lt;6 percent) may be indicated for individual patients with type 1 diabetes and during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link&amp;anchor=H6#H6\">",
"       \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\", section on 'Target blood glucose values'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A higher target A1C (eg, &lt;8 percent) may be preferable for some type 2 patients with comorbidities or with an anticipated lifespan, owing to advanced age or other factors, that is too brief to benefit from the effects of intensive therapy on long-term complications. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Monitoring and target A1C'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"       \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The majority of diabetic patients are not receiving recommended levels of healthcare, and development of systems of care, involving disease management principles, may be important in delivering improved care. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Adequacy of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/1\">",
"      Cory, S, Ussery-Hall, A, Griffin-Blake, S, et, al. Prevalence of selected risk behaviors and chronic diseases and conditions-steps communities, United States, 2006-2007. MMWR CDC Surveill Summ 2010; 59:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/2\">",
"      Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76.",
"     </a>",
"    </li>",
"    <li>",
"     Diabetes in America, 2nd, Harris MI (Ed), National Institutes of Health, Bethesda, MD 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/4\">",
"      Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/5\">",
"      Tunceli K, Bradley CJ, Nerenz D, et al. The impact of diabetes on employment and work productivity. Diabetes Care 2005; 28:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/6\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/7\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/8\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/9\">",
"      Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Correctable visual impairment among persons with diabetes--United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2006; 55:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/11\">",
"      Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 1990; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/12\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/13\">",
"      Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/14\">",
"      Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/15\">",
"      Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 1996; 39:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/16\">",
"      Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/17\">",
"      Scognamiglio R, Negut C, Ramondo A, et al. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/18\">",
"      Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33:e147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/19\">",
"      Franco OH, Steyerberg EW, Hu FB, et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007; 167:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/20\">",
"      Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/21\">",
"      Uusitupa MI, Niskanen LK, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/22\">",
"      Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/23\">",
"      Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/24\">",
"      Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/25\">",
"      Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction. BMJ 1998; 317:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/26\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/27\">",
"      Ford ES, Malarcher AM, Herman WH, Aubert RE. Diabetes mellitus and cigarette smoking. Findings from the 1989 National Health Interview Survey. Diabetes Care 1994; 17:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/28\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/29\">",
"      Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/30\">",
"      Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992; 268:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/31\">",
"      Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/32\">",
"      Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/33\">",
"      De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/34\">",
"      Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA 2008; 300:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/35\">",
"      Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/36\">",
"      De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/37\">",
"      Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/38\">",
"      Persell SD, Baker DW. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 2004; 164:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/39\">",
"      Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/40\">",
"      Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998; 352:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/41\">",
"      Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/42\">",
"      Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/43\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/44\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/45\">",
"      United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/46\">",
"      Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/47\">",
"      ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/48\">",
"      Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/49\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/50\">",
"      Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/51\">",
"      U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/52\">",
"      Fenton JJ, Von Korff M, Lin EH, et al. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 2006; 4:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/53\">",
"      Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/54\">",
"      Stattin P, Bj&ouml;r O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/55\">",
"      Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010; 15:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/56\">",
"      Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/57\">",
"      Lipscombe LL, Hux JE, Booth GL. Reduced screening mammography among women with diabetes. Arch Intern Med 2005; 165:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/58\">",
"      Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/59\">",
"      West J, Brousil J, Gazis A, et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM 2006; 99:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/60\">",
"      Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/61\">",
"      Saremi A, Nelson RG, Tulloch-Reid M, et al. Periodontal disease and mortality in type 2 diabetes. Diabetes Care 2005; 28:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Dental visits among dentate adults with diabetes--United States, 1999 and 2004. MMWR Morb Mortal Wkly Rep 2005; 54:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/63\">",
"      Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/64\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/65\">",
"      Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006; 144:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/66\">",
"      Jackson GL, Edelman D, Weinberger M. Simultaneous control of intermediate diabetes outcomes among Veterans Affairs primary care patients. J Gen Intern Med 2006; 21:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/67\">",
"      Wenger NK. Heightened cardiovascular risk in diabetic women: can the tide be turned? Ann Intern Med 2007; 147:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/68\">",
"      Gregg EW, Gu Q, Cheng YJ, et al. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007; 147:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/69\">",
"      Kenny SJ, Smith PJ, Goldschmid MG, et al. Survey of physician practice behaviors related to diabetes mellitus in the U.S. Physician adherence to consensus recommendations. Diabetes Care 1993; 16:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/70\">",
"      Peters AL, Legorreta AP, Ossorio RC, Davidson MB. Quality of outpatient care provided to diabetic patients. A health maintenance organization experience. Diabetes Care 1996; 19:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/71\">",
"      Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet 2004; 364:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/72\">",
"      Del Aguila MA, Reiber GE, Koepsell TD. How does provider and patient awareness of high-risk status for lower-extremity amputation influence foot-care practice? Diabetes Care 1994; 17:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/73\">",
"      Edelman D, Matchar DB, Oddone EZ. Clinical and radiographic findings that lead to intervention in diabetic patients with foot ulcers. A nationwide survey of primary care physicians. Diabetes Care 1996; 19:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/74\">",
"      Lutfiyya MN, McCullough JE, Mitchell L, et al. Adequacy of diabetes care for older U.S. rural adults: a cross-sectional population based study using 2009 BRFSS data. BMC Public Health 2011; 11:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/75\">",
"      Persell SD, Zaslavsky AM, Weissman JS, Ayanian JZ. Age-related differences in preventive care among adults with diabetes. Am J Med 2004; 116:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/76\">",
"      Wexler DJ, Grant RW, Meigs JB, et al. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005; 28:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/77\">",
"      McBean AM, Yu X. The underuse of screening services among elderly women with diabetes. Diabetes Care 2007; 30:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/78\">",
"      Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/79\">",
"      Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q 1996; 74:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/80\">",
"      Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001; 135:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/81\">",
"      Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 2006; 144:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/82\">",
"      Hayes TM, Harries J. Randomised controlled trial of routine hospital clinic care versus routine general practice care for type II diabetics. Br Med J (Clin Res Ed) 1984; 289:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/83\">",
"      Verlato G, Muggeo M, Bonora E, et al. Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study. Diabetes Care 1996; 19:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/84\">",
"      Greenfield S, Rogers W, Mangotich M, et al. Outcomes of patients with hypertension and non-insulin dependent diabetes mellitus treated by different systems and specialties. Results from the medical outcomes study. JAMA 1995; 274:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/85\">",
"      Greenfield, S. Comparison by systems and specialties of medical outcomes in patients with hypertension and non-insulin dependent diabetes mellitus. Am J Manag Care 1996; 2:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/86\">",
"      Ho M, Marger M, Beart J, et al. Is the quality of diabetes care better in a diabetes clinic or in a general medicine clinic? Diabetes Care 1997; 20:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/87\">",
"      Zgibor JC, Songer TJ, Kelsey SF, et al. Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2002; 25:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/88\">",
"      Riddle, MC, Karl, DM. Treatment of NIDDM by endocrinologists and generalists: a critique of the Medical Outcomes Study report. Clin Diabet 1996; 14:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/89\">",
"      Hurwitz B, Goodman C, Yudkin J. Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. BMJ 1993; 306:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/90\">",
"      MacKinnon M. General practice diabetes care: the past, the present and the future. Diabet Med 1990; 7:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/91\">",
"      Gruesser M, Bott U, Ellermann P, et al. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 1993; 16:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/92\">",
"      Sperl-Hillen J, Beaton S, Fernandes O, et al. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med 2011; 171:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/93\">",
"      Weinger K, Beverly EA, Lee Y, et al. The effect of a structured behavioral intervention on poorly controlled diabetes: a randomized controlled trial. Arch Intern Med 2011; 171:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/94\">",
"      Frosch DL, Uy V, Ochoa S, Mangione CM. Evaluation of a behavior support intervention for patients with poorly controlled diabetes. Arch Intern Med 2011; 171:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/95\">",
"      Thompson DM, Kozak SE, Sheps S. Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: a randomized trial. CMAJ 1999; 161:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/96\">",
"      Legorreta, AP, Peters, AL, Ossorio, RC, et al. Effect of a comprehensive nurse-managed program: an HMO prospective study. Am J Manag Care 1996; 2:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/97\">",
"      Espinet LM, Osmick MJ, Ahmed T, Villagra VG. A cohort study of the impact of a national disease management program on HEDIS diabetes outcomes. Dis Manag 2005; 8:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/98\">",
"      Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005; 118:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/99\">",
"      Mangione CM, Gerzoff RB, Williamson DF, et al. The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med 2006; 145:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/100\">",
"      Kirkman MS, Williams SR, Caffrey HH, Marrero DG. Impact of a program to improve adherence to diabetes guidelines by primary care physicians. Diabetes Care 2002; 25:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/101\">",
"      M&eacute;nard J, Payette H, Baillargeon JP, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ 2005; 173:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/38/36458/abstract/102\">",
"      Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 2006; 296:427.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1750 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36458=[""].join("\n");
var outline_f35_38_36458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION FOR DIABETIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Routine eye examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Correctable visual impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Routine foot examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening for increased urinary albumin excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REDUCING THE RISK OF MACROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Multifactorial risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Monitoring and target A1C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nonpharmacologic therapy in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacologic therapy for type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER ASPECTS OF HEALTH MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Routine health maintenance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Dental screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Women of childbearing age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ADEQUACY OF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Who should take care of the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Strategies to improve diabetes primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1750|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/63/20467\" title=\"algorithm 1\">",
"      Insulin titration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1750|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/16/2318\" title=\"figure 1\">",
"      Retinopathy onset in NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/45/25309\" title=\"figure 2\">",
"      Retinopathy and duration of DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/55/34687\" title=\"figure 3\">",
"      Test sites in diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/50/14125\" title=\"figure 4A\">",
"      ACEI delays moderately increased albuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/22/29037\" title=\"figure 4B\">",
"      ACEI in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/57/21406\" title=\"figure 5\">",
"      Cardiovascular risk in NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/5/17502\" title=\"figure 6\">",
"      HbA1c with intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/36/37452\" title=\"table 1\">",
"      Monitoring in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/18/17707\" title=\"table 2\">",
"      ADA opthalmologic exam schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/33/36380\" title=\"table 3\">",
"      Preconception control in IDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/1/29723\" title=\"table 4\">",
"      ADA recognition measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/38/43618?source=related_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/20/18761?source=related_link\">",
"      Screening for coronary heart disease in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5189?source=related_link\">",
"      Smoking and cardiovascular risk in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/42/682?source=related_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_38_36459="Cystic fibrosis screening panel";
var content_f35_38_36459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic screening panels for cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Standard or basic mutation panel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &Delta;F508, &Delta;I507, G542X, G551D, W1282X, N1303K, R553X, 621+1G&gt;T, R117H, 1717-1G&gt;A, A455E, R560T, R1162X, G85E, R334W, R347P, 711+1G&gt;T, 1898+1G&gt;A, 2184delA, 3849+10kbC&gt;T, 2789+5G&gt;A, 3659delC, 3120+1G&gt;A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Expanded 32 mutation panel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G85E, &Delta;I507, R553X, 711+1G&gt;T, 3659delC, R117H, &Delta;F508, R560T, 1078delT, 3849+10kbC&gt;T, I148T, V520F, R1162X, 1717-1G&gt;A, 3876delA, R334W, G542X, W1282X, 1898+1G&gt;A, 3905insT, R347P, S549N, N1303K, 2184delA, R347H, S549R, 394delTT, 2789+5G&gt;A, A455E, G551D, 621+1G&gt;T, 3120+1G&gt;A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Reflex tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I506V*, I507V*, F508C*, 5T/7T/9T&bull;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Benign Variants. This test distinguishes between the &Delta;F508 CF mutation and these benign variants. I506V, I507V, and F508C testing is performed only as reflex tests for unexpected homozygosity for &Delta;F508 and/or &Delta;I507.",
"     <br>",
"      <br>",
"       &bull;5T / 7T /9T analysis is performed only when R117H is detected, for the following reasons:",
"       <br>",
"        the R117H mutation can result in classic CF only if there is a 5T variant on the same chromosome and another CF mutation on the opposite chromosome. R117H on one chromosome and 5T or 7T on the opposite chromosome, or homozygosity for 5T (5T on each chromosome) can result in congenital bilateral absence of the vas deferens (CBAVD);",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Technical Standards and Guidelines for CFTR Mutation Testing. American College of Medical Genetics, 2006 and ACOG Committee Opinion #325, Update on carrier screening for cystic fibrosis; December 2005",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36459=[""].join("\n");
var outline_f35_38_36459=null;
var title_f35_38_36460="Major causes of short stature";
var content_f35_38_36460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of short stature in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrinsic shortness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial (genetic) short stature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turner's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Delayed growth*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subtle undernutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Underlying disease of mild to moderate severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Attenuated growth",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer - includes chemotherapy and cranial radiotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoid excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Gastrointestinal disease",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Immunologic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Human immunodeficiency virus (HIV) infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Severe combined immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Metabolic and endocrine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D deficiency or resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Growth hormone deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Growth hormone insensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Accelerated early growth but more accelerated epiphyseal closure",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central precocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudoprecocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Virilizing forms of congenital adrenal hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Longstanding hyperthyroidism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Delayed growth is characterized by bone age that is closer to height age than to chronologic age; adult height is often normal.",
"     <br>",
"      &bull; Attenuated growth is characterized by progressive deviation from previously defined growth channel or percentile.",
"      <br>",
"       &Delta; Patients with underlying gastrointestinal diseases are often underweight for height.",
"       <br>",
"        &loz; If untreated, these tall children become short adults.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36460=[""].join("\n");
var outline_f35_38_36460=null;
var title_f35_38_36461="Most popular birth control methods";
var content_f35_38_36461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Primary contraceptive methods among women age 15 to 44 years: United States 2002",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 335px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     MMWR Weekly 2005; 54:152.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36461=[""].join("\n");
var outline_f35_38_36461=null;
var title_f35_38_36462="Relative risk and odds ratio";
var content_f35_38_36462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Relative risk and odds ratio",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a cohort study, the relative risk of a disease can be calculated because all patients under study are available for the analysis comparing risk in exposed and unexposed individuals. In contrast, in a case-control study, cases are drawn from a population of patients who have the disease, and controls from a population without the disease. Thus, the relative risk cannot be calculated since the samples do not necessarily reflect the true proportion of patients who have been exposed to a risk factor. Instead, the relative risk can be estimated using the odds ratio.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36462=[""].join("\n");
var outline_f35_38_36462=null;
var title_f35_38_36463="False positive radiograph";
var content_f35_38_36463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    False positive abdominal radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An admitted body packer presented to the Emergency Department for medical clearance, and a plain abdominal radiograph demonstrated a radiolucency overlying the L1 vertebral body. Although suspicious for a drug packet, the lucency was subsequently determined to be due to intra-abdominal calcifications, in this case in the pancreas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Traub, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_38_36463=[""].join("\n");
var outline_f35_38_36463=null;
